( 12 ) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY ( PCT ) . ( 19 ) W0rld Intellectual Pr0perty Organizati0n 1nternati0r1a1 Bureau. . ( 10 ) Internati0nal Publicati0n Number. . ( 43 ) Internati0nal Publicati0n Date M WO 2013 / 097947 A1 4 July 2013 ( 04.07.2013 ) WI P O | P C T ( 51 ) Internati0nal Patent Classiﬁcati0n : ( 81 ) Designated States ( unZess 0therwise indicated , f0r every. ( 21 ) . ( 22 ) . C07D 211 / 60 ( 2006.01 ) C07D 405 / 12 ( 2006.01 ) kind 0f nati0naZ pr0tecti0n avaiZabZe ) : AE , AG , AL , AM , A61K31 / 445 ( 2006.01 ) C07D 409 / 12 ( 2006.01 ) AO , AT , AU , AZ , BA , BB , BG , BH , BN , BR , BW , BY , A61P 25 / 24 ( 2006.01 ) C07D 413 / 12 ( 2006.01 ) BZ , CA , CH , CL , CN , CO , CR , CU , CZ , DE , DK , DM , C07D 401 / 12 ( 2006.01 ) C07D 417 / 12 ( 2006.01 ) DO , DZ , EC , EE , EG , ES , FI , GB , GD , GE , GH , GM , GT , . Internati0nal Applicati0n Number : PCT / EP2012 / 005387. Internati0nal Filing Date : 28 December 2012 ( 28.12.2012 ) . HN , HR , HU , ID , IL , 1N , Is , JP , KE , KG , KM , KN , KP , KR , KZ , LA , LC , LK , LR , Ls , LT , LU , LY , MA , MD , ME , MG , MK , MN , MW , MX , MY , MZ , NA , NG , NI , NO , NZ , 0M , PA , PE , PG , PH , PL , PT , QA , R0 , Rs , RU , RW , sC , sD , sE , SG , sK , sL , SM , ST , SV , sY , TH , TJ , TM , TN , TR , TT , TZ , UA , UG , Us , UZ , VC , VN , ZA , . ( 25 ) Filing Language : Eng1iSh ZM , ZW. ( 26 ) Pub1icati0n Language : Eng1ish ( 84 ) Designated States ( unless 0therwise indicated , f0r every. ( 30 ) Pri0rity Data : kind 0f regi0naI pmteCtiOn availabZe ) : ARIPO ( BW , GH , 111959706 28 December 2011 ( 28.12.2011 ) EP GM KE LR LS MW M2 NA RW SD SL SZ TZ. ( 71 ) . ( 72 ) . ( 74 ) . Applicant : MAX - PLANCK - GESELLSCHAFT ZUR FORDERUNG DER WISSENSCHAFTEN E. V. [ DE / DE ] ; H0fgartenstrasse 8 , 80539 Miinchen ( DE ) . InVent0rs : GOPALAKRISHNAN , Ranganath ; C - 306 Sumeya Apartments , Nr. St. XaVier ' s Sch001 , ( L0y011a ) , . UG , ZM , ZW ) , Eurasian ( AM , AZ , BY , KG , KZ , RU , TJ , TM ) , European ( AL , AT , BE , BG , CH , CY , CZ , DE , DK , EE , Es , FI , FR , GB , GR , HR , HU , IE , Is , IT , LT , LU , LV , MC , MK , MT , NL , NO , PL , PT , RO , Rs , SE , SI , sK , SM , TR ) , OAPI ( BF , BJ , CF , CG , CI , CM , GA , GN , GQ , GW , ML , MR , NE , sN , TD , TG ) . G0pa111agar , Ahmedabad - 380052 , Gujarat ( IN ) . HAUSCH , Published : . FeliX ; H0henZ011ernstr. 146 , 80796 Munich ( DE ) . Agent : ARTH , Hans - L0thar ; ABK Patent Att0rneys , Jasminweg 9 , 14052 Ber1in ( DE ) . with internati0naI search rep0rt ( Art. 21 ( 3 ) ) . . ( 54 ) Title : PIPECOLATE - SULFONAMIDES FOR TREATMENT OF PSYCHIATRIC DISORDERS. W0 2013 / 097947 A1 |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||. ( 57 ) Abstract : The present inVenti011 re1ates t0 00mp0u11ds haVing a pipec01ate sulf011amide scaff01d , pharmaceutica11y acceptab1e sa1ts 0f these 00mp0unds and pharmaceutica1 00mp0siti0ns 00ntaining at 1east 0ne 0f these 00mp0unds t0gether with pharmaceutic - a11y acceptab1e carrier , eXcipient and / 0r di1uents. Said pipec01ate su1f011amide 00mp0u11ds can be used f0r pr0phy1aXis and / 0r treatment 0f psychiatric dis0rders and neur0degeneratiVe diseases , dis0rders and 00nditi0ns. 10. 15. 20. 25. 30. 35. WO 2013 / 097947 PCT / EP2012 / 005387. Pipecolate - su|fonamides for treatment of psychiatric disorders. Specification. The present invention relates to pipeco|ate su|fonamide derivatives and stereoisomeric forms , solvates , hydrates and / or pharmaceutica||y acceptable sa|ts of these compounds as we|| as pharmaceutical compositions containing at |east one of these pipecoIate sulfonamide derivatives together with pharmaceutica||y acceptab|e carrier , excipient and / or di|uents. Said pipeCo|ate su|fonamide derivatives have been identified as specific inhibitors of the FK506 binding proteins ( FKBP ' s ) , especia|ly the FKBP - 51 and FKBP - 52 , and are useful for the treatment of psychiatric disorders and neurodegenerative diseases , disorders and conditions , for treating vision disorders and / or improving vision ; for treating memory impairment and / or enhancing memory performance and for treating a|opecia and promoting hair growth. Background of the invention. The FK506 - binding protein ( FKBP ) fami|y of immunophi|ins consists of proteins with a variety of protein - protein interaction domains and versati|e ce||u|ar functions. This high|y conserved protein fami|y binds with immunosuppressive drugs , such as FK506 and rapamycin. This protein fami|y displays peptidy| propy| isomerase ( PP|ase ) activity as seen with cyc|ophi|ins and parvu|ins. FKBP12 , a 12 kD protein is themost wide|y studied member of this fami|y. The immunosuppressant drugs FK506 , rapamycin , and cyc|osporin are we|| known as potent T - ce|| specific immunosuppressants , and are effective against autoimmunity , transplant or graft rejection , inflammation , a|lergic responses , other autoimmune or immune - mediated diseases , and infectious diseases. FK506 and rapamycin apart from binding to FKBP12 a|so interact and inhibit ca|cineurin ( CaN ) and mTOR respective|y thereby mediating their immunosuppressive action. The high molecu|ar weight multidomain homologs of FKBP12 ( FKBP51 / 52 ) act as co chaperons for the heat shock protein ( Hsp90 ) and modu|ate the signal transduction of the g|ucocorticoid receptor by participating in the Heat shock protein 90 ( Hsp90 ) - steroid receptor comp|ex. comamnon con. 10. 15. 25. 30. 35. WO 2013 / 097947 PCT / EP2012 / 005387 2. |n this comp|ex , FKBP 51 and 52 modu|ate the binding competence and signa||ing of steroid hormone receptors and thereby regu|ate the ce||u|ar responsiveness to circu|ating hormone |eve|s. This is supported by a natura| anima| mode| ( squirrel monkey ) and by knockout mice , where the essentia| ro|e of FKPB 51 and 52 on the G|ucocorticoid Receptor ( GR ) activity have been c|ear|y demonstrated. Moreover , po|ymorphisms in the FKBP51 - encoding gene of psychiatric patients have been associated with a faster response to antidepressants , with a higher incidence in depressive episodes and with a higher susceptibi|ity for peritraumatic dissociation. The immunosuppressive compounds disclosed in the prior art suppress the immune system , by definition , and also exhibit other toxic side effects. According|y , there is a need for non - immunosuppressant , sma|| mo|ecu|e compounds , and compositions and methods for use of such compounds , that are useful in treating psychiatric disorders and neurodegenerative diseases , disorders and conditions. Further studies |ed to d - ketoamide ana|ogs of FKBP 12 inhibitors devoid of immunosuppressive activity. The e|ectrophi|icity of the o - ketoamide moiety in the non - immunosuppressive ana|ogs is an undesired reactive |iabi|ity that could result in metabo|ic instability or potentia| toxicity. A so|ution cou|d be found in su|fonamide ana|ogs that |ack a reactive |iability and show simi|ar affinities. |t is the object of the present invention to provide compounds and / or pharmaceutica||y acceptab|e sa|ts thereof which inhibit FKBP 51 and FKBP 52 but which show no immunosuppressive activity , are metabo|ic stab|e and non toxic. A further aspect of the invention is to provide compounds and / or pharmaceutical|y acceptab|e sa|ts thereof which can be used as pharmaceutical|y active agents , especia||y for the treatment of psychiatric disorders and neurodegenerative diseases , disorders and conditions , for treating vision disorders and / or improving vision , for treating memory impairment and / or enhancing memory performance and for treating a|opecia , as we|| as compositions comprising at |east one of those compounds and / or pharmaceutica||y acceptab|e sa|ts thereof as pharmaceutica||y active ingredients. The object of the present invention is so|ved by the teaching of the independent c|aims. Further advantageous features , aspects and detai|s of the invention are evident from the dependent c|aims , the description , and the examp|es of the present app|ication. I. 10. 15. 25. W0 2013 / 097947 PCT / EP2012 / 005387 3 Description of the invention The novel pipeco|ate su|fonamide derivatives according to the present invention are represented by the fo||owing genera| formula ( | ) : . . wherein. R1 - R17 represent independent|y of each other —H , —OH , —OCH3 , —OC2H5 , —OC3H7 , —O—cyclo - C3H5 , —OCH ( CH3 ) 2 , —OC ( CH3 ) 3 , —OC4H9 , —OCH2 - COOH , —OPh , —OCH2—Ph , —OCPh3 , —CH2—OCH3 , —C2H4—OCH3 , —C3H5—OCH3 , —CH2—OC2H5 , —C2H4—OC2H5 , —C3H5—OC2H5 , - CH2—OC3H7 , . —C2H4—OC3H7 , —C3H5—OC3H7 , —CH2 - —O— - cyc|o - C3H5 , —C2H4—O—cyc|o - C3H5 , —C3H5—O——cyc|o - C3H5 , —CH2—OCH ( CH3 ) 2 , —C2H4—OCH ( CH3 ) 2 , —C3H5—OCH ( CH3 ) 2 , —CH2—OC ( CH3 ) 3 , —C2H4—OC ( CH3 ) 3 , —C3H5—OC ( CH3 ) 3 , —CH2—OC4Hg , —C2H4—OC4H9 , —C3H6—OC4Hg , —CH2 - —OFh , —C2H4 - - OFh , ——C3H5—OPh , —CH2—OCH2—Ph , —C2H4 - OCH2—Ph , —C3H5 - —OCH2—Ph , —SH , —SCH3 , —SC2H5 , - —SC3H7 , —S—cyc|o - C3H5 , —SCH ( CH3 ) 2 , —SC ( CH3 ) 3 , —NO2 , —F , —C| , —Br , —l , - P ( 0 ) ( 0H ) 2. - F ( 0 ) ( 0CH3 ) 2. - P ( 0 ) ( 0C2H5 ) 2 , - P ( 0 ) ( 0CH ( CH3 ) 2 ) 2. - C ( OH ) [ P ( O ) ( OH ) 2 ] 2 , —3i ( CH3 ) 2 ( C ( CH3 ) 3 ) : * Si ( C2H5 ) 3. "Si ( CH3 ) 3. —N3 , —CN , —OCN , —NCO , —SCN , —NCS , —CHO , —COCH3 , —COC2H5 , —COC3H7 , —CO—cyc|o - C3H5 , - COCH ( CH3 ) 2 , —COC ( CH3 ) 3 , —COOH , —COCN , —COOCH3 , —COOC2H5 , —COOC3H7 , —COO—cyclo - C3H5 , —COOCH ( CH3 ) 2 , —COOC ( CH3 ) 3 , —OOC—CH3 , —OOC—C2H5 , —OOC—C3H7 , —OOC—CyC|O - C3H5 , —OOC—CH ( CH3 ) 2. —OOC - —C ( CH3 ) 3 , —CONH2 , —CONHCH3 , —CONHC2H5 , . —CONHC3H7 , —CONH——CyC|0 - C3H5 , —CONH [ CH ( CH3 ) 2 ] , —CONH [ C ( CH3 ) 3 ] , —CON ( CH3 ) 2 , - —CON ( C2H5 ) 2 , —CON ( C3H7 ) 2. —CON ( cyc|0 - C3H5 ) 2. —CON [ CH ( CH3 ) 2 ] 2 , —CON [ C ( CH3 ) 3 ] 2 , —NHCOCH3 , —NHCOC2H5 , . —NHCOC3H7 , ——NHCO—CyC|0 - C3H5 , —NHCO—CH ( CH3 ) 2. —NHCO—C ( CH3 ) 3 , . 10. 15. 20. 25. 30. 35. WO 2013 / 097947 PCT / EP2012 / 005387 4. —NHCO—OCH3 , —NHCO—OC2H5 , —NHCO—OC3H7 , —NHCO—O—cyc|o - C3H5 , . —NHCO—OCH ( CH3 ) 2 , —NHCO—OC ( CH3 ) 3 , —NH2 , —NHCH3 , —NHC2H5 , —NHC3H7 , —NH—cyc|o - C3H5 , —NHCH ( CH3 ) 2 , —NHC ( CH3 ) 3 , —N ( CH3 ) 2 , —N ( C2H5 ) 2. —N ( C3H7 ) 2. —N ( CYC|0 - C3H5 ) 2. - N [ CH ( CH3 ) 212. —N [ C ( CH3 ) 3 ] 2. —SOCH3 , —SOC2H5 , - SOC3H7 , —SO—cyc|o - C3H5 , —SOCH ( CH3 ) 2 , - SOC ( CH3 ) 3 , —SO2CH3 , - SO2C2H5 , —SO2C3H7 , —SO2—cyc|o - C3H5 , . —SO2CH ( CH3 ) 2 , —SO2C ( CH3 ) 3 , —SO3H , —SO3CH3 , —SO3C2H5 , —SO3C3H7 , —SO3—cyclo - C3H5 , —SO3CH ( CH3 ) 2 , —SO3C ( CH3 ) 3 , —SO2NH2 , —SO2NHCH3 , —SO2NHC2H5 , —SO2NHC3H7 , —SO2NH—cyc|o - C3H5 , —SO2NHCH ( CH3 ) 2 , —SO2NHC ( CH3 ) 3 , —SO2N ( CH3 ) 2 , —SO2N ( C2H5 ) 2 , —SO2N ( C3H7 ) 2 , - SO2N ( CyC|0 ' C3H5 ) 2. —SO2N [ CH ( CH3 ) 2 ] 2. - SO2N [ C ( CH3 ) 3 ] 2. - O - S ( =O ) CH3. —O—S ( =O ) C2H5 , —O—S ( =O ) C3H7 , —O—S ( =O ) —cyc|o - C3H5 , —O—S ( =O ) CH ( CH3 ) 2 , —O - —S ( =O ) C ( CH3 ) 3 , , —S ( =O ) ( =NH ) CH3 , —S ( =O ) ( =NH ) C2H5 , —S ( =O ) ( =NH ) C3H7 , —S ( =O ) ( =NH ) —cyclo - C3H5 , —S ( =O ) ( =NH ) CH ( CH3 ) 2. —S ( =O ) ( : NH ) C ( CH3 ) 3 , —NH—SO2—CH3 , - —NH—SO2—C2H5 , —NH—SO2—C3H7 , —NH—SO2—CyC|O - C3H5 , —NH—SO2—CH ( CH3 ) 2 , ——NH—SO2—C ( CH3 ) 3 , —O - —SO2—CH3 , —O—SO2—C2H5 , —O—SO2—C3H7 , —O—SO2—cyclo - C3H5 , —O—SO2—CH ( CH3 ) 2 , —O—SO2—C ( CH3 ) 3 , —OCF3 , —CH2—OCF3 , - C2H4—OCF3 , —C3H5—OCF3 , —OC2F5 , —CH2—OC2F5 , —C2H4—OC2F5 , —C3He—OC2F5 , —O—COOCH3 , —O—COOC2H5 , —O - COOC3H7 , —O—COO— - cyc|o - C3H5 , —O - - COOCH ( CH3 ) 2 , —O - COOC ( CH3 ) 3 , —NH—CO—NH2 , —NH—CO—NHCH3 , —NH—CO—NHC2H5 , —NH—CS—N ( C3H7 ) 2 , - NH - CO—NHC3H7 , . —NH—CO—N ( C3H7 ) 2 , —NH—CO—NH [ CH ( CH3 ) 2 ] , —NH—CO—NH [ C ( CH3 ) 3 ] , —NH—CO—N ( CH3 ) 2 , —NH—CO—N ( C2H5 ) 2 , —NH—CO—NH - —cyc|o - C3H5 , —NH—CO—N ( cyc|o - C3H5 ) 2 , —NH—CO—N [ CH ( CH3 ) 2 ] 2 , —NH—CS—N ( C2H5 ) 2 , —NH—CO—N [ C ( CH3 ) 3 ] 2 , —NH—CS—NH2 , —NH—CS—NHCH3 , —NH—CS—N ( CH3 ) 2 , —NH—CS—NHC2H5 , —NH—CS—NHC3H7 , —NH—CS—NH—cyc|o - C3H5 , —NH—CS—NH [ CH ( CH3 ) 2 ] , —NH—CS—NH [ C ( CH3 ) 3 ] , —NH—CS—N ( cyc|o - C3H5 ) 2 , —NH—CS—N [ CH ( CH3 ) 2 ] 2 , —NH—CS—N [ C ( CH3 ) 3 ] 2 , —NH—C ( =NH ) —NH2 , —NH—C ( =NH ) —NHCH3 , —NH—C ( =NH ) —NHC2H5 , —NH—C ( =NH ) —NHC3H7 , —O—CO—NH—cyclo - C3H5 , —NH—C ( =NH ) —NH—cyc|o - C3H5 , - NH— - C ( =NH ) —NH [ CH ( CH3 ) 2 ] , —O—CO—NH [ CH ( CH3 ) 2 ] , ~—NH—C ( =NH ) ~—NH [ C ( CH3 ) 3 ] , —NH—C ( =NH ) —N ( CH3 ) 2. —NH—C ( =NH ) —N ( C2H5 ) 2. —NH— - C ( =NH ) —N ( C3H7 ) 2 , ——NH—C ( =NH ) —N ( cyclo—C3H5 ) 2. —O—CO—NHC3H7 , —NH—C ( =NH ) —N [ CH ( CH3 ) 2 ] 2 , . —NH—C ( =NH ) —N [ C ( CH3 ) 3 ] 2 , —O—CO—NH2 , —O—CO—NHCH3 , —O—CO—NHC2H5 , —O—CO—NH [ C ( CH3 ) 3 ] , —O—CO—N ( CH3 ) 2. ——O—CO—N ( C2H5 ) 2 , —O - CO—N ( C3H7 ) 2 , —O - CO— - N ( cyc|o - C3H5 ) 2 , —O—CO—N [ CH ( CH3 ) 2 ] 2 , — - O—CO—N [ C ( CH3 ) 3 ] 2 , —O—CO— - OCH3 , —O—CO—OC2H5 , —O—CO—OC3H7 , —O - —CO—O—cyc|o - C3H5 , - O—CO—OCH ( CH3 ) 2 , —O— - CO—OC ( CH3 ) 3 , —CH2F , —CHF2 , —CF3 , —CH2Cl , —CH2Br , —CH2| , “CH2—CH2F , —CH2—CHF2 , - CH2—CF3 , —CH2 - CH2C1 , —CH2—CH2Bl ' , - CH2—CH2| , . 10. 15. 20. 25. 30. 35. WO 2013 / 097947 PCT / EP2012 / 005387 5. —CycI0 - C3H15 , - Ph , —CH2 - Ph , —CH2—CH2—Ph , —CH=CH—Ph , —CPh3 , —CH3 , . - C2H5 , —C3H7 , - CH ( CH3 ) 2 , —C4Hg , —CH2—CH ( CH3 ) 2 , —CH ( CH3 ) —C2H5 , - C ( CH3 ) 3 , —C5H11 , —CH ( CH3 ) —C3H7 , —CH2—CH ( CH3 ) - C2H5 , —CH ( CH3 ) —CH ( CH3 ) 2 , —C ( CH3 ) 2—C2H5 , —CH2—C ( CH3 ) 3 , —CH ( C2H5 ) 2 , - C2H4—CH ( CH3 ) 2. - C6H13. "C7H15. - CsH17. - C3H6 - CH ( CH3 ) 2. - C2H4 - CH ( CH3 ) —C2H5. —CH ( CH3 ) —C4Hg , —CH2—CH ( CH3 ) —C3H7 , —CH ( CH3 ) —CH2—CH ( CH3 ) 2 , —CH ( CH3 ) —CH ( CH3 ) —C2H5 , —CH2—CH ( CH3 ) —CH ( CH3 ) 2 , —CH2—C ( CH3 ) 2—C2H5 , . —C ( CH3 ) 2—C3H7 , —C ( CH3 ) 2—CH ( CH3 ) 2 , —C2H4— - C ( CH3 ) 3 , —CH ( CH3 ) —C ( CH3 ) 3 , —CH=CH2 , —CH2—CH=CH2 , —C ( CH3 ) =CH2 , —CH=CH - —CH3 , —C2H4—CH=CH2 , —CH2—CH=CH—CH3 , —CH=CH—C2H5 , —CH2—C ( CH3 ) =CH2 , —CH ( CH3 ) —CH=CH , . —CH=C ( CH3 ) 2 , —C ( CH3 ) =CH—CH3 , —CH=CH—CH=CH2 , —C3H5—CH=CH2 , —C2H4—CH=CH—CH3 , —CH2—CH=CH - —C2H5 , —CH=CH—C3H7 , —CH2—CH=CH—CH=CH2 , —CH=CH—CH=CH—CH3 , —CH=CH—CH2—CH=CH2 , - - C ( CH3 ) =CH—CH=CH2 , —CH=C ( CH3 ) —CH=CH2 , —CH=CH—C ( CH3 ) =CH2 , —C2H4—C ( CH3 ) =CH2 , —CH2—CH ( CH3 ) —CH=CH2 , —CH ( CH3 ) —CH2—CH=CH2 , —CH2—CH=C ( CH3 ) 2. —CH2—C ( CH3 ) =CH—CH3 , —CH ( CH3 ) —CH=CH—CH3 , —CH=CH—CH ( CH3 ) 2 , —CH=C ( CH3 ) —C2H5 , —C ( CH3 ) =CH—C2H5 , —C ( CH3 ) =C ( CH3 ) 2 , —C ( CH3 ) 2—CH=CH2 , —CH ( CH3 ) —C ( CH3 ) =CH2 , —C ( CH3 ) =CH - —CH=CH2 , —CH=C ( CH3 ) —CH=CH2 , —CH=CH— - C ( CH3 ) =CH2 , —C4H3—CH=CH2 , . - C3H5—CH=CH—CH3 , - C2H4—CH=CH—C2H5 , —CH2—CH=CH—C3H7 , —CH=CH—C4Hg , —C3H5—C ( CH3 ) =CH2 , —C2H4—CH ( CH3 ) —CH=CH2 , —CH2—CH ( CH3 ) —CH2—CH=CH2 , . —C2H4—CH=C ( CH3 ) 2 , —CH ( CH3 ) —C2H4—CH=CH2 , —C2H4—C ( CH3 ) =CH—CH3 , —CH2—CH ( CH3 ) —CH=CH—CH3 , —CH ( CH3 ) —CH2—CH=CH—CH3 , —CH2—CH=CH—CH ( CH3 ) 2 , —CH2—CH=C ( CH3 ) —C2H5 , —CH2—C ( CH3 ) =CH—C2H5 , —CH ( CH3 ) —CH=CH—C2H5 , —CH=CH—CH2—CH ( CH3 ) 2 , —CH=CH— - CH ( CH3 ) —C2H5 , —CH=C ( CH3 ) —C3H7 , —C ( CH3 ) =CH—C3H7 , . —CH2—CH ( CH3 ) —C ( CH3 ) =CH2 , —C [ C ( CH3 ) 3 ] =CH2 , —CH ( CH3 ) —CH2—C ( CH3 ) =CH2 , — - CH ( CH3 ) —CH ( CH3 ) —CH=CH2 , —CH=CH— - C2H4— - CH=CH2 , —CH2—C ( CH3 ) 2—CH=CH2 , . - C ( CH3 ) 2—CH2—CH=CH2 , * CH2 - C ( CH3 ) =C ( CH3 ) 2 , —CH ( CH3 ) - CH=C ( CH3 ) 2 , —C ( CH3 ) 2—CH=CH—CH3 , —CH=CH—CH2 - CH=CH—CH3 , - CH ( CH3 ) —C ( CH3 ) =CH——CH3 , —CH=C ( CH3 ) —CH ( CH3 ) 2. —C ( CH3 ) =CH—CH ( CH3 ) 2 , —C ( CH3 ) =C ( CH3 ) —C2H5 , —CH=CH—C ( CH3 ) 3 , —C ( CH3 ) 2—C ( CH3 ) =CH2 , —CH ( C2H5 ) —C ( CH3 ) =CH2 , —C ( CH3 ) ( C2H5 ) —CH=CH2 , —CH ( CH3 ) —C ( C2H5 ) =CH2 , —CH2— - C ( C3H7 ) =CH2 , - — - CH2—C ( C2H5 ) =CH—CH3 , —CH ( C2H5 ) —CH=CH—CH3 , —C ( C4Hg ) =CH2 , —C ( C3H7 ) =CH - CH3. —C ( C2H5 ) =CH - C2H5. - C ( C2H5 ) =C ( CH3 ) 2 , . —C [ CH ( CH3 ) ( C2H5 ) ] =CH2 , —C [ CH2—CH ( CH3 ) 2 ] =CH2 , —C2H4—CH=CH—CH=CH2 , * CH2 - CH=CH—CH2—CH=CH2 , —C3H5—CEC - CH3 , —CH2—CH=CH—CH=CH—CH3 , —CH=CH—CH=CH—C2H5 , —CH2 - —CH=CH——C ( CH3 ) =CH2 , —CH2—CH=C ( CH3 ) —CH=CH2 , —CH2—C ( CH3 ) =CH—CH=CH2 , —CH ( CH3 ) —CH2—CECH , . 10. 15. 20. 25. 30. 35. WO 2013 / 097947 PCT / EP2012 / 005387 6 —CH ( CH3 ) —CH=CH - —CH=CH2 , —CH=CH—CH2—C ( CH3 ) =CH2 , —CH ( CH3 ) —CEC—CH3 , —CH=CH—CH ( CH3 ) —CH=CH2 , —CH=C ( CH3 ) —CH2—CH=CH2 , —C2H4—CH ( CH3 ) —CECH , —C ( CH3 ) =CH—CH2—CH=CH2 , —CH=CH—CH=C ( CH3 ) 2 , —CH2—CH ( CH3 ) —CH2—CECH , —CH=CH—C ( CH3 ) =CH—CH3 , —CH=C ( CH3 ) —CH=CH—CH3 , —CH2—CH ( CH3 ) —CECH , —C ( CH3 ) =CH—CH=CH—CH3 , —CH=C ( CH3 ) —C ( CH3 ) =CH2 , —C ( CH3 ) =CH—C ( CH3 ) =CH2 , —C ( CH3 ) =C ( CH3 ) —CH=CH2 , —CH=CH—CH=CH—CH=CH2 , —CECH , - CEC—CH3 , —CH2 - CECH , —C2H4—CECH , wCH2—CEC—CH3 , —CEC—C2H5 , - C3H5—CECH , —C2H4 - CEC—CH3 , —CH2—CEC - C2H5 , —CEC - C3H7 , —CH ( CH3 ) —CECH , - C4H3—CECH , —C2H4—CEC—C2H5 , —CH2—CEC—C3H7 , —CEC—C4H9 , —CEC—C ( CH3 ) 3 , —CH ( CH3 ) —C2H4 - CECH , —CH2—CH ( CH3 ) —CEC—CH3 , . —CH ( CH3 ) —CH2—CEC—CH3 , —CH ( CH3 ) —CEC—C2H5 , —CH2—CEC—CH ( CH3 ) 2 , —CEC—CH ( CH3 ) —C2H5 , —CEC—CH2—CH ( CH3 ) 2 , —CH ( C2H5 } - CEC—CH3 , —C ( CH3 ) 2—CEC—CH3 , —CH ( C2H5 ) —CH2—CECH , —CH2—CH ( C2H5 ) —CECH , —C ( CH3 ) 2—CH2—CECH , —CH2—C ( CH3 ) 2—CECH , —CH ( CH3 ) —CH ( CH3 ) —CECH , —CH ( C3H7 ) —CECH , —C ( CH3 ) ( C2H5 ) —CECH , —CH2—CH ( C‘=‘CH ) 2 , —CEC—CECH , —CH2 - —C‘=‘C - CECH , —C.=. C— - C.=. C—CH3 , —CH ( CECH ) 2 , —C2H4—CEC— - CECH , —CH2—CEC—CH2—CECH , —CEC—C2H4—CECH , —CH2 - CEC - —CEC—CH3 , . —CEC—CH2—C - : - C—CH3 , —CEC—CEC—C2H5 , —C ( CECH ) 2—CH3 , —CEC—CH ( CH3 ) —CECH , —CH ( CH3 ) —CEC—CECH , —CH ( CECH ) —CH2—CECH , —CH ( CECH ) —CEC—CH3 , . —o N o \_ / . RN represents the fo||owing —H , —CH2—OCH3 , —C2H4—OCH3 , —C3H5—OCH3 , —CH2 - —OC2H5 , —C2H4—OC2H5 , —C3H6—OC2H5 , —CHz - OC3H7 , —C2H4—OC3H7 , —C3H5—OC3H7 , ~CH2—O—cyc|o - C3H5 , —C2H4—O—cyc|o - C3H5 , —C3H6 - —O—cyc|o - C3H5 , —CH2—OCH ( CH3 ) 2 , —C2H4—OCH ( CH3 ) 2 , —C3H5—OCH ( CH3 ) 2 , —CHz—OC ( CH3 ) 3 , —C2H4 - —OC ( CH3 ) 3 , —C3H5—OC ( CH3 ) 3 , —CHz—OC4Hg , —C2H4—OC4H9 , —C3H5—OC4H9 , —CH2—OPh , —C2H4—OPh , —C3H6—OPh , —CH2 - OCH2—Ph , — - —C2H4—OCH2—Ph , —C3H5—OCH2—Ph , - CHO , —COCH3 , —COC2H5 , . —COC3H7 , —CO—cyc|o - C3H5 , —COCH ( CH3 ) 2 , —COC ( CH3 ) 3 , —COCN , —COOCH3 , —COOC2H5 , —COOC3H7 , - COO—cyC|o - C3H5 , - COOCH ( CH3 ) 2 , —COOC ( CH3 ) 3 , —CONH2 , —CONHCH3 , —CONHC2H5 , —CONHC3H7 , —CONH—cyc|o - C3H5 , —CONH [ CH ( CH3 ) 2 ] , —CONH [ C ( CH3 ) 3 ] , - - CON ( CH3 ) 2 , —CON ( C2H5 ) 2 , —CON ( C3H7 ) 2 , —CON ( cyclo - C3H5 ) 2 , —CON [ CH ( CH3 ) 2 ] 2 , —CON [ C ( CH3 ) 3 ] 2 , —SO2CH3 , —SO2C2H5 , —SO2C3H7 , —SO2—cycl0 - C3H5 , —SO2CH ( CH3 ) 2. —SO2C ( CH3 ) 3 , . —CH2—OCF3 , —C2H4—OCF3 , —C3H6—OCF3 , - OC2F5 , —CH2 - —OC2F5 , —C2H4—OC2F5 , —C3H5—OC2F5 , —CH2F , —CHF2 , - CF3 , —CH2C| , —CH2Br , —CH2| , . 10. 15. 20. 25. 30. 35. WO 2013 / 097947 PCT / EP2012 / 005387 7. —CH2—CH2F , —CH2—CHF2 , —CH2—CF3 , —CH2—CH2C| , ——CH2— - CH2Br , —CH2—CH2| , —CyC|o - C3H15 , —Ph , - CH2—Ph , —CH2—CH2—Ph , —CH=CH—Ph , —CPh3 , —CH3 , . —C2H5 , —C3H7 , —CH ( CH3 ) 2 , —c4H9 , —CH2 - CH ( CH3 ) 2 , —CH ( CH3 ) —C2H5 , —C ( CH3 ) 3 , —C5H11 , —CH ( CH3 ) - C3H7 , —CH2—CH ( CH3 ) —C2H5 , —CH ( CH3 ) —CH ( CH3 ) 2 , —C ( CH3 ) 2—C2H5 , —cH2—C ( cH3 ) 3 , —CH ( C2H5 ) 2 , —C2H4—CH ( CH3 ) 2 , —C5H13 , —C7H15 , —C3H17 , —C3H5—CH ( CH3 ) 2 , —C2H4 - —CH ( CH3 ) - C2H5 , —CH ( CH3 ) - —C4Hg , —CH2 - —CH ( CH3 ) —C3H7 , —CH ( CH3 ) —CH2——CH ( CH3 ) 2 , —CH ( CH3 ) —CH ( CH3 ) —C2H5 , —CH2—CH ( CH3 ) —CH ( CH3 ) 2 , —CH2—C ( CH3 ) 2 - C2H5 , . —C ( CH3 ) 2—C3H7 , —C ( CH3 ) 2—CH ( CH3 ) 2 , —C2H4— - C ( CH3 ) 3 , —CH ( CH3 ) - C ( CH3 ) 3 , —CH=CH2 , —CH2—CH=CH2 , —C ( CH3 ) =CH2 , —CH=CH—CH3 , —C2H4—CH=CH2 , —CH2—CH=CH—CH3 , — - CH=CH— - C2H5 , —CH2—C ( CH3 ) =CH2 , - CH ( CH3 ) —CH=CH , . —CH=C ( CH3 ) 2 , — - C ( CH3 ) =CH - CH3 , —CH=CH—CH=CH2 , —C3H6—CH=CH2 , —C2H4—CH=CH—CH3 , —CH2—CH=CH—C2H5 , —CH=CH—C3H7 , —CH2—CH=CH—CH=CH2 , —CH=CH—CH=CH - —CH3 , —CH=CH—CH2—CH=CH2 , —C ( CH3 ) =CH—CH=CH2 , —CH=C ( CH3 ) —CH=CH2 , —CH=CH—C ( CH3 ) =CH2 , —C2H4—C ( CH3 ) =CH2 , —CH2—CH ( CH3 ) —CH=CH2 , —CH ( CH3 ) —CH2—CH=CH2 , —CH2—CH=C ( CH3 ) 2 , —CH2—C ( CH3 ) =CH—CH3 , —CH ( CH3 ) —CH=CH—CH3 , - —CH=CH—CH ( CH3 ) 2. —CH=C ( CH3 ) —C2H5 , —C ( CH3 ) =CH—C2H5 , —C ( CH3 ) =C ( CH3 ) 2 , —C ( CH3 ) 2—CH=CH2 , —CH ( CH3 ) —C ( CH3 ) =CH2 , —C ( CH3 ) =CH—CH=CH2 , —CH=C ( CH3 ) —CH=CH2 , —CH=CH—C ( CH3 ) =CH2 , —C4H8—CH=CH2 , . wC3H5—CH=CH—CH3 , —C2H4—CH=CH—C2H5 , wCH2—CH=CH - —C3H7 , —CH=CH—C4H9 , —C3H5—C ( CH3 ) =CH2 , —C2H4—CH ( CH3 ) —CH=CH2 , - CH2—CH ( CH3 ) —CH2—CH=CH2 , . —C2H4—CH=C ( CH3 ) 2 , —CH ( CH3 ) —C2H4—CH=CH2 , —C2H4—C ( CH3 ) =CH—CH3 , —CH2—CH ( CH3 ) —CH=CH - CH3 , —CH ( CH3 ) —CH2—CH=CH—CH3 , —CH2—CH=CH—CH ( CH3 ) 2 , —CH2—CH=C ( CH3 ) —C2H5 , —CH2—C ( CH3 ) =CH—C2H5 , —CH ( CH3 ) —CH=CH—C2H5 , —CH=CH—CHrCH ( CH3 ) 2 , —CH=CH— - CH ( CH3 ) —C2H5 , —CH=C ( CH3 ) —C3H7 , —C ( CH3 ) =CH - C3H7 , . —CH2—CH ( CH3 ) —C ( CH3 ) =CH2 , —C [ C ( CH3 ) 3 ] =CH2 , —CH ( CH3 ) —CH2 - C ( CH3 ) =CH2 , —CH ( CH3 ) —CH ( CH3 ) —CH=CH2 , —CH=CH—C2H4 - —CH=CH2 , —CH2—C ( CH3 ) 2—CH=CH2 , . —C ( CH3 ) 2—CH2 - CH=CH2 , —CH2—C ( CH3 ) =C ( CH3 ) 2. —CH ( CH3 ) —CH=C ( CH3 ) 2 , —C ( CH3 ) 2—CH=CH—CH3 , —CH=CH—CH2—CH=CH—CH3 , —CH ( CH3 ) —C ( CH3 ) =CH—CH3 , —CH=C ( CH3 ) —CH ( CH3 ) 2. —C ( CH3 ) =CH—CH ( CH3 ) 2. —C ( CH3 ) =C ( CH3 ) —C2H5 , —CH=CH—C ( CH3 ) 3 , —C ( CH3 ) 2—C ( CH3 ) =CH2 , —CH ( C2H5 ) —C ( CH3 ) =CH2 , —C ( CH3 ) ( C2H5 ) —CH=CH2 , —CH ( CH3 ) —C ( C2H5 ) =CH2 , —CH2—C ( C3H7 ) =CH2 , —CH2—C ( C2H5 ) =CH—CH3 , - —CH ( C2H5 ) —CH=CH—CH3 , —C ( C4H9 ) =CH2 , —C ( C3H7 ) =CH—CH3 , —C ( C2H5 ) =CH—C2H5 , —C ( C2H5 ) =C ( CH3 ) 2 , . —C [ CH ( CH3 ) ( C2H5 ) ] =CH2 , - C [ CH2— - CH ( CH3 ) 2 ] =CH2 , —C2H4—CH=CH—CH=CH2 , —CH2—CH=CH—CH2—CH=CH2 , —C3H5—CEC—CH3 , —CH2—CH=CH—CH=CH—CH3 , —CH=CH—CH=CH—C2H5 , —CH2—CH=CH—C ( CH3 ) =CH2 , . 10. 15. 20. WO 2013 / 097947 PCT / EP2012 / 005387 8. —CH2—CH=C ( CH3 ) —CH=CH2 , —CH2—C ( CH3 ) =CH—CH=CH2 , - CH ( CH3 ) —CH2—CECH , —CH ( CH3 ) —CH=CH—CH=CH2 , —CH=CH—CH2—C ( CH3 ) =CH2 , —CH ( CH3 ) —CEC—CH3 , —CH=CH—CH ( CH3 ) —CH=CH2 , —CH=C ( CH3 ) —CH2—CH=CH2 , —C2H4—CH ( CH3 ) —C‘ - _“CH , —C ( CH3 ) =CH—CH2—CH=CH2 , —CH=CH—CH=C ( CH3 ) 2 , —CH2—CH ( CH3 ) —CH2—CECH , —CH=CH—C ( CH3 ) =CH—CH3 , - CH=C ( CH3 ) —CH=CH—CH3 , - CH2—CH ( CH3 ) —CECH , —C ( CH3 ) =CH—CH=CH—CH3 , —CH=C ( CH3 ) —C ( CH3 ) =CH2 , —C ( CH3 ) =CH—C ( CH3 ) =CH2 , —C ( CH3 ) =C ( CH3 ) —CH=CH2 , —CH=CH—CH=CH—CH=CH2 , —CECH , —CEC—CH3 , —CH2 - CECH , —C2H4—CECH , —CH2—CEC - —CH3 , —CEC—C2H5 , —C3H6—CECH , —C2H4—CEC—CH3 , —CH2—CEC - —C2H5 , ——CEC—C3H7 , —CH ( CH3 ) —CECH , —C4H8—CECH , —C2H4—CEC—C2H5 , —CH2—CEC—C3H7 , —CEC—C4H9 , —CEC—C ( CH3 ) 3 , —CH ( CH3 ) —C2H4—CECH , —CH2—CH ( CH3 ) —CEC—CH3 , . —CH ( CH3 ) —CH2—CEC—CH3 , - CH ( CH3 ) —CEC—C2H5 , - CH2—CEC—CH ( CH3 ) 2 , —C.=_C—CH ( CH3 ) —C2H5 , —CEC— - CH2—CH ( CH3 ) 2. —CH ( C2H5 ) —CEC - CH3 , —C ( CH3 ) 2—CEC~—CH3 , —CH ( C2H5 ) —CH2—CECH , —CH2—CH ( C2H5 ) —CECH , —C ( CH3 ) 2—CH2—CECH , —CH2—C ( CH3 ) 2—CECH , —CH ( CH3 ) —CH ( CH3 ) —CECH , —CH ( C3H7 ) —CECH , - —C ( CH3 ) ( C2H5 ) —CECH , —CH2—CH ( CECH ) 2 , - CEC—CECH , —CH2—CEC—CECH , —CEC—CEC—CH3 , —CH ( CECH ) 2 , —C2H4—CEC—CECH , —CH2—CEC—CH2—CECH , —CEC—C2H4—CECH , —CH2—CEC—CEC—CH3 , . —CEC—CH2—CEC—CH3 , —CEC—CEC—C2H5 , —C ( CECH ) 2——CH3 , —CEC—CH ( CH3 ) —CECH , . —CH ( CH3 ) —C‘=‘C—C ' = ' CH , — - CH ( CECH ) —CH2—CECH , —CH ( CECH ) — - C.=. C—CH3 ; . and A represents the fol|owing. WO 2013 / 097947 PCT / EP2012 / 005387. R13 R12 R13 R12 R13 0 R11 R11 8 R11 R11 RN \ I / S ﬂ / N / R1 R12 / R12 R13 R12 / R12 , R13 R13 N 11 11 R\N Ra R R12 R“ RN R <I —~\ W 1 R12 / R13 NAR12 N R12 R13 R14 RN 11 R L RN\ R11 / \ R11 N‘\N / RN ———N \N NI —N / / / % 12 —<\ R12 R11 R13 R N R12 R13 R12 R11 R11 R11 O“ : N ¢” WW M . / i N\ \ R / N R12 RN N / O R12 R12 R11 N R11 O\|| / R11 S\N | a m w \ N R12 R R12 R12. WO 2013 / 097947 PCT / EP2012 / 005387. 10 R11 WW \ \N / S R11 H —<JN\ —< / ”1 o A . A T 2. ———N> / N / N R N / N / N R1 R . R . . WO 2013 / 097947. 11. R12 R11 N R13 / \ R14 R16 R15. PCT / EP2012 / 005387. . WO 2013 / 097947. PCT / EP2012 / 005387. RN\ R11 N R12 —<\ * N R13 R14 R12 R13 / N\ N R11 R17 R16 R15 R12 Hqu R13 R11 R12 / R13 R15 R14 R12 0. WO 2013 / 097947 PCT / EP2012 / 005387 13. . and enantiomers , stereoisomeric forms , mixtures of enantiomers , anomers , diastereomers , mixtures of diastereomers , tautomers , hydrates , so|vates and. 10. 15. 20. 25. 30. 35. WO 2013 / 097947 PCT / EP2012 / 005387 14. racemates of the above mentioned compounds and pharmaceutica||y acceptab|e sa|ts thereof. The present invention is a|so directed to compounds of the genera| formu|a ( i ) , wherein one or at |east one of the substituents R1 — R5 is not —H. The present invention is a|so directed to compounds of the genera| formu|a ( I ) , wherein one or at |east one of the substituents R6 — R1O is not — - H. The present invention is a|so re|ated to compounds of the general formu|a ( l ) except the compound , wherein A represents —Ph and R1 to R10 represent - H. The expression tautomer is defined as an organic compound that is interconvertib|e by a chemical reaction ca||ed tautomerization. Tautomerization can be cata|yzed preferab|y by bases or acids or other suitab|e compounds. Preferred substituents for R1 — R5 are : —H , —OH , —OCH3 , —OC2H5 , . —OC3H7 , —O—cyclo - C3H5 , —OCH ( CH3 ) 2 , —OC ( CH3 ) 3 , —OC4H9 , —OCH2—COOH , —CH3 , —CH2—OH , —C2H5 , —C3H7 , —CH ( CH3 ) 2. —C4H9 , —CH2—CH ( CH3 ) 2 , —CH ( CH3 ) —C2H5 , —C ( CH3 ) 3 , ——C5H11 , —CH ( CH3 ) —C3H7 , . —CH2—CH ( CH3 ) - C2H5 , —CH ( CH3 ) —CH ( CH3 ) 2 , —C ( CH3 ) 2—C2H5 , —CH2—C ( CH3 ) 3 , —CH ( C2H5 ) 2 , —CH ( CH3 ) —C ( CH3 ) 3 , —C2H4—CH ( CH3 ) 2 , - C6H13 , —C7H15 , —C8H17 , —C3H5—CH ( CH3 ) 2 , —C2H4—CH ( CH3 ) —C2H5 , —CH ( CH3 ) - C4H9 , —CH2—CH ( CH3 ) —C3H7 , —CH ( CH3 ) —CH2—CH ( CH3 ) 2 , —CH ( CH3 ) —CH ( CH3 ) —C2H5 , —CH2—CH ( CH3 ) —CH ( CH3 ) 2 , —CH2—C ( CH3 ) 2—C2H5 , —C ( CH3 ) 2—C3H7 , —C ( CH3 ) 2—CH ( CH3 ) 2 , —C2H4—C ( CH3 ) 3 , or. / _\. —O N O. \___ / \_ / Preferred substituents for R6 — R10 are : —H , —OH , —OCH3 , — - OC2H5 , —OC3H7 , —O—cyc|o - C3H5 , —0CH ( CH3 ) 2 , - OC ( CH3 ) 3 , —OC4H9 , . - OCH2 - —COOH , —CH3 , —CH2—OH , —C2H5 , —C3H7 , —CH ( CH3 ) 2 , - C4H9 , —CH2—CH ( CH3 ) 2 , —CH ( CH3 ) —C2H5 , —C ( CH3 ) 3 , —C5H11 , —CH ( CH3 ) —C3H7 , —CH2—CH ( CH3 ) —C2H5 , —CH ( CH3 ) —CH ( CH3 ) 2 , —C ( CH3 ) 2—C2H5 , —CH2—C ( CH3 ) 3 , —CH ( C2H5 ) 2 , —C2H4—CH ( CH3 ) 2 , —C5H13 , —C7H15 , ——C8H17 , —C3H5—CH ( CH3 ) 2 , —C2H4—CH ( CH3 ) ~—C2H5 , —CH ( CH3 ) —C ( CH3 ) 3 , —CH ( CH3 ) ——C4Hg , ——CH2—CH ( CH3 ) —C3H7 , —CH ( CH3 ) —CH2—CH ( CH3 ) 2 , —CH ( CH3 ) —CH ( CH3 ) —C2H5 , —CH2—CH ( CH3 ) —CH ( CH3 ) 2 , —CH2—C ( CH3 ) 2—C2H5 , —C ( CH3 ) 2—C3H7 , - C ( CH3 ) 2—CH ( CH3 ) 2 , and —C2H4—C ( CH3 ) 3. WO 2013 / 097947 15. Preferred substituents A are. R11 R12 R11. 0 RQ. R15 R14 R12 R11 N\N X11 —< / A “"N / I1l / N R11 R12 RN ﬂ‘ ) —<N“0 R11 / N N¢1\R11 N\S / NYR12 4 —N N7J\R11 N. PCT / EP2012 / 005387 _N / N‘\\N —N / NTQN > 1 VN R“ R12 R11 —< / N\| [ ( | ] OYRH / N / N —<\N / |N RN SYRH / N\ : _< / \N / N R11 R11 R11 / 0 / 3 R12 R12 R15 R15. . WO 2013 / 097947. 16. R15 3 R14 \ 0 R13. PCT / EP2012 / 005387. 11 RN\ R N A O N R14 R12. . WO 2013 / 097947 PCT / EP2012 / 005387. . WO 2013 / 097947 PCT / EP2012 / 005387. 18 R13 R12 R13 R12 R13 R12. * W R“ 0 R11 R11 IO / KQ. N . R13 R12 R13 R\N R12 O—> Q : NH \ N / N\RN R11 O , R11 R12 R11 , . wherein R" , R11 — R‘l7 have the meanings as defined herein. Further preferred substituents A are : . , R13 R13 RN\N R11 R1 1 s\| ( R1 1 R“ O ﬂ 12 / / 12 —% / N A R13 R R13 R R12 N R12. \. PCT / EP2012 / 005387 19. WO 2013 / 097947. R11 R12 R15 8. N a N O / O 2 1 . O . 3 mm N\S / N. WO 2013 / 097947 PCT / EP2012 / 005387 20. . wherein RN , R11 — R17 have the meanings as defined herein. 10. WO 2013 / 097947 PCT / EP2012 / 005387 21. Particu|ar|y preferred substituents for A are R11 R12 R11 R12 R11 R12 * R13 * NH —‘xN \ R15 R14 R15 S / KO R15 S / i\R16 wherein R11 — R16 have the meanings as defined herein and more preferab|y wherein substituent R12 represents —H , —C| , —F , —Br , and. R11 and R15 represent —H , and R13 , R14 and R16 are as defined herein. The fo||owing formulas ( | ) —| l ) ( \ / are a|so preferred. QrJ R4 % O=S =O O O=S=O 0 R1. R15 R1 l \ R12 R14 0 R12 / N R7 R13 R13 R3. . O—S O O 1 R / X R12 R13 0 R7. ( |V ) wherein X represents O , S ; and the substituents R4 , R7 , R8 and R11 — R15 have the meanings. as defined herein , except the compound of the genera| formu|a ( l| ) , wherein R4 , R7 , R8 , R11 — R15 are —H. 5. 10. WO 2013 / 097947 PCT / EP2012 / 005387 22. The present invention is a|so directed to compounds of the genera| formu|a ( l| ) , wherein one or at |east one of the substituents R4 , R7 , R8 and R11 — R15 is different from —H. A particular|y preferred embodiment of the present invention is directed to compounds of the formu|a ( V ) , ( Vl ) , ( V|| ) and ( V||| ) . O“—"S=O O o 0 0 R12 R13 R7 R8 ( V| ) . , | , , 0 O 0 / \ O=S=OO N. O R12 / <>\R14 O R7. . R12 R13 R8 ( vm ) , wherein R4 represents—OCH COOH or —O N / —\O 2 \_ / \_ / R7 and R8 are independent|y of each other —OH , —OCH3 , —OC2H5 , —OC3H7 , - O—cyclo - C3H5 , —0CH ( CH3 ) 2. —OC ( CH3 ) 3 , —OC4H9 , . —OCH2—COOH , —CH3 , —CH2—OH , —C2H5 , —C3H7 , —CH ( CH3 ) 2 , —C4H9 ; R12 represents —H , —C| , —F , or —Br , preferab|y —C| , —F , or —Br ; and R13 and R14 are as defined herein , . WO 2013 / 097947 PCT / EP2012 / 005387 23. or R13 together with R14 can form a heterocyc|ic 5 - or 6 - membered ring with the two carbon atoms of the benzo ring to which R13 and R14 are attached resu|ting in a bicyc|ic substituent and that 5 - or 6 - membered ring formed can be partly saturated , . 5 unsaturated or aromatic and can be substituted with a substituent R” , R16 and / or at a suitab|e carbon atom with an oxygen atom to form a carbony| group =O , wherein RN and R16 are as defined herein ; preferab|y R13 together with R14 can form a heterocyclic 5 - or 6 - membered ring with the two carbon atoms of the benzo ring to which R13 and R14 are attached with one of the fo||owing moieties : . 10 _____N / RN ______NH E w """t ' He e " ' 10 - - - - —s - - - - —s - - - - —s - - - - —s ““—S ""—S ""‘i w ""10 > - o - - - - —N ——————N - - - - —N \RN - - - - —NH \RN : \o : \S ————s ———o - - =N\ = / = / ____ / ) J __ ; —_ / O RN / R“ ——S ———O __ - - - - ——N / - - - - —N W > / > / > F J _____O ——N _N ———o =N\ "—\\ ———N\\ —_N\ "=N\ p / N / N s / S ; N ——S —s " : / . ; N —s ——o —N , , , - / NsN , , / N\ N J g _o / ~ - \2 - J AN / Nﬁ ' , / N\ / \N V ' lu VN “\NJ "\2. 10. 15. 20. 25. 30. 35. W0 2013 / 097947 PCT / EP2012 / 005387 24 wherein RN and R16 are as defined herein ; most preferab|y R13 together with R14 can form a heterocyc|ic 5 - or 6 - membered ring with the two carbon atoms of the benzo ring to which R13 and R14 are attached with one of the fol|owing moieties : . - - - - —N N / RN - - - - —NH N / RN \ 1e ""— ____ - - - - — - S>—R >_R16 - - - - —S> : O __ > : O. - - - - —S - - ———S - - - - —S - — - _—s - - - - —S - - _ - _3 16 H : - - - - _NH >=0 - - - - _N>=O - - - - —N \RN - - - - —NH \RN. wherein R16 and RN are as defined herein. According to the general formula ( | ) the fo|lowing compounds are especia||y preferred : 2 - ( 3 - ( ( R ) - 3 - ( 3 , 4 - dimethoxypheny| ) - 1 - ( ( S ) - 1 - ( 4 - ( pyrimidin - 2 - y| ) pheny|su|fonyl ) pipridine - 2 - carbony|oxy ) propyl ) phenoxy ) acetic acid , 2 - ( 3 - ( ( R ) - 1 - ( ( S ) - 1 - ( 3 - ch|orophenylsu|fonyl ) piperidine - 2 - carbonyloxy ) - 3 - ( 3 , 4 - dimethoxy pheny| ) propyl - phenoxy ) acetic acid , 2 - ( 3 - ( ( R ) - 1 - ( ( S ) - 1 - ( benzo [ d ] thiazol - 5 - y|su|fonyl ) piperidine - 2 - carbony|oxy ) - 3 - ( 3 , 4 - dimethoxy pheny| ) propy| ) phenoxy ) acetic acid , 2 - ( 3 - ( ( R ) - 3 - ( 3 , 4 - dimethoxypheny| ) - 1 - ( ( S ) - 1 - ( furan - 3 - ylsulfony| ) piperidine - 2 - carbony|oxy ) propy| ) phenoxy ) acetic acid , 2 - ( 3 - ( ( R ) - 1 - ( ( S ) - 1 - ( benzo [ b ] thiophen - 2 - ylsu|fony| ) piperidine - 2 - carbonyloxy ) - 3 - ( 3 , 4 - dimeth xy pheny| propyl ) phenoxy ) acetic acid , 2 - ( 3 - ( ( R ) - 1 - ( ( S ) - 1 - ( 3 - cyanopheny|su|fonyl ) piperidine - 2 - carbonyloxy ) - 3 - ( 3 , 4 - dimethoxyphen - y| ) propy| ) phenoxy ) acetic acid , 2 - ( 3 - ( ( R ) - 3 - ( 3 , 4 - dimethoxypheny| ) - 1 - ( ( S ) - 1 - ( 3 - nitrophenylsulfony| ) piperidine - 2 - carbony|o - xy propy| ) phenoxy ) acetic acid , 2 - ( 3 - ( ( R ) - 3 - ( 3 , 4 - dimethoxypheny| ) - 1 - ( ( S ) - 1 - ( 3 - ( 2 - methy|pyrimidin - 4 - y| ) phenylsu|fony| ) piperidine - 2 - carbony|oxy ) propy| ) phenoxy ) acetic acid , 2 - ( 3 - ( ( R ) - 3 - ( 3 , 4 - dimethoxypheny| ) - 1 - ( ( S ) - 1 - ( 3 - ( pyrimidin - 4 - yl ) pheny| su|fony| ) piperidine - 2 - carbony|oxy ) propy| ) phenoxy ) acetic acid , . 10. 15. 20. 25. 30. 35. 40. 45. 50. WO 2013 / 097947 PCT / EP2012 / 005387 25. 2 - ( 3 - ( ( R ) - 1 - ( ( S ) - 1 - ( 3 , 5 - dich|oropheny|sulfony| ) piperidine - 2 - carbony|oxy ) - 3 - ( 3 , 4 - dimethoxy - pheny| ) propy| ) phenoxy ) acetic acid , 2 - ( 3 - ( ( R ) - 1 - ( ( S ) - 1 - ( 2 , 3 - dich|oropheny|sulfonyl ) piperidine - 2—carbony|oxy ) - 3 - ( 3 , 4 - dimethoxy pheny| ) propyl ) phenoxy ) acetic acid , 2 - ( 3 - ( ( R ) - 3 - ( 3 , 4 - dimethoxypheny| ) - 1 - ( ( S ) - 1 - ( 3 , 4 - dimethoxypheny|sulfony| ) piperidine - 2 - carbony|oxy ) propyl ) phenoxy ) acetic acid , 2 - ( 3 - ( ( R ) - 1 - ( ( S ) - 1— ( 3 , 5 - bis ( trif|uoromethyl ) pheny|su|fonyl ) piperidine - 2 - carbonyloxy ) - 3 - ( 3 , 4 - dimethoxypheny| ) propy| ) phenoxy ) acetic acid , 2 - ( 3 - ( ( R ) - 1 - ( ( S ) - 1 - ( 3 - bromo - 5 - ( triﬂuoromethy| ) phenylsu|fony| ) piperidine - 2 - carbony|oxy ) - 3 - ( 3 , 4 - dimethoxypheny| ) propy| ) phenoxy ) acetic acid , 2 - ( 3 - ( ( R ) - 1 - ( ( S ) - 1 - ( 3 , 5 - dich|oro - 4 - hydroxypheny|su|fony| ) piperidine - 2 - carbony|oxy ) - 3 - ( 3 , 4 - dimethoxypheny| ) propy| ) phenoxy ) acetic acid , 2 - ( 3 - ( ( R ) —1 - ( ( S ) - 1 - ( 3 , 5 - dichloro - 4 - methoxypheny|su|fony| ) piperidine - 2 - carbony|oxy ) - 3 - ( 3 , 4 - dimethoxyphenyl ) propyl ) phenoxy ) acetic acid , ( S ) - ( ( R ) - 3 - ( 3 , 4 - dimethoxypheny| ) - 1 - ( 3 - ( 2 - morpho|inoethoxy ) phenyl ) propy| ) 1 - ( 3 , 5 - dich|oro - pheny|su|fony| ) piperidine - 2 - carboxy|ate , ( S ) - ( ( R ) - 3 - ( 3 , 4 - dimethoxypheny| ) - 1 - ( 3 - ( 2 - morpho|inoethoxy ) pheny| ) prop - y| ) 1 - ( benzo [ d ] thi - azo| - 6 - y|sulfony| ) piperidine - 2 - carboxylate , ( S ) - ( ( R ) - 3 - ( 3 , 4 - dimethoxypheny| ) - 1 - ( 3 - ( 2 - morpho|inoethoxy ) pheny| ) propy| ) 1 - ( 3 , 5 - dichloro - 4 - hydroxypheny|su|fony| ) piperidine - 2 - carboxy|ate , ( S ) - ( ( R ) - 3 - ( 3 , 4 - dimethoxyphenyl ) - 1 - ( 3 - ( 2 - morpho|inoethoxy ) pheny| ) propy| ) 1 - ( 3 , 5 - dichloro - 4 - methoxypheny|su|fonyl ) piperidine - 2 - carboxy|ate , ( S ) — ( ( R ) - 3 - ( 3 , 4 - dimethoxypheny| ) - 1 - ( 3 - ( 2 - morpho|inoethoxy ) pheny| ) propyl ) 1 - ( 2 - oxo - 2 , 3 - dihydrobenzo [ d ] thiazo| - 6 - ylsulfony| ) piperidine - 2 - carboxylate , 2 - ( 3 - ( ( R ) - 3 - ( 3 , 4 - dimethoxyphenyl ) - 1 - ( ( S ) - 1 - ( 2 - oxoindo|in - 5 - y|su|fony| ) piperidine—2 - carbony|oxy ) propyl ) phenoxy ) acetic acid , 2 - ( 3 - ( ( R ) - 3 - ( 3 , 4 - dimethoxyphenyl ) - 1 - ( ( S ) - 1 - ( 2 - oxo - 2 , 3 - dihydrobenzo [ d ] oxazo| - 6 - y|su|fony| ) piperidine - 2 - carbony|oxy ) propy| ) phenoxy ) aceticacid , 2 - ( 3 - ( ( R ) - 1 - ( ( S ) - 1 - ( 4 - acetamido - 3 , 5 - dich|oropheny|su|fony| ) piperidine - 2 - carbo ny|oxy ) - 3 - ( 3 , 4 - dimethoxypheny| ) propy| ) phenoxy ) acetic acid , 5 - ( ( S ) - 2 - ( ( ( R ) - 1 - ( 3 - ( carboxymethoxy ) pheny| ) —3 - ( 3 , 4 - dimethoxyphenyl ) propoxy ) carbony| ) piperidin - 1 - y|su|fony| ) - 2 , 3 - dimethoxybenzoic acid , 2 - ( 3 - ( ( R ) - 3 - ( 3 , 4 - dimethoxypheny| ) - 1 - ( ( S ) - 1 - ( 7 - nitr0 - 2 , 3 - dihyd robenzofu ran - 5 - y|sulfony| ) piperidine - 2 - carbony|oxy ) propy| ) phenoxy ) acetic acid , . 10. 15. 2O. 25. 30. 35. 40. 45. 50. WO 2013 / 097947 PCT / EP2012 / 005387 26. 2 - ( 3 - ( ( R ) - 1 - ( ( S ) - 1 - ( 7 - amino - 2 , 3 - dihydrobenzofuran - 5 - ylsu|fony| ) piperidine - 2 - carbony|oxy ) - 3 - ( 3 , 4 - dimethoxypheny| ) propy| ) phenoxy ) aceticacid , 2 - ( 3 - ( ( R ) - 3 - ( 3 , 4 - dimethoxypheny| ) - 1 - ( ( S ) - 1 - ( 2 - methy|benzo [ d ] thiazo| - 6 - y|su|f ony| ) piperidine - 2 - carbony|oxy ) propy| ) phenoxy ) acetic acid , 2 - ( 3 - ( ( R ) - 3 - ( 3 , 4 - dimethoxypheny| ) - 1 - ( ( S ) - 1 - ( 2 - oxo - 2 , 3 - dihyd robenzo [ d ] thiazol - 6— ylsulfony| ) piperidine - 2 - carbony|oxy ) propy| ) phenoxy ) aceticacid , 2 - ( 3 - ( ( R ) - 1 - ( ( S ) - 1 - ( 3 , 5 - bis ( methoxycarbony| ) pheny|su|fonyl ) piperidine - 2 - carbonyoxy ) - 3 - ( 3 , 4 - dimethoxypheny| ) propyl ) phenoxy ) acetic acid , 2 - ( 3 - ( ( R ) - 1 - ( ( S ) - 1 - ( 3 , 5 - dif|uoropheny|su|fony| ) piperidine - 2 - carbony|oxy ) - 3 - ( 3 , 4 - dimethoxypheny| ) propy| ) phenoxy ) acetic acid , 2 - ( 3 - ( ( R ) - 1 - ( ( S ) - 1 - ( 3 - chloro - 4 - methoxypheny|su|fony| ) piperidine - 2 - carbony|oxy ) - 3 - ( 3 , 4 - dimethoxyphenyl ) propy| ) phenoxy ) aceticacid , 2— ( 3 - ( ( R ) - 3 - ( 3 , 4 - dimethoxyphenyl ) - 1 - ( ( S ) - 1 - ( 3 - ﬂuoropheny|sulfonyl ) piperidine - 2 - carbony|oxy ) propyl ) phenoxy ) acetic acid , 2 - ( 3 - ( ( R ) - 1 - ( ( S ) - 1 - ( 3 - bromopheny|su|fonyl ) piperidine - 2—carbony|oxy ) - 3 - ( 3 , 4 - dimethoxypheny| ) propy| ) phenoxy ) acetic acid , 2 - ( 3 - ( ( R ) - 1 - ( ( S ) —1 - ( 3 - aminopheny|su|fony| ) piperidine - 2 - ca rbonyloxy ) - 3 - ( 3 , 4 - dimethoxypheny| ) propy| ) phenoxy ) acetic acid. 2 - ( 3 - ( ( R ) - 1 - ( ( S ) - 1 - ( 4 - ch|oropheny|su|fony| ) piperidine - 2 - carbonyloxy ) - 3 - ( 3 , 4 - dimethoxypheny| ) propy| ) phenoxy ) acetic acid , 2 - ( 3 - ( ( R ) - 1 - ( ( S ) - 1 - ( 4 - tert - buty|pheny|su|fonyl ) piperidine - 2 - carbony|oxy ) - 3 - ( 3 , 4 - dimethoxypheny| ) propy| ) phenoxy ) acetic acid , 2 - ( 3 - ( ( R ) - 3 - ( 3 , 4 - dimethoxypheny| ) - 1 - ( ( S ) - 1 - ( 4 - f|uoropheny|sulfonyl ) piperidine - 2 - carbony|oxy ) propy| ) phenoxy ) acetic acid , 2 - ( 3 - ( ( R ) - 1 - ( ( S ) - 1 - ( 4 - chlorobenzy|su|fony| ) piperidine - 2 - carbony|oxy ) - 3 - ( 3 , 4 - dimethoxyphenyl ) propyl ) phenoxy ) acetic acid , 2 - ( 3 - ( ( R ) - 3 - ( 3 , 4 - dimethoxyphenyl ) - 1 - ( ( S ) - 1 - ( 4 - ( trif|uoromethyl ) pheny|sulfonyl ) piperidine - 2 - carbonyloxy ) propy| ) phenoxy ) acetic acid , ' 2 - ( 3 - ( ( R ) - 3 - ( 3 , 4 - dimethoxypheny| ) - 1 - ( ( S ) - 1 - ( 4 - phenoxypheny|su|fony| ) piperidine - 2 - carbonyloxy ) propy| ) phenoxy ) acetic acid , 2 - ( 3 - ( ( R ) - 3— ( 3 , 4 - dimethoxyphenyl ) - 1 - ( ( S ) - 1 - ( pyridin - 3 - y|su|fony| ) piperidine - 2 - carbony|oxy ) propy| ) phenoxy ) acetic acid , 2 - ( 3 - ( ( R ) - 3 - ( 3 , 4 - dimethoxypheny| ) - 1 - ( ( S ) - 1 - ( 6 - phenoxypyridin - 3 - y|su|fony| ) piperidine - 2 - carbony|oxy ) propy| ) phenoxy ) acetic acid , . 10. 15. 20. 25. 30. 35. 40. 45. 50. WO 2013 / 097947 PCT / EP2012 / 005387 27. 2 - ( 3 - ( ( R ) - 3 - ( 3 , 4 - dimethoxyphenyl ) - 1 - ( ( S ) - 1 - ( 6 - pheny|pyridin - 3 - ylsu|fonyl ) piperidine - 2 - carbony|oxy ) propy| ) phenoxy ) acetic acid , 2 - ( 3 - ( ( R ) - 1 - ( ( S ) - 1 - ( 2 - chloropheny|su|fonyl ) piperidine - 2 - carbonyloxy ) - 3 - ( 3 , 4 - dimethoxypheny| ) propy| ) phenoxy ) acetic acid , 2 - ( 3 - ( ( R ) - 1 - ( ( S ) - 1 - ( 2 , 6 - dich|oropheny|su|fony| ) piperidine - 2 - carbonyloxy ) - 3 - ( 3 , 4 - dimethoxyphenyl ) propyl ) phenoxy ) acetic acid , 2 - ( 3 - ( ( R ) - 3 - ( 3 , 4 - dimethoxyphenyl ) - 1 - ( ( S ) - 1 - ( 3 - ( 5 - methy|—1 , 3 , 4 - oxadiazo| - 2 - y| ) pheny|su|fony| ) piperidine - 2 - carbonyloxy ) propyl ) phenoxy ) acetic acid , 2 - ( 3 - ( ( R ) - 1 - ( ( S ) - 1 - ( 3 - ch|oro - 4 - ( trif|uoromethy| ) pheny|su|fonyl ) piperidine - 2 - carbony|oxy ) - 3 - ( 3 , 4 - dimethoxyphenyl ) propyl ) phenoxy ) acetic acid , 2 - ( 3 - ( ( R ) - 3 - ( 3 , 4 - dimethoxypheny| ) - 1 - ( ( S ) - 1 - ( 1 - methy| - 1H - indo| - 4 - ylsu|fony| ) piperidine - 2 - carbony|oxy ) propyl ) phenoxy ) acetic acid , 2— ( 3 - ( ( R ) - 3 - ( 3 , 4 - dimethoxypheny| ) - 1 - ( ( S ) —1 - ( 1 - methy| - 1H—indol - 5 - y|su|fony| ) piperidine - 2 - carbony|oxy ) propy| ) phenoxy ) acetic acid , 2 - ( 3 - ( ( R ) - 3 - ( 3 , 4 - dimethoxyphenyl ) - 1 - ( ( S ) - 1 - ( 4 - methy|—3 , 4 - dihydro - 2H— benzo [ b ] [ 1 , 4 ] oxazin - 6 - y|su|fonyl ) piperidine - 2 - carbonyloxy ) propyl ) phenoxy ) acetic acid , 2 - ( 3 - ( ( R ) - 3 - ( 3 , 4 - dimethoxypheny| ) —1 - ( ( S ) - 1 - ( 4 - methyl - 3 , 4 - dihydro - 2H - pyrido [ 3 , 2 - b ] [ 1 , 4 ] oxazin - 7 - y|su|fony| ) piperidine - 2 - carbony|oxy ) propy| ) phenoxy ) acetic acid , 2 - ( 3 - ( ( R ) - 3 - ( 3 , 4 - dimethoxyphenyl ) - 1 - ( ( S ) - 1 - ( fura n - 3 - y|su|fonyl ) piperidine - 2 - carbononxy ) propy| ) phenoxy ) acetic acid , 2 - ( 3 - ( ( R ) - 1 - ( ( S ) - 1 - ( benzofuran - 2 - ylsu|fony| ) piperidine - 2 - carbony|oxy ) - 3 - ( 3 , 4 - dimethoxyphenyl ) propy| ) phenoxy ) acetic acid , 2 - ( 3 - ( ( R ) - 3 - ( 3 , 4 - dimethoxypheny| ) - 1 - ( ( S ) - 1 - ( thiophen - 2 - y|su|fonyl ) piperidine - 2 - carbonyloxy ) propy| ) phenoxy ) acetic acid , 2 - ( 3 - ( ( R ) - 3 - ( 3 , 4 - dimethoxypheny| ) - 1 - ( ( S ) - 1 - ( 5 - pheny|thiophen - 2 - y|su|fony| ) piperidine - 2 - carbony|oxy ) propy| ) phenoxy ) acetic acid , 2— ( 3 - ( ( R ) - 1 - ( ( S ) - 1 - ( benzo [ b ] thiophen - 3 - ylsu|fony| ) piperidine - 2 - carbony|oxy ) - 3 - ( 3 , 4 - dimethoxyphenyl ) propy| ) phenoxy ) acetic acid , ‘ 2 - ( 3 - ( ( R ) - 3 - ( 3 , 4 - dimethoxypheny| ) - 1 - ( ( S ) - 1 - ( 3 , 5 - dimethy|isoxazo| - 4— y|su|fony| ) piperidine - 2 - carbonyloxy ) propyl ) phenoxy ) acetic acid , . 2 - ( 3 - ( ( 1 R ) - 3 - ( 3 , 4 - dimethoxyphenyl ) - 1— ( ( 2S ) —1 - ( 1 - methy| - 4 , 5 - dihydro - 1 H - pyrazo| - 5 - y|su|fony| ) piperidine - 2 - carbonyloxy ) propy| ) phenoxy ) acetic acid , 2 - ( 3 - ( ( R ) - 3 - ( 3 , 4 - dimethoxypheny| ) - 1 - ( ( S ) - 1 - ( 1 - methy| - 1H - imidazo| - 4 - ylsu|fonyl ) piperidine - 2 - carbonyloxy ) propyl ) phenoxy ) acetic acid , . 10. 15. 20. 25. 30. 35. 4O. W0 2013 / 097947 PCT / EP2012 / 005387 28 2 - ( 3 - ( ( R ) - 3 - ( 3 , 4 - dimethoxypheny| ) - 1 - ( ( S ) - 1 - ( 1 , 3 , 5 - trimethyl - 1 H—pyrazo| - 4 - y|su|fony| ) piperidine - 2 - carbony|oxy ) propy| ) phenoxy ) acetic acid , . 2 - ( 3 - ( ( R ) - 3 - ( 3 , 4 - dimethoxyphenyl ) - 1 - ( ( S ) - 1 - ( 3 , 5 - dimethyl - 1 - pheny| - 1H - pyrazol - 4 - ylsu|fony| ) piperidine - 2 - carbony|oxy ) propyl ) phenoxy ) acetic acid , . 2 - ( 3 - ( ( R ) - 3 - ( 3 , 4 - dimethoxypheny| ) - 1 - ( ( S ) - 1 - tosy|piperidine - 2 - carbonyloxy ) propy| ) phenoxy ) acetic acid , . 2 - ( 3 - ( ( R ) - 3 - ( 3 , 4 - dimethoxyphenyl ) - 1 - ( ( S ) - 1 - ( 4 - nitropheny|sulfonyl ) piperidine - 2 - carbony|oxy ) propy| ) phenoxy ) acetic acid , . ( S ) - ( ( R ) - 3 - ( 3 , 4 - dimethoxypheny| ) - 1 - ( 3— ( 2 - morpholinoethoxy ) phenyl ) propy| ) 1 - ( 4 - acetamido - 3 , 5 - dich|oropheny|sulfony| ) piperidine - 2 - carboxy|ate. As used herein , the term “heterocyc|ic 5 - membered ring" refers to a substituted or non substituted ring system of five atoms inc|uding at least one heteroatom such as O , S , SO , SO2 , N , wherein two of the five ring atoms are carbon atoms that be|ong to a pheny| ring , forming in tota| a [ 4 , 3 , 0 ] bicyc|us. m that , the heterocyc|ic 5 - membered ring and the pheny| ring are fused as they share two carbon atoms. As used herein , the term “heterocyc|ic 6 - membered ring" refers to a substituted or non substituted ring system of six atoms inc|uding at least one heteroatom such as O , S , SO , SO2 , N , wherein two of the six ring atoms are carbon atoms that be|ong to a pheny| ring , forming in tota| a [ 4 , 4 , 0 ] bicyc|us. |n that , the heterocyc|ic 6 - membered ring and the pheny| ring are fused as they share two carbon atoms. The present invention also comprises pharmaceutica||y acceptable sa|ts of the compounds according to the genera| formula ( | ) , ( || ) , ( l|l ) , ( |V ) , ( V ) , ( V| ) , ( V|| ) and ( V||| ) a|l stereoisomeric forms of the compounds according to the general formu|a ( | ) , ( ll ) , ( |l| ) , ( |V ) , ( V ) , ( V| ) , ( V|| ) and ( V||l ) as we|| as so|vates and hydrates thereof. |n case , the inventive compounds bear basic and / or acidic substituents , they may form sa|ts with organic or inorganic acids or bases. Examp|es of suitab|e acids for such acid addition sa|t formation are hydroch|oric acid , hydrobromic acid , su|furic acid , phosphoric acid , acetic acid , citric acid , oxa|ic acid , malonic acid , sa|icy|ic acid , p - aminosa|icy|ic acid , ma|ic acid , fumaric acid , succinic acid , ascorbic acid , ma|eic acid , su|fonic acid , phosphonic acid , perchloric acid , nitric acid , formic acid , propionic acid , gluconic acid , |actic acid , tartaric acid , hydroxyma|eic acid , pyruvic acid , pheny|acetic acid , benzoic acid , p - aminobenzoic acid , p - hydroxybenzoic acid , methanesu|fonic acid , ethanesu|fonic acid , nitrous acid , hydroxyethanesu|fonic acid , ethy|enesu|fonic acid , p - toluenesu|fonic acid , naphthylsu|fonic acid , sulfani|ic acid , . 10. 15. 20. 25. 30. 35. WO 2013 / 097947 PCT / EP2012 / 005387 29. camphorsu|fonic acid , china acid , mande|ic acid , o - methylmandelic acid , hydrogenbenzenesulfonic acid , picric acid , adipic acid , d - o - to|y|tartaric acid , tartronic acid , ( o , m , p ) - to|uic acid , naphthy|amine su|fonic acid , and other minera| or carboxylic acids we|l known to those ski||ed in the art. The sa|ts are prepared by contacting the free base form with a sufficient amount of the desired acid to produce a salt in the conventiona| manner. Examp|es for suitable inorganic or organic bases are , for examp|e , NaOH , KOH , NH4OH , tetraalky|ammonium hydroxide , |ysine or arginine and the |ike. Sa|ts may be prepared in a conventiona| manner using methods wel| known in the art , for examp|e by treatment of a so|ution of the compound of the genera| formu|a ( | ) , ( || ) , ( ll| ) , ( |V ) , ( V ) , ( V| ) , ( V|| ) and ( Vl|| ) with a solution of an acid , selected out of the group mentioned above. Some of the compounds of the present invention may be crystal|ised or recrystallised from solvents such as aqueous and organic so|vents. m such cases so|vates may be formed. This invention inc|udes within its scope stoichiometric so|vates including hydrates as we|| as compounds containing variable amounts of water that may be produced by processes such as lyophi|isation. Certain compounds of the genera| formu|a ( | ) , ( l| ) , ( ||| ) , ( |V ) , ( V ) , ( V| ) , ( Vll ) and ( Vl|| ) may exist in the form of optica| isomers if substituents with at |east one asymmetric center are present , e. g. diastereoisomers and mixtures of isomers in a|| ratios , e. g. racemic mixtures. The invention includes al| such forms , in particu|ar the pure isomeric forms. The different isomeric forms may be separated or resolved one from the other by conventiona| methods , or any given isomer may be obtained by conventiona| synthetic methods or by stereospecific or asymmetric syntheses. Where a compound according to the genera| formu|a ( | ) , ( || ) , ( l|| ) , ( |V ) , ( V ) , ( V| ) , ( V|l ) or ( V||| ) contains an alkene moiety , the a|kene can be presented as a cis or trans isomer or a mixture thereof. When an isomeric form of a compound of the invention is provided substantia||y free of other isomers , it wi|| preferab|y contain |ess than 5% w / w , more preferab|y less than 2% w / w and especia||y |ess than 1% w / w of the other isomers. Another aspect of the present invention re|ates to the use of the inventive pipeco|ate - su|fonamide according to the general formu|a ( | ) , ( l| ) , ( ll| ) , ( lV ) , ( V ) , ( V| ) , ( V|| ) or ( V||l ) and derivatives thereof as drugs , i. e. as pharmaceutica||y active agents applicab|e in medicine. 10. lS. 20. 25. 30. 35. 40. WO 2013 / 097947 PCT / EP2012 / 005387 30. Surprisingly it was found that the above - mentioned pipeco|ate - su|fonamide derivatives as we|l as the pharmaceutica| compositions comprising said pipeco|ate - su|fonamide derivatives are usefu| for the inhibition of the FK506 binding proteins ( FKBP‘s ) , especial|y the inhibition of FKBP51 and 52. Therefore one aspect of the present invention is that the compounds according to the general formu|a ( | ) , ( || ) , ( ||| ) , ( |V ) , ( V ) , ( V| ) , ( V|| ) and ( V||| ) are suitab|e for use as inhibitor of FK506 - binding proteins ( FKBP ) . H is preferred if said compound is suitable for use as inhibitor of the FK506 - binding protein ( s ) 51 ( FKBP51 ) and 52 ( FKBP52 ) or for use as inhibitor of the FK506 - binding proteins FKBP51 and FKBP52. Thus , one aspect of the present invention is directed to the use of the compounds according to the genera| formu|a ( | ) , ( l| ) , ( ||| ) , ( lV ) , ( V ) , ( V| ) , ( V|l ) and ( V||| ) for the inhibition of the FK506 - binding protein ( s ) 51 ( FKBP51 ) and / or 52 ( FKBP52 ) . |n that , one embodiment of the present invention is directed to the use of the compounds according to the genera| formu|a ( | ) , ( l| ) , ( l|| ) , ( lV ) , ( V ) , ( V| ) , ( V|| ) and ( V||l ) for the treatment and prophy|axis of diseases as defined below. FKBP inhibitors as used herein is defined as compounds that inhibit the peptidylprolyl isomerase activity of FKBPs ( PPlase inhbitors , also referred to as rotamase inhibitors ) and compounds that disp|ace FK506 or FK506 ana|ogs form the PP|ase active site of FKBPs. Thus , the pipeco|ate - su|fonamide compounds of the present invention can be used for treatment , or for the preparation of a pharmaceutica| formu|ation for prophy|axis and treatment of psychiatric and neurodegenerative diseases , disorders and conditions , for neuroprotection or neuroregeneration , for the treatment of neuro|ogical disorders , for the treatment of diseases re|ating to neurodegeneration , for the treatment of cancers and especia||y steroid - hormone dependent cancers , for the treatment of g|ucocorticoid hyposensitivity syndromes and for periphera| g|ucocorticoid resistance , and for the treatment of infectious diseases , for the treatment of a|opecia and promoting hair growth , for the treatment or prevention of multi - drug resistance , for stimulating neurite growth , for the use as wound hea|ing agents for treating wounds resu|ting from injury or surgery ; for the use in antiglaucomatous medications for treating abnormal|y e|evated intraocu|ar pressure ; for the use in |imiting or preventing hemorrhage or neovascu|arization for treating macu|ar degeneration , and for treating oxidative damage to eye tissues , for treating a vision disorder , for improving vision , for treating memory impairment or enhancing memory performance. 10. 15. 20. 25. 3O. 35. 40. W0 2013 / 097947 PCT / EP2012 / 005387 31. Thus , the pipecolate - su|fonamide compounds of the present invention may further be used for induction of abortion and especially the inhibition of embryo imp|antation. The pipecolate - su|fonamide compounds of the present invention are preferab|y suitab|e for treatment , or for the preparation of a pharmaceutica| formulation for prophylaxis and treatment of psychiatric diseases. H is especially preferred if this psychiatric diseases is an affective disorder ( |CD - 1O c|assification : F30 - F39 ) or an anxiety disorder. Affective disorder is a menta| disorder characterized by dramatic changes or extremes of mood. The affective disorder according to the invention is se|ected from the group comprising or consisting of depression , bipo|ar disorder , mania , substance induced mood disorder and seasona| affective disorder ( SAD ) . Among the psychiatric diseases and disorders , the most preferred is depression , the most commonly diagnosed psychiatric disorder. The anxiety disorder according to the invention is se|ected from the group comprising or consisting of genera|ized anxiety disorder , panic disorder , panic disorder with agoraphobia , phobias , obsessive—compu|sive disorder , post - traumatic stress disorder , separation anxiety and childhood anxiety disorders. Among the hundreds of different neurodegenerative disorders , the attention has been given on|y to a handful , inc|uding A|zheimer ' s Disease , Parkinson ' s Disease , and amyotrophic |atera| sclerosis. Among the g|ucocorticoid hyposensitivity syndromes , the attention has been given to the group of re|ated diseases enclosing resistant asthma , AlDS , rheumatoid arthritis , hypertension and obesity. Among the cancers , the attention has been given to ma|ignant melanoma , steroidhormone dependent cancers or prostate cancer. Among the hundreds of infectious diseases , the attention has been given to malaria and the Legionnaires disease. Among the vision disorders , the attention has been given to visua| impairments ; orbital disorders ; disorders of the |acrima| apparatus ; disorders of the eye|ids ; disorders of the conjunctiva ; disorders of the Cornea ; cataract ; disorders of the uveatract ; disorders of the retina ; disorders of the optic nerve or visua| pathways ; free radica| induced eye disorders and diseases ; immuno|ogical|y - mediated eye disorders and diseases ; eye injuries ; and symptoms and comp|ications of eye disease , eye disorder , or eye injury. 10. 15. 2O. 25. 3O. 35. 40. WO 2013 / O97947 PCT / EP2012 / O05387 32. Therefore , another aspect of the present invention is directed to pharmaceuticacompositions comprising at least one compound of the present invention as active ingredient , together with at least one pharmaceutical|y acceptab|e carrier , excipient and / or di|uents or so|vents. The pharmaceutica| compositions of the present invention can be prepared in a conventiona| solid or |iquid carrier or diluent and a conventional pharmaceutica||y - made adjuvant at suitab|e dosage level in a known way. The preferred preparations are adapted for ora| app|ication. These administration forms inc|ude , for examp|e , pi|ls , tab|ets , fi|m tab|ets , coated tab|ets , capsules , powders and deposits. Furthermore , the present invention also inc|udes pharmaceutica| preparations for parentera| app|ication , inc|uding derma| , intradermaL intragastraL intracutan , intravasa| , intravenous , intramuscular , intraperitonea| , intranasal , intravagina| , intrabuccal , percutan , recta| , subcutaneous , sublingual , topical , or transdermaapplication , which preparations in addition to typica| vehic|es and / or diluents contain at |east one compound according to the present invention and / or a pharmaceuticaacceptable sa|t thereof as active ingredient. The pharmaceutica| compositions according to the present invention containing at |east one compound according to the present invention , and / or a pharmaceuticaacceptable salt thereof as active ingredient wi|| typical|y be administered together with suitab|e carrier materia|s se|ected with respect to the intended form of administration , i. e. for ora| administration in the form of tab|ets , capsu|es ( either solid fi|led , semi - so|id fi|led or |iquid fi||ed ) , powders for constitution , extrudates , deposits , ge|s , e|ixirs , dispersab|e granu|es , syrups , suspensions , and the |ike , and consistent with conventiona| pharmaceutica| practices. For examp|e , for ora| administration in the form of tab|ets or capsu|es , the active drug component may be combined with any ora| non - toxic pharmaceutical|y acceptab|e carrier , preferab|y with an inert carrier |ike |actose , starch , sucrose , cel|u|ose , magnesium stearate , dica|cium phosphate , calcium su|fate , ta|c , mannito| , ethy| a|coho| ( |iquid fi||ed capsu|es ) and the |ike. Moreover , suitab|e binders , lubricants , disintegrating agents and co|oring agents may a|so be incorporated into the tab|et or capsu|e. Powders and tab|ets may contain about 5 to about 95 weight % of the benzothiophene - 1 , 1 - dioxide derived compound and / or the respective pharmaceutica||y active sa|t as active ingredient. Suitab|e binders inc|ude starch , gelatin , natural sugars , corn sweeteners , natura| and synthetic gums such as acacia , sodium a|ginate , carboxymethy|cel|ulose , po|yethy|ene g|yco| and waxes. Among suitab|e |ubricants there may be mentioned boric acid , sodium benzoate , sodium acetate , sodium ch|oride , and the like. Suitab|e. 10. 15. 20. 25. 3O. 35. W0 2013 / 097947 PCT / EP2012 / 005387 33 disintegrants inc|ude starch , methy|ce|lu|ose , guar gum , and the |ike. Sweetening and f|avoring agents as we|l as preservatives may also be inc|uded , where appropriate. The disintegrants , di|uents , lubricants , binders etc. are discussed in more detail below. Moreover , the pharmaceutica| compositions of the present invention may be formu|ated in sustained re|ease form to provide the rate contro||ed re|ease of any one or more of the components or active ingredients to optimise the therapeutic effect ( s ) , e. g. antihistaminic activity and the |ike. Suitab|e dosage forms for sustained release include tablets having layers of varying disintegration rates or contro||ed re|ease po|ymeric matrices impregnated with the active components and shaped in tab|et form or capsu|es containing such impregnated or encapsu|ated porous po|ymeric matrices. Liquid form preparations inc|ude so|utions , suspensions , and emu|sions. As an example , there may be mentioned water or water / propylene g|ycol solutions for parentera| injections or addition of sweeteners and opacifiers for oral so|utions , suspensions , and emu|sions. Liquid form preparations may a|so include so|utions for intranasa| administration. Aerosol preparations suitab|e for inha|ation may inc|ude so|utions and solids in powder form , which may be present in combination with a pharmaceutica||y acceptab|e carrier such as an inert , compressed gas , e. g. nitrogen. For preparing suppositories , a low me|ting fat or wax , such as a mixture of fatty acid g|ycerides |ike cocoa butter is me|ted first , and the active ingredient is then dispersed homogeneously therein e. g. by stirring. The molten , homogeneous mixture is then poured into convenient|y sized moulds , al|owed to coo| , and thereby so|idified. A|so inc|uded are so|id form preparations which are intended to be converted , short|y before use , to |iquid form preparations for either ora| or parenteral administration. Such liquid forms include solutions , suspensions , and emu|sions. The compounds according to the present invention may a|so be de|ivered transderma||y. The transderma| compositions may have the form of a cream , a lotion , an aerosol and / or an emu|sion and may be inc|uded in a transderma| patch of the matrix or reservoir type as is known in the art for this purpose. The term capsu|e as recited herein refers to a specific container or enc|osure made e. g. of methy| cel|u|ose , po|yviny| a|coho|s , or denatured ge|atins or starch for ho|ding or containing compositions comprising the active ingredient ( s ) . Capsu|es with hard she||s are typica||y made of b|ended 0f re|ative|y high gel strength ge|atins from. 10. 15. 2O. 25. 3O. 35. 40. W0 2013 / 097947 PCT / EP2012 / 005387 34. bones or pork skin. The capsu|e itse|f may contain smal| amounts of dyes , opaquing agents , p|asticisers and / or preservatives. Under tab|et a compressed or moulded solid dosage form is understood which comprises the active ingredients with suitab|e di|uents. The tab|et may be prepared by compression of mixtures or granu|ations obtained by wet granu|ation , dry granulation , or by compaction we|| known to a person of ordinary ski” in the art. Oral ge|s refer to the active ingredients dispersed or so|ubi|ised in a hydrophilic semisolid matrix. Powders for constitution refers to powder blends containing the active ingredients and suitab|e di|uents which can be suspended e. g. in water or in juice. Suitab|e di|uents are substances that usua||y make up the major portion of the composition or dosage form. Suitab|e di|uents inc|ude sugars such as |actose , sucrose , mannito| , and sorbitol , starches derived from wheat , corn rice , and potato , and ce||uloses such as microcrysta||ine cellu|ose. The amount of di|uent in the composition can range from about 5 to about 95 % by weight of the total composition , preferab|y from about 25 to about 75 weight % , and more preferab|y from about 3O to about 60 weight %. The term disintegrants refers to materials added to the composition to support break apart ( disintegrate ) and release the pharmaceutica||y active ingredients of a medicament. Suitab|e disintegrants include starches , “cold water so|ub|e" modified starches such as sodium carboxymethyl starch , natura| and synthetic gums such as |ocust bean , karaya , guar , tragacanth and agar , ce||ulose derivatives such as methy|ce||u|ose and sodium carboxymethy|ce||u|ose , microcrysta|line ce||u|oses , and cross - |inked microcrysta||ine cel|u|oses such as sodium croscaramel|ose , a|ginates such as a|ginic acid and sodium a|ginate , c|ays such as bentonites , and effervescent mixtures. The amount of disintegrant in the composition may range from about 2 to about 20 weight % 0f the composition , more preferab|y from about 5 to about 1O weight %. Binders are substances which bind or “g|ue" together powder partic|es and make them cohesive by forming granu|es , thus serving as the “adhesive" in the formulation. Binders add cohesive strength a|ready avai|ab|e in the di|uent or bu|king agent. Suitab|e binders inc|ude sugars such as sucrose , starches derived from wheat corn rice and potato , natural gums such as acacia , ge|atin and tragacanth , derivatives 0f seaweed such as a|ginic acid , sodium alginate and ammonium calcium a|ginate , cel|u|ose materia|s such as methy|ce||u|ose , sodium carboxymethylce||u|ose and hydroxypropylmethy|ce||u|ose , po|yviny|pyrro|idone , and inorganic compounds such as magnesium a|uminum silicate. The amount of binder in the composition may. 10. 15. 20. 25. 3O. 35. WO 2013 / O97947 PCT / EP2012 / O05387 35. range from about 2 to about 2O weight % of the composition , preferab|y from about 3 to about 10 weight % , and more preferab|y from about 3 to about 6 weight %. Lubricants refer to a c|ass of substances which are added to the dosage form to enab|e the tab|et granu|es etc. after being compressed to re|ease from the mould or die by reducing friction or wear. Suitable |ubricants inc|ude meta||ic stearates such as magnesium stearate , ca|cium stearate , or potassium stearate , stearic acid , high me|ting point waxes , and other water soluble |ubricants such as sodium ch|oride , sodium benzoate , sodium acetate , sodium oleate , po|yethy|ene g|yco|s and D , L - |eucine. Lubricants are usua||y added at the very |ast step before compression , since they must be present at the surface of the granu|es. The amount of |ubricant in the composition may range from about 0.2 to about 5 weight % of the composition , preferab|y from about 0.5 to about 2 weight % , and more preferab|y from about 0.3 to about 1.5 weight % of the composition. G|idents are materia|s that prevent caking of the components of the pharmaceuticacomposition and improve the ﬂow characteristics of granulate so that flow is smooth and uniform. Suitable glidents inc|ude si|icon dioxide and ta|c. The amount of g|ident in the composition may range from about 0.1 to about 5 weight % of the finacomp0siti0n , preferab|y from about 0.5 to about 2 weight %. Co|oring agents are excipients that provide co|oration to the composition or the dosage form. Such excipients can include food grade dyes adsorbed onto a suitable adsorbent such as c|ay or aluminum oxide. The amount of the co|oring agent may vary from about 0.1 to about 5 weight % of the composition , preferab|y from about 0.1 to about 1 weight %. Said pharmaceutica| compositions may further comprise at |east one active pipeco|ate su|fonamide of the genera| formu|a ( | ) , ( l| ) , ( |l| ) , ( lV ) , ( V ) , ( Vl ) , ( V|| ) and ( V||| ) . The pharmaceutica| compositions may further comprise at |east one further active agent. |t is preferred if this active agent is se|ected from the group consisting of antidepressant and other psychotropic drugs. |t is further preferred if the anti - depressant is se|ected from amitriptyline , amioxide clomipramine , doxepine , duloxetine , imipramine trimipramine , mirtazapine , reboxetine , cita|oprame , ﬂuoxetine , moc|obemide and sertraline. 10. 15. 20. WO 2013 / 097947 PCT / EP2012 / 0O5387 36. Examples. This ﬁrst FKBP domain consists of ﬁve antiparal|e| B - strands curved around a centra| or - he|ix , the usua| FK fo|d A three - dimensiona| alignment of the binding pockets of the first FKBP domain of FKBP 51 , of FKBP 52 ( FKBP51FK1 and FKBP52FK1 ) and FKBP12 revea|ed the |argest structura| divergences at the 80s |oop ( Serm - lle122 of FKBP51 / 52 ) . The 80s |oop of FKBP51 contains Leu119which is rep|aced by Pro119 in FKBP52 possibly contributing for the structural difference in this region. |mportant|y the residue at position 119 was shown to be a major functional determinant for the effect on steroid hormone receptor. Hence an optimization of interactions with this part of the protein has a higher probabi|ity of achieving se|ectivity and functionarelevance within the FKBP family. The X ray structure of FK506 with the FK1 ' domain of FKBP51 and FKBP52 revea|ed that the pyranose group in FK506 contacts the 80s loop. For a rapid derivatization of compounds targeting the 80s |oop we envisaged a so|id phase strategy for synthesis of a focused su|fonamide |ibrary. Generic route to pipeco|ate - su|fonamides. 1. DCC , DMAP , 0°C to r. t. 2. 20% 4 - Me - piperidine , CH2C|2 , r. t. , 5h. 7. R2 R1 R3 Qc O N R4 A 0 Rs m R10 R5 | A DlPEA , A - SO2C| , R9 O R7 R8. R10 R5 O CH2C|2 , r. t. , 16h R9 R7. . 10. 15. 20. 25. 3O. 35. 40. W0 2013 / 097947 PCT / EP2012 / 005387 37. Genera| procedure for the synthesis of pipecolate sulfonamides. A so|ution of the a|cohol a ) ( 15 mmo| ) , which has been synthesized as described in example 1 , pipeco|ic carboxy|ic acid ( 1.1 equ. ) , and DMAP ( 0.1 equ. ) in 50mL DCM at 0°C was treated with DCC ( 1.1 equ. ) . The mixture was a||owed to warm to room temperature and was stirred for 20h after which time the organic solvent was dried and the so|id was disso|ved in diethy| ether ( 50mL ) and filtered through a p|ug of ce|ite. The fi|trate was concentrated and then f|ash chromatographed to afford pipecolic ester. The Ester was immobi|ized on a 2 - Ch|oro trity|resin by coupling one of the substituents R1 - R10 with the trityl - chloride moieties of the resin. The coupled resin was weighed ( 210 mg , 0.08mmol ) and added to syringes , swollen in DCM ( 4 mL ) for 1h , and the Fmoc protecting group was removed using 20% 4 - methy| piperidine / DCM ( 4m| ) for 1h. After fi|tration , the resin was washed with DCM ( 3 x 5ml ) and was used for the next coup|ing step. To the above resin was added i - Pr2EtN ( 40mg , 0.32 mmol ) in dry DCM ( 3 mL ) and stirred for 20min. To this solution was added the su|fony| ch|oride ( A - SO2 - C| , 0.75 equ. ) in 500 pL of DCM and the reaction was stirred for 4h at room temperature. The coupling procedure was repeated. The resin was washed with DCM ( 3 x 5 ml ) and dried to give the derivatized resin which was re - swol|en in DCM and reacted with 1% TFA / DCM ( 3 m| ) for 1h to c|eave the su|fonamides from the resin. The combined fi|trates were concentrated in vacuo to afford the crude su|fonamides , which were further purified by preparative HPLC. By this genera| procedure the fol|owing pipeco|ate su|fonamides were synthesized : 2 - ( 3 - ( ( R ) - 3 - ( 3 , 4 - dimethoxypheny| ) - 1 - ( ( S ) - 1 - ( 4 - ( pyrimidin - 2 - y| ) pheny|su|fony| ) pipridine - 2 - carbony|oxy ) propyl ) phenoxy ) acetic acid ( compound 1 ) , 2 - ( 3 - ( ( R ) - 1 - ( ( S ) - 1 - ( 3 - chloropheny|sulfonyl ) piperidine - 2 - carbonyloxy ) - 3 - ( 3 , 4 - dimethoxy pheny| ) propy| - phenoxy ) acetic acid ( compound 2 ) , 2 - ( 3 - ( ( R ) - 1 - ( ( S ) - 1 - ( benzo [ d ] thiazo| - 5 - y|su|fony| ) piperidine - 2 - carbony|oxy ) - 3 - ( 3 , 4 - dimethoxy pheny| ) propy| ) phenoxy ) acetic acid ( compound 3 ) , 2 - ( 3 - ( ( R ) - 3 - ( 3 , 4 - dimethoxypheny| ) - 1 - ( ( S ) —1 - ( furan - 3 - y|su|fony| ) piperidine—2 - carbony|oxy ) propy| ) phenoxy ) acetic acid ( compound 4 ) , 2 - ( 3 - ( ( R ) - 1 - ( ( S ) - 1 - ( benzo [ b ] thiophen - 2 - y|sulfony| ) piperidine - 2 - carbony|oxy ) - 3 - ( 3 , 4 - dimeth xy phenyl propy| ) phenoxy ) acetic acid ( compound 5 ) , 2 - ( 3 - ( ( R ) - 1 - ( ( S ) - 1 - ( 3 - cyanopheny|su|fonyl ) piperidine - 2 - carbony|oxy ) - 3 - ( 3 , 4 - dimethoxyphen - yl ) propyl ) phenoxy ) acetic acid ( compound 6 ) , . 10. 15. 2O. 25. 30. 35. 4O. 45. 50. WO 2013 / O97947 PCT / EP2012 / O05387 38. 2 - ( 3 - ( ( R ) - - - 3 - , ( 3 4 - dimethoxypheny| ) 4 - ( ( S ) - 1 - - ( 3 - - nitrophenylsulfony| ) piperidine - - - 2 carbony|o - xy propy| ) phenoxy ) acetic acid ( compound 7 ) , . 2 - ( 3 - ( ( R ) - 1 - ( ( S ) - 1 - ( 3 - aminopheny|su|fony| ) piperidine - 2 - carbony|oxy ) - 3 - ( 3 , 4 - dimethoxypheny| ) propy| ) phenoxy ) acetic acid ( compound 8 ) , . 23 - ( - ( ( R ) - 3 - ( 3 , 4 - dimethoxypheny| ) - 1 - ( ( S ) - 1 - - ( 3 - ( 2 - m - ethy|pyrimidin - - 4 - - y - | ) phenysquony| ) piperidine - 2 - - - carbony|oxy ) pr0py| ) phenoxy ) acetic acid ( compound 9 ) , ) - 3. 23 - ( - ( ( R - ( 3 , 4 - - dimethoxypheny| ) - 1 - - ( ( S ) - - 1 - - ( - 3 - ( pyrimidin - - 4 - y| ) phenysulfonyl ) piperidine - 2 - carbony|oxy ) propy| ) phenoxy ) acetic acid ( compound 10 ) , . 2 - ( 3 - ( ( R ) - 3 - ( 3 , 4 - dimethoxypheny| ) - 1 - ( ( S ) - 1 - ( 3 - f|uorophenylsu|fony| ) piperidine - 2 - carbony|oxy ) propy| ) phenoxy ) acetic acid ( compound11 ) , 2 - ( 3 - ( ( R ) - 1 - ( ( S ) - 1 - ( 3 - bromophenylsu|fonyl ) piperidine - 2 - carbonyloxy ) - 3 - ( 3 , 4 - dimethoxypheny| ) propy| ) phenoxy ) acetic acid ( compound 12 ) , . - ( - 3 ( ( R ) - 1 - - S ( ( ) - 1 - ( 3 , 5 - - dich|oropheny|su|fony| ) piperidine - - 2 - carbony|oxy ) - - - 3 - ( 3 , 4 - dimethoxy - pheny| ) propy| ) phenoxy ) acetic acid ( compound 13 ) , . 2 - ( - ( ( R ) - - 1 - - ( ( S ) - 1 - ( 2 , 3 - dich|orophenylsu|fony| ) piperidine - - 2 - carbony|oxy ) - - - 3 ( 3 , 4 - dimethoxy phenyl ) propy| ) phenoxy ) acetic acid ( compound 14 ) , 2 - ( 3 - ( ( R ) - 3 - ( 3 , 4 - dimethoxypheny| ) - 1 - ( ( S ) - 1 - ( 3 , 4 - dimethoxyphenylsu|fony| ) piperidine - 2 - carbony|oxy ) propyl ) phenoxy ) acetic acid ( compound 15 ) , 2 - ( 3 - ( ( R ) - 1 - ( ( S ) - 1 - ( 3 - ch|oro - 4 - methoxypheny|sulfony| ) piperidine - 2 - carbony| oxy ) - 3 - ( 3 , 4 - dimethoxypheny| ) propy| ) phenoxy ) aceticacid ( compound 16 ) , . 2 - ( 3 - ( ( R ) - 1 - ( ( S ) - 1 - ( 3 , 5 - difluoropheny|su|fony| ) piperidine - 2 - - c - arb0ny|oxy ) - - - 3 ( 3 , 4 dimethoxypheny| ) propy| ) phenoxy ) acetic acid ( compound 17 ) , . - ( - 3 ( ( R ) - - 1 - ( ( S ) - 1 - , ( 3 5 - - bis ( triﬂuoromethyl ) pheny|sulfonyl ) piperidine - - - 2 - carbonyloxy ) - 3 - - , ( 3 4 - - dimethoxypheny| ) propy| ) phenoxy ) acetic acid ( compound 18 ) , . 2 - ( 3 - ( ( R ) - 1 - ( ( S ) - 1 - ( 3 - bromo - 5 - - ( trifluoromethy| ) pheny|su|f0nyl ) piperidine - - 2 - carbony|oxy ) - 3 - ( 3 , 4 - dimethoxypheny| ) propy| ) phenoxy ) acetic acid ( compound 19 ) , . 2— — ( - 3 ( ( R ) - 1 - ( ( S ) - 1 - ( 3 , 5 - bis ( methoxycarbony| ) pheny|sulfony| ) piperidine - - 2 - - carbonyoxy ) - 3 - , ( 3 4 - dimethoxypheny| ) propy| ) phenoxy ) acetic acid ( compound 20 ) , . 2 - - ( 3 - ( ( R ) - 1 - - ( ( S ) - 1 - , ( 3 5 - dich|oro - 4 - - hydroxypheny|su|fony| ) piperidine - - 2 - c - arbony|oxy ) - 3 - ( 3 , 4 - - dimethoxypheny| ) propyl ) phenoxy ) acetic acid ( compound 21 ) , . 2 - ( 3 ( ( R ) - - 1 - - ( ( S ) - 1 - ( 3 , 5 - dichloro - 4 - methoxypheny|su|fony| ) piperidine - - 2 - - - carbonyoxy ) - - 3 - - ( 3 , 4 - dimethoxypheny| ) propy| ) phenoxy ) acetic acid ( compound 22 ) , 2 - ( 3 - ( ( R ) - 1 - ( ( S ) - 1 - ( 4 - acetamido - 3 , 5 - dichlorophenyIsu|fony| ) piperidine - 2 - carbo ny|oxy ) - 3 - ( 3 , 4 - dimethoxypheny| ) propy| ) phenoxy ) acetic acid ( compound 23 ) , . 10. 15. 2O. 25. 3O. 35. 40. 45. 50. WO 2013 / 097947 PCT / EP2012 / 0O5387 39. 5 - ( ( S ) - 2 - ( ( ( R ) - 1 - ( 3 - ( carboxymethoxy ) pheny| ) - 3 - ( 3 , 4 - dimethoxypheny| ) propoxy ) carbony| ) piperidin - 1 - ylsu|fony| ) - 2 , 3 - dimethoxybenzoic acid ( compound 24 ) , 2 - ( 3 - ( ( R ) - 3 - ( 3 , 4 - dimethoxypheny| ) - 1 - ( ( S ) - 1 - ( 7 - nitro - 2 , 3 - dihydrobenzofuran - 5 - y|su|fony| ) piperidine - 2 - carbonyloxy ) propy| ) phenoxy ) acetic acid ( compound 25 ) , 2 - ( 3 - ( ( R ) - 1 - ( ( S ) - 1 - ( 7 - amino - 2 , 3 - dihydrobenzofuran - 5 - y|sulfony| ) piperidine - 2 - carbony|oxy ) - 3 - ( 3 , 4 - dimethoxypheny| ) propy| ) phenoxy ) aceticacid ( compound 26 ) , 2 - ( 3 - ( ( R ) - 3 - ( 3 , 4 - dimethoxypheny| ) - 1 - ( ( S ) - 1 - ( 2—methy|benzo [ d ] thiazo| - 6 - ylsu|f onyl ) piperidine - 2 - carbony|oxy ) propyl ) phenoxy ) acetic acid ( compound 27 ) , 2 - ( 3 - ( ( R ) - 3 - ( 3 , 4 - dimethoxypheny| ) - 1 - ( ( S ) - 1 - ( 2 - oxo - 2 , 3 - dihydrobenzo [ d ] thiazo| - 6 - y|sulfony| ) piperidine - 2 - carbony|oxy ) propy| ) phenoxy ) aceticacid ( compound 28 ) , 2— ( 3 - ( ( R ) - 3 - ( 3 , 4 - dimethoxypheny| ) - 1 - ( ( S ) - 1 - ( 2 - oxoindo|in - 5 - y|su|fonyl ) piperidine - 2 - carbonyl0xy ) propyl ) phenoxy ) acetic acid ( compound 29 ) , 2 - ( 3 - ( ( R ) - 3 - ( 3 , 4 - dimethoxypheny| ) - 1 - ( ( S ) - 1 - ( 2 - oxo - 2 , 3 - dihydrobenzo [ d ] oxazo| - 6 - y|sulfony| ) piperidine - 2 - carbony|oxy ) propy| ) phenoxy ) aceticacid ( compound 30 ) , ( S ) - ( ( R ) - 3 - ( 3 , 4 - dimethoxyphenyl ) - 1 - ( 3 - ( 2 - morpho|inoethoxy ) pheny| ) propy| ) 1 - ( 3 , 5 - dich|oro - phenylsu|fonyl ) piperidine - 2 - carboxy|ate ( compound 31 ) , ( S ) - ( ( R ) - 3 - ( 3 , 4 - dimethoxypheny| ) - 1 - ( 3 - ( 2 - morpho|inoethoxy ) pheny| ) prop - yl ) 1 - ( benzo [ d ] thi - azo| - 6 - y|sulfony| ) piperidine - 2 - carb0xylate ( compound 32 ) , ( S ) - ( ( R ) - 3 - ( 3 , 4—dimethoxypheny| ) - 1 - ( 3 - ( 2 - morpho|inoethoxy ) pheny| ) propyl ) 1 - ( 3 , 5 - dich|oro - 4 - hydroxyphenylsu|fony| ) piperidine - 2 - carboxylate ( compound 33 ) , ( S ) - ( ( R ) - 3 - ( 3 , 4 - dimethoxypheny| ) - 1 - ( 3 - ( 2 - morpho|inoethoxy ) pheny| ) propyl ) 1 - ( 4 - acetamido - 3 , 5 - dich|oropheny|su|fonyl ) piperidine - 2 - carboxy|ate ( compound 34 ) , ( S ) - ( ( R ) - 3 - ( 3 , 4 - dimethoxyphenyl ) - 1 - ( 3 - ( 2 - morpho|inoethoxy ) pheny| ) propy| ) 1 - ( 2 - oxo - 2 , 3 - dihydrobenzo [ d ] thiazo| - 6 - y|su|fony| ) piperidine - 2 - carboxy|ate ( compound 35 ) . 2 - ( 3 - ( ( R ) - 1 - ( ( S ) - 1 - ( 4 - ch|oropheny|su|fony| ) piperidine - 2 - carbony|oxy ) - 3 - ( 3 , 4 - dimethoxypheny| ) propy| ) phenoxy ) acetic acid ( compound 36 ) , 2 - ( 3 - ( ( R ) - 1 - ( ( S ) - 1 - ( 4 - tert—buty|pheny|su|fonyl ) piperidine - 2 - carbonyloxy ) - 3 - ( 3 , 4 - dimethoxypheny| ) propy| ) phenoxy ) acetic acid ( compound 37 ) , 2 - ( 3 - ( ( R ) - 3 - ( 3 , 4 - dimethoxypheny| ) - 1 - ( ( S ) - 1 - ( 4 - ﬂuoropheny|su|fony| ) piperidine - 2 - carbonyloxy ) propy| ) phenoxy ) acetic acid ( compound 38 ) , 2 - ( 3 - ( ( R ) - 1 - ( ( S ) - 1 - ( 4 - ch|orobenzy|sulfonyl ) piperidine - 2 - carbony|oxy ) - 3 - ( 3 , 4 - dimethoxypheny| ) propy| ) phenoxy ) acetic acid ( compound 39 ) , . 10. 15. 2O. 25. 3O. 35. 4O. 45. WO 2013 / O97947 PCT / EP2012 / 0O5387 40. 2 - ( 3 - ( ( R ) - 3 - ( 3 , 4 - dimethoxypheny| ) - 1 - ( ( S ) - 1 - ( 4 - ( trif|uoromethy| ) pheny|su|fony| ) piperidine - 2 - carbony|oxy ) propy| ) phenoxy ) acetic acid ( compound 40 ) , . 2 - ( 3 - ( ( R ) - 3 - ( 3 , 4 - dimethoxypheny| ) - 1 - ( ( S ) —1— ( 4 - phenoxypheny|su|fony| ) piperidine - 2 - carbony|oxy ) propy| ) phenoxy ) acetic acid ( compound 41 ) , 2 - ( 3 - ( ( R ) - 3 - ( 3 , 4 - dimethoxypheny| ) —1 - ( ( S ) - 1 - ( pyridin - 3 - y|su|fony| ) piperidine - 2 - carbonyloxy ) propyl ) phenoxy ) acetic acid ( compound 42 ) , 2 - ( 3 - ( ( R ) - 3 - ( 3 , 4—dimethoxypheny| ) - 1 - ( ( S ) - 1 - ( 6 - phenoxypyridin - 3 - ylsu|fonyl ) piperidine - 2 - carbony|oxy ) propy| ) phenoxy ) acetic acid ( compound 43 ) , 2 - ( 3 - ( ( R ) - 3 - ( 3 , 4 - dimethoxypheny| ) - 1 - ( ( S ) - 1 - ( 6 - pheny|pyridin - 3 - y|sulfony| ) piperidine - 2 - carbony|oxy ) propy| ) phenoxy ) acetic acid ( compound 44 ) , 2 - ( 3 - ( ( R ) —1 - ( ( S ) - 1 - ( 2 - ch|oropheny|sulfonyl ) piperidine - 2 - carbonyloxy ) - 3 - ( 3 , 4 - dimethoxypheny| ) propy| ) phenoxy ) acetic acid ( compound 45 ) , 2 - ( 3 - ( ( R ) - 1 - ( ( S ) - 1 - ( 2 , 6 - dichloropheny|su|fony| ) piperidine - 2 - carbony|oxy ) - 3 - ( 3 , 4 - dimethoxyphenyl ) propy| ) phenoxy ) acetic acid ( compound 46 ) , 2 - ( 3 - ( ( R ) - 3 - ( 3 , 4 - dimethoxypheny| ) - 1 - ( ( S ) - 1 - ( 3 - ( 5 - methy| - 1 , 3 , 4 - oxadiazo| - 2 - yl ) phenylsu|fonyl ) piperidine - 2 - carbony|oxy ) propy| ) phenoxy ) acetic acid ( compound 47 ) , . 2 - ( 3 - ( ( R ) —1 - ( ( S ) - 1 - ( 3 - ch|or0 - 4 - ( triﬂuoromethyl ) pheny|sulfony| ) piperidine - 2 - carbony|oxy ) - 3 - ( 3 , 4 - dimethoxyphenyl ) propy| ) phenoxy ) acetic acid ( compound 48 ) , 2 - ( 3 - ( ( R ) - 3 - ( 3 , 4 - dimethoxyphenyl ) - 1 - ( ( S ) - 1 - ( 1 - methyl - 1H - indo| - 4 - y|su|fony| ) piperidine - 2 - carbony|oxy ) propy| ) phenoxy ) acetic acid ( compound 49 ) , 2 - ( 3 - ( ( R ) - 3 - ( 3 , 4 - dimethoxyphenyl ) - 1— ( ( S ) - 1 - ( 1 - methyl - 1H - indo| - 5 - ylsu|fonyl ) piperidine - 2 - carbony|oxy ) propyl ) phenoxy ) acetic acid ( compound 50 ) , 2 - ( 3 - ( ( R ) - 3 - ( 3 , 4 - dimethoxyphenyl ) - 1 - ( ( S ) - 1 - ( 4 - methyl - 3 , 4 - dihydro - 2H - . benzo [ b ] [ 1 , 4 ] oxazin - 6 - y|su|fony| ) piperidine - 2 - carbony|oxy ) propy| ) phenoxy ) acetic acid ( compound 51 ) , 2 - ( 3 - ( ( R ) - 3 - ( 3 , 4 - dimethoxypheny| ) - 1 - ( ( S ) - 1 - ( 4 - methy| - 3 , 4 - dihydro - 2H - pyrido [ 3 , 2 - b ] [ 1 , 4 ] oxazin - 7 - y|su|fony| ) piperidine - 2 - carbonyloxy ) propy| ) phenoxy ) acetic acid ( compound 52 ) , 2 - ( 3 - ( ( R ) - 3 - ( 3 , 4 - dimethoxypheny| ) - 1 - ( ( S ) - 1 - ( furan - 3 - y|su|fony| ) piperidine - 2 - carbony|oxy ) propy| ) phenoxy ) acetic acid ( compound 53 ) , 2 - ( 3 - ( ( R ) - 1 - ( ( S ) - 1 - ( benzofuran - 2 - y|su|fony| ) piperidine - 2 - carbony|oxy ) - 3 - ( 3 , 4 - dimethoxypheny| ) propy| ) phenoxy ) acetic acid ( compound 54 ) , . 10. 15. 20. 25. 3O. 35. 40. 45. WO 2013 / O97947 PCT / EP2012 / OO5387 41. 2 - ( 3 - ( ( R ) - 3 - ( 3 , 4 - dimethoxypheny| ) - 1 - ( ( S ) - 1 - ( thiophen - 2 - y|sulfony| ) piperidine - 2 - carbony|oxy ) propyl ) phenoxy ) acetic acid ( compound 55 ) , 2 - ( 3 - ( ( R ) - 3 - ( 3 , 4 - dimethoxypheny| ) - 1 - ( ( S ) - 1 - ( 5 - pheny|thiophen - 2 - y|su|fony| ) piperidine - 2 - carbony|oxy ) propyl ) phenoxy ) acetic acid ( compound 56 ) , 2 - ( 3 - ( ( R ) - 1 - ( ( S ) - 1 - ( benzo [ b ] thiophen - 3 - y|su|fonyl ) piperidine - 2 - carbony|oxy ) - 3 - ( 3 , 4 - dimethoxypheny| ) propy| ) phenoxy ) acetic acid ( compound 57 ) , 2 - ( 3— ( ( R ) - 3 - ( 3 , 4 - dimethoxyphenyl ) - 1 - ( ( S ) - 1 - ( 3 , 5 - dimethylisoxazo| - 4 - y|sulfony| ) piperidine - 2 - carbonyloxy ) propyl ) phenoxy ) acetic acid ( compound 58 ) , 2 - ( 3 - ( ( 1R ) - 3 - ( 3 , 4 - dimethoxypheny| ) - 1 - ( ( 2S ) - 1 - ( 1 - methy| - 4 , 5 - dihydro - 1H - pyrazo| - 5 - y|su|fony| ) piperidine - 2 - carbony|oxy ) propyl ) phenoxy ) acetic acid ( compound 59 ) , 2— ( 3 - ( ( R ) - 3 - ( 3 , 4 - dimethoxypheny| ) - 1 - ( ( S ) - 1 - ( 1 - methyl - 1H - imidazo| - 4 - y|su|fonyl ) piperidine - 2 - carbony|oxy ) propyl ) phenoxy ) acetic acid ( compound 60 ) , 2 - ( 3 - ( ( R ) - 3 - ( 3 , 4 - dimethoxyphenyl ) - 1 - ( ( S ) - 1 - ( 1 , 3 , 5 - trimethy| - 1H - pyrazol - 4 - ylsulfony| ) piperidine - 2 - carbony|oxy ) propy| ) phenoxy ) acetic acid ( compound 61 ) , 2 - ( 3 - ( ( R ) - 3 - ( 3 , 4 - dimeth0xypheny| ) - 1 - ( ( S ) - 1 - ( 3 , 5 - dimethy| - 1 - pheny| - 1H - pyrazo| - 4 - y|su|fonyl ) piperidine - 2 - carbony|oxy ) propy| ) phenoxy ) acetic acid ( compound 62 ) , 2 - ( 3 - ( ( R ) —3 - ( 3 , 4 - dimethoxypheny| ) - 1 - ( ( S ) - 1 - tosy|piperidine - 2 - carbonyloxy ) propy| ) phenoxy ) acetic acid ( compound 63 ) , 2 - ( 3 - ( ( R ) - 3 - ( 3 , 4 - dimethoxyphenyl ) - 1 - ( ( S ) - 1 - ( 4 - nitrophenylsulfony| ) piperidine - 2 - carbony|oxy ) propy| ) phenoxy ) acetic acid ( compound 64 ) , ( S ) - ( ( R ) - 3 - ( 3 , 4 - dimethoxypheny| ) - 1 - ( 3 - ( 2 - morpho|inoethoxy ) pheny| ) propy| ) 1 - ( 3 , 5 - dich|oro - 4 - methoxyphenylsulfony| ) piperidine - 2 - carboxylate ( compound 65 ) . Example 1. Synthesis of a|coho| a ) : ( R ) - tert - butyl 2 - ( 3 - ( 3 - ( 3 , 4 - dimethoxypheny| ) - 1 - hydroxypropyl ) phenoxy ) acetate. A so|ution of the corresponding pheno| ( T. Keenan et a|. / Bioorg. Med. Chem. 6 ( 1998 ) 1309 - 1335 ) ( 5g , 15.46 mmo| ) and K2CO3 ( 4.8g , 34.9mmo| ) in acetone ( 30mL ) was treated with tert - buty| bromoacetate ( 3.7g , 19.21mmo| ) and a||owed to stir at room temperature for 20h. After this time the reaction mixture was filtered , concentrated and ﬂash chr0matographed to afford tert - buty| 2 - ( 3 - ( 3 - ( 3 , 4 - dimethoxypheny| ) propanoy| ) phenoxy ) acetate ( 6.6g , 16.5mmo| , 94% ) . TLC ( hexane : EtOAc 8 : 2 ) : RF = 0.50. 10. 15. 20. 25. 3O. 35. WO 2013 / 097947 PCT / EP2012 / O05387 42. 1H NMR ( 4oo MHz , CDCl3 ) 5 1.45 ( s , 9H ) , 2.97 ( 1 , 2H , J = 8 Hz ) , 3.22 ( t , 2H , J = 8 Hz ) , 3.82 ( s , 3H ) , 3.83 ( s , 3H ) , 4.52 ( s , 2H ) , 6.73 - 6.78 ( m , 3H ) , 7. o9 ( dd , 1H , J = 0.8 , 2.4 Hz ) , 7.33 ( t , 1H , J = 8 Hz ) , 7.43 ( m , 1H ) , 7.53 ( dd , 1H , J = 1.2 , 7.5 ) . 13C NMR ( 100 MHz , CDC|3 ) 5 27.99 , 29.77 , 4o.70 , 55.80 , 55.53 , 82.55 , 111.35 , 111.81 , 113.05 , 119.99 , 12o.12 , 121.39 , 129.55 , 133.77 , 138.22 , 147.38 , 148.88. 158.12 , 157.57 , 198.77. Ms ( ESl ) m / z 439.13 [ M + K ] * . A so|ution of tert - buty| 2 - ( 3 - ( 3 - ( 3 , 4 - dimethoxypheny| ) propanoy| ) phenoxy ) acetate ( 6.5g , 16.48mmo| ) in isopropano| was charged into the hydrogenation reactor ( Highpressure |aboratory autoclave Model N from Roth ) a|0ng with K2CO3 ( 2.3g , 16.48mmo| ) . The reactor was f|ushed twice with argon and to the above so|ution was added Noyuri cata|yst ( ABCR ) . The reactor was f|ushed with argon to remove any traces of air and was sealed. Hydrogen gas was f|ushed into the reactor twice , to ﬂush out argon. The reaction was then stirred at room temperature with hydrogen gas held at 15 bar pressure for 6 days after which time the reaction was ﬁ|tered through celite pad , and washed continuous|y with diethyl ether. The organic so|vent was dried under vacuum to yie|d ( R ) - tert - buty| 2 - ( 3 - ( 3 - ( 3 , 4—dimethoxypheny| ) - 1 - hydroxypropy| ) phenoxy ) acetate ( 6.2g. 15.42mmo| , 94% ) . TLC ( hexane : EtOAc 8 : 2 ) : Rf = 0.3. 1H NMR ( 300 MHz , CDC|3 ) 5 1.47 ( s , 9H ) , 2.03 ( m , 2H ) , 2.642 ( m , 2H ) , 3.83 ( s , 3H ) , 3.84 ( s , 3H ) , 4.49 ( s , 2H ) , 4.66 - 4.61 ( m , 1H ) , 6.70 - 6.80 ( m , 4H ) , 6.95 - 6.91 ( m , 2H ) , 7.24 ( t , 1H , J = 7.8 Hz ) . 13C NMR ( 75 MHz , CDCl3 ) 6 28.01 , 31.56 , 40.62 , 55.79 , 55.90 , 65.62 , 73.55 , 82.32 , 111.31 , 111.80 , 112.18 , 113.53 , 119.08 , 120.19 , 129.48 , 134.40 , 146.56 , 147.16 , 148.82 , 158.07 , 168.01. Ms ( ESl ) m / z 425.20 [ M + Na ] + , 441.17 [ M + K ] * . Synthesis of 3 - ( 3 , 4 - Dimethoxypheny| ) - 1 - ( 3 - ( 2 - morpholinoethoxy ) pheny| ) - propan - 1 - one. A so|ution of the corresponding pheno| ( 15.6 g , 59.5 mmo| ) in dry DMF ( 300 m| ) under an atmosphere of nitrogen was treated with K2CO3 ( 33.2 g , 240 mmol ) and 4 - ( 2 - ch|oroethy| ) morpho|ine hydrochloride ( 11.1 g , 59.6 mmo| ) . The mixture was heated with stirring at 90°C for 2 hours unti| TLC indicated comp|ete conversion. The. 10. 15. 2O. 25. 3O. 35. W0 2013 / 097947 PCT / EP2012 / 005387 43 mixture was cooled to room temperature and poured into ice - co|d water ( 3.2 | ) . The precipitate of the tit|e compound was co|lected by fi|tration , washed with water ( 3 x 200 m| ) and dried in vacuo to yie|d 3 - ( 3 , 4 - Dimethoxypheny| ) - 1 - ( 3 - ( 2 - morpho|inoethoxy ) pheny| ) propan - 1 - one ( 17.7 g , 44.3 mmo| , 74% ) The product was used for the next step without further purification. 1H NMR ( 300MHz , CDCl3 ) 5= 2.49 - 2.54 ( m , 4H ) , 2.75 ( t , J = 5.7 Hz , 2H ) , 2.94 ( t , J = 7.7 Hz , 2H ) . 3.20 ( t , J = 7.7 Hz , 2H ) , 3.55 - 3.59 ( m , 4H ) , 3.79 ( s , 3H ) , 3.81 ( s , 3H ) , 4.08 ( t , J = 5.5 Hz , 2H ) , 5.59 - 5.74 ( m , 3H ) , 7.04 ( dd , J = 0.8 Hz , J = 2.5 Hz , 1H ) , 7.29 ( t , J = 7.9 Hz , 1H ) , 7.41 - 7.49 , ( m , 2H ) . Synthesis of ( R ) - 3 - ( 3 , 4 - Dimethoxyphenyl ) - 1 - ( 3 - ( 2 - morpholinoethoxy ) phenyl ) - propan - 1 - o|. Dry THF ( 35 ml ) was added under an atmosphere of nitrogen to 3— ( 3 , 4 - dimethoxypheny| ) - 1 - ( 3 - ( 2 - morpho|inoethoxy ) pheny| ) propan - 1 - one ( 25 g , 62.6 mmol ) . The mixture was coo|ed to - 20°C and a 1.8 M solution of ( + ) - B - chlorodiisopinocamphey|borane [ ( + ) - D|P chloride ] in hexane ( 53 m| , 95.4 mmol ) which had been diluted with dry THF ( 70 m| ) was s|owly added dropwise. The temperature was kept be|ow - 10°C and the mixture stirred for 3 hours. H was p|aced in a refrigerator overnight and another 0.2 equiva|ents of ( + ) - DlP ch|oride was added. After another day at - 20°C the solvent was removed under reduced pressure , the residue treated with ether ( 170 ml ) and the mixture cooled to 0°C. Diethano|amine ( 60 m| ) was added and it was stirred for a whi|e. The formed precipitate was removed by filtration and washed with ether. The combined fi|trates were concentrated under reduced pressure , and the tit|e compound was obtained from the residue by co|umn chromatography as oi| ( si|ica ge| ; CH2C|2 / MeOH gradient 100 : 0 to 94 : 6 ) to give ( R ) - 3 - ( 3 , 4 - Dimethoxypheny| ) - 1 - ( 3 - ( 2 - morpho|inoethoxy ) pheny| ) propan - 1 - o| ( 17.2 g , mmo| , 68 % ) . 1H NMR ( 30OMHz , CDC|3 ) 5= 1.84 - 2.08 ( m , 2H ) , 2.27 ( bs , 1H ) , 2.45 - 2.52 ( m , 4H ) , 2.52 - 2.57 ( m , 2H ) , 2.70 ( t , J = 5.8 Hz , 2H ) , 3.51 - 3.57 ( m , 4H ) , 3.78 ( 2s , 5H ) , 4.02 ( t , J = 5.8 Hz , 2H ) , 4.54 - 4.50 ( m , 1H ) , 5.52 - 5.75 ( m , 4H ) , 5.82 - 5.87 ( m , 2H ) , 7.14 - 7.21 ( m , 1H ) . Ms ( ES| ) m / z 402 [ M + H ] + ; 424 [ M + Na ] + , ca|c. 402 [ M + H ] i 424 [ M + Na ] + . Synthesis of 2 - ( 3 - ( ( R ) - 3 - ( 3 , 4 - dimethoxyphenyl ) - 1 - ( ( S ) - 1 - ( 4 - ( pyrimidin - 2 - yl ) - pheny|su|fonyl ) pipridine - 2 - carbonyloxy ) propyl ) phenoxy ) acetic acid ( compound 1 ) . 10. 15. 20. WO 2013 / O97947 PCT / EP2012 / OO5387 44. 1. DCC , DMAP , 0°C to r. t. 0 Y 2 20 / TFA m CH 202 %ckH H / O OWO 3. 2foﬁ2ro trityIresin , DlPEA YA. o . o . . —J CH2C|2 , r. t. , 6h | o\. 0 OH 0 0 ( 93 / . ° / 01 / * - ( PW o. O=S =O O. 00 c ' - E { H3 O. N \N o\ 1 D|PEA , CH2C|2 , r. t , 16h U 2.1° / TFAin CH2C|2 , / r. t. , 1h. . A so|ution 0f alcoho| ( 6.2g , 15.44mmol ) , pipeco|ic carboxy|ic acid ( 6.2g , 17.64 mmo| ) , and DMAP ( 0.2 g , 1.76mmo| ) in 50mL DCM at 0°C was treated with DCC ( 3.6g , 17.6mmo| ) . The mixture was a||owed to warm to room temperature and was stirred for 20h after which time the organic so|vent was dried and the so|id was dissolved in diethy| ether ( 50mL ) and fi|tered through a p|ug of ce|ite. The fi|trate was concentrated and then f|ash chromatographed using hexane : EtOAc 2 : 1 to afford pipeco|ic ester ( 9.8g , 13.3 mmo| , 84% ) . TLC ( hexane : EtOAc 2 : 1 ) : Rf = 0.4. To the pipeco|ic ester ( 3g , 4mmo| ) was added a so|ution of 20% TFA in DCM ( 20mL ) at 0°C to remove the t - Bu protective group. The mixture was a||owed to warm to room temperature and stirred for 6h after which time it was diluted with DCM and evaporated under vacuo to remove of TFA. The crude materia| was then subjected to column chromatography using hexane : EtOAc : TFA 7.2 : 2.8 : 0.2 to afford the product ( 2 - ( 3— ( ( 1R ) - 1 - ( 1 - ( ( ( 9H - f|uoren - 9—y| ) methoxy ) carbonyl ) piperidine—2—carbonyloxy ) - 3 - ( 3 , 4 - dimethoxypheny| ) propyl ) phenoxy ) acetic acid ) ( 2.7g , 4mmo| , 100% ) . TLC ( hexanehexane : EtOAc : TFA 7 : 2.8 : 0.2 ) : Rf = 0.375. 2 - Chloro trity|resin ( 6.1g , 7.9mmol , Novabiochem ) was swollen in DCM for 1h , and added to a mixture of 2 - ( 3 - ( ( 1R ) - 1 - ( 1 - ( ( ( 9H - fluoren - 9 - y| ) methoxy ) carbony| ) piperidine - 2 - carbonyloxy ) - 3 - ( 3 , 4 - dimethoxypheny| ) propyl ) phenoxy ) acetic acid ( 2.7g , 3.97mmol ) . 10. 15. 2O. 25. 3O. 35. W0 2013 / 097947 PCT / EP2012 / 005387 45. and i - Pr2EtN ( 2g , 15.89mmo| ) in 20 m| dry DCM. The reaction was monitored by removing a|iquots of the reactant mixture ( 10 [ . IL ) over a period of 1 - 24h fi|tered and dried. The ana|yte was then re - disso|ved in buffer A and subjected to HPLC ana|ysis for the disappearance of the educts. The s|urry was agitated for 16h. The slurry was then filtered , and the resin was washed with DCM ( 3 x 50m| ) ; DCM : MeOH : i - Pr2EtN : : 17 : 2 : 1 ( 3 x 50m| ) ; DCM ( 3 x 20m| ) ; DMF ( 3 x 25m| ) ; MeOH ( 3 x 50ml ) ; CHC|3 ( 3 x 50m| ) and diethy| ether ( 3 x 50m| ) The resin was dried under high vacuum overnight to yield a free f|owing resin immobilized with ( 2 - ( 3 - ( ( 1R ) - 1 - ( 1 - ( ( ( 9H - ﬂuoren - 9 - y| ) methoxy ) carbony| ) piperidine - 2 - carbony|oxy ) - 3 - ( 3 , 4 - dimethoxypheny| ) propy| ) - phenoxy ) acetic acid ) . The |oading of the free acid was calcu|ated using Fmoc deprotection strategy , and measuring the Fmoc absorbance. The coup|ed resin was weighed ( 210 mg , 0.08mmo| ) and added to syringes , swo|len in DCM ( 4 mL ) for 1h , and the Fmoc protecting group was removed using 20% 4 - methy| piperidine / DCM ( 4m| ) for 1h. After fi|tration , the resin was washed with DCM ( 3 x 5m| ) and was used for the next coup|ing step. To the above resin was added i - Pr2EtN ( 40mg , 0.317mmol ) in dry DCM ( 3 mL ) and stirred for 20min. To this so|ution was added the su|fony| ch|oride ( 0.237mmo| ) in 500 [ JL of DCM and the reaction was stirred for 4h at rt. After the first coup|ing strategy the resin was fi|tered washed with DCM ( 3 x 10ml ) and then subjected to second coupling with i - Pr2EtN ( 30mg , 0.237mmol ) , su|fony| chloride ( 0.158 mmo| ) in DCM ( 3 mL ) and stirred for 16h at rt. The resin was washed with DCM ( 3 x 5m| ) and dried to give the derivatized resin which was re - swo||en in DCM and reacted with 1% TFA / DCM ( 3m| ) for 1h and then washed with 1% TFA / DCM ( 3 x 3m| ) , DCM ( 3 x 5m| ) . The combined fi|trates were concentrated in vacuo to yie|d the crude product. The crude compound was further purified by preparative HPLC using the gradient : MEOH : H2O : CF3COOH ( 0.1% ) gradient of 40 - 70% B in 15 min at 25m| / min. The purified peaks were further dried by |yophi|ization and then given for NMR characterization in CDC|3. TLC ( hexane : EtOAc : TFA 6 : 3.8 : 0.2 ) : Rf = 0.18 , Yie|d - 13.5mg , % Yie|d - 30%. HPLC ( MeCN : H2O CF3COOH ( 0.1% ) gradient of 0 — 100% in 45 min at 1m| / min ) retention time - 25.1 - 25.3 min. 1H NMR ( 500 MHz , CDC|3 ) 5 1.29 ( 1 , 1H , J = 7.2 Hz ) , 1.55 ( dd , 1H , J = 3.5 , 9 Hz ) , 1.57 ( d , 1H , J = 12.5 ) , 1.72 ( d , 1H , J = 13.8 Hz ) , 1.85 - 1.91 ( m , 1H ) , 1.93 - 1.99 ( m , 1H ) , 2.13 - 2.19 ( m , 1H ) , 2.24 ( d , 1H , J = 13.2 Hz ) , 2.45 - 2.50 ( m , 2H ) , 2.55 - 2.59 ( m. 1H ) , 3.11 - 3.15 ( m , 2H ) , 3.75 ( d , 1H , J = 9.5 Hz ) , 3.82 ( s , 3H ) , 3.83 ( s , 3H ) , 4.91 ( d , . 10. 15. 20. 25. 30. 35. WO 2013 / 097947 PCT / EP2012 / 005387 46. 1H , J = 4.8 Hz ) , 5.53 ( q , 1 H , J = 3 , 4.8 Hz ) , 5.51 ( s , 1H ) , 5.53 ( d , 1H , J = 7.8 Hz ) , 5.74 ( d , 1H , J = 7.8 Hz ) , 5.80 ( s , 1H ) , 5.92 ( d , 1H , J = 7.2 Hz ) , 7.01 ( d , 1H , J = 7.8 Hz ) , 7.32 - 7.35 ( m , 2H ) , 7.59 ( d. 2H , J = 8.4 Hz ) , 8.25 ( d , 2H , J = 8.4 Hz ) , 8.91 ( d , 2H , J = 4.8 Hz ) . 13c NMR ( 150 MHz , CDCl3 ) 5 20.02 , 24.74 , 28.17 , 31.42 , 38.30 , 42.45 , 45.55 , 55.33 , 55.82 , 55.24 , 75.43 , 111.28 , 111.50 , 112.94 , 114.37 , 118.85 , 120.02 , 120.09 , 127.51 , 128.51 , 130.01 , 133.25 , 140.05 , 141.31 , 142.19. 147.34 , 148.85 , 157.41 , 157.77 , 152.90 , 159.73 Ms ( ESl ) m / z : found RT 11.74 min. ( Method LCMS ) , 575.12 [ M + H ] * , 598.15 [ M + Na ] + , HRMS 575.2305 [ M + H ] * , ca|cu|ated 575.2251. The 2 - morpho|inoethoxy derivatives were prepared according|y with 3 - ( 3 , 4 - dimethoxypheny| ) - 1 - ( 3 - ( 2 - morpho|inoethoxy ) pheny| ) propan - 1 - one |eaving out the deprotection step for the Boc group and the coup|ing and decoup|ing to the trity|resin. Examp|e 2 2 - ( 3 - ( ( R ) - 1 - ( ( S ) - 1 - ( 3 - chloropheny|su|fony| ) piperidine - 2 - carbo - nyloxy ) - 3 - ( 3 , 4 - dimethoxy pheny| ) propy| - phenoxy ) acetic acid ( compound 2 ) . TLC ( hexane : EtOAc : TFA 6 : 3.8 : 0.2 ) : Rf = 0.50 , Yield - 25.4 mg , % Yie|d - 57%. HPLC ( MeCN : H2O CF3COOH ( 0.1% ) gradient of 0 — 100% in 45 min at 1m| / min ) retention time - 26.1 - 26.5 min. 1H NMR ( 400 MHz , DMSO ) 6 1.12 - 1.18 ( m , 4H ) , 1.59 ( t , 2H , J = 13.6 Hz ) , 1.98 - 2.13 ( m , 2H ) , 2.40 ( t , 2H , J = 6.8 Hz ) , 3.07 ( t. 1H , J =12 Hz ) , 3.61 ( d , 1H , J =12 Hz ) , 3.69 ( s , 3H ) , 3.70 ( s , 3H ) , 4.55 ( s , 2H ) , 4.68 ( d , 1H , J = 4Hz ) , 5.50 ( t , 1H , J = 4.8Hz ) , 6.56 ( d , 1H , J = 7.6 Hz ) , 6.60 ( s , 1H ) , 6.72 ( d , 1H , J = 8 Hz ) , 6.76 - 6.80 ( m , 3H ) , 7.19 - 7.26 ( m , 2H ) , 7.46 ( d , 2H , J = 7.2 Hz ) , 7.61 ( s , 1H ) . 130 NMR ( 100 MHz , DMSO ) 5 20.05 , 24.51 , 27.74 , 31.05 , 37.92 , 42.79 , 55.32 , 55.76 , 64.99 , 76.13 , 111.95 , 112.23 , 112.85 , 114.11 , 119.22 , 120.33 , 125.36 , 126.62 , 129.77 , 130.88 , 132.66 , 133.48 , 134.48 , 141.75 , 141.95 , 147.34 , 148.92 , 158.18 , 169.61 , 172.41. MS ( ES| ) m / z : found RT 12.34 min. ( Meth0d LCMS ) , 654.17 [ M + Na ] + , 656.16 [ M + 2 + Na ] + , HRMS 632.2212 [ M + H ] + , 634.2205 [ M + 2 + H ] + , ca|culated 632.1643. Examp|e 3 2 - ( 3 - ( ( R ) - 1 - ( ( S ) - 1 - ( benzo [ d ] thiazo| - 5 - ylsulfony| ) piperidine - 2 - carbonyloxy ) - 3 - ( 3 , 4 - dimethoxy pheny| ) propy| ) phenoxy ) acetic acid ( compound 3 ) . TLC ( hexane : EtOAc : TFA 6 : 3.8 : 0.2 ) : Rf = 0.20 , Yie|d - 25.4mg , % Yie|d - 59%. HPLC ( MeCN : H2O CF3COOH ( 0.1% ) gradient of 0 — 100% in 45 min at 1ml / min ) retention time - 24.6 - 25.0 min. 10. 15. 2O. 25. 3O. 35. WO 2013 / O97947 PCT / EP2012 / OO5387 47. 1H NMR ( 500 MHz , CDC|3 ) 5 1.08 - 1.15 ( m , 1H ) , 1.38 - 1.45 ( m , 1H ) , 1.50 ( t , 2H , J = 12 Hz ) , 1.70—1.75 ( m , 1H ) , 1.94 - 2.00 ( m , 1H ) , , 2.11 - 2.18 ( m , 1H ) , 2.43 - 2.54 ( m , 1H ) , 3.23 ( dt , 1H , J = 3 , 5 Hz ) , 3.76 - 3.78 ( m , 1 H ) , 3.85 ( s , 6H ) , 4.55 ( s , 2H ) , 4.84 ( d , 1H , J = 4.2 Hz ) , 5.55 ( t , 1H , J = 7.2 Hz ) ) , 5.53 ( s , 1H ) , 5.54 ( d , 1H , J =1.8 Hz ) ) , 5.78 ( d , 2H , J = 5.4 Hz ) , 5.81 ( dd , 1H , J = 2.4.5 Hz ) , 5.85 ( d , 2H , J = 8.5 Hz ) , 7.22 ( t , 1H , J = 7.8 Hz ) , 7.8 ( dd , 1H , J =1.8 , 8.4 Hz ) , 8.13 ( d , 1H , J = 8.4 Hz ) , 8.45 ( d , 1H , J =1.8 Hz ) , 9.18 ( s , 1H ) . 13c NMR ( 150 MHz , CDC|3 ) 5 19.91 , 24.51 , 27.59. 31.22 , 37.87 , 42.81 , 55.27 , 55.91 , 55.92 , 55.00 , 75.54 , 111.34 , 111.73 , 112.91 , 114.15 , 119.88 , 120.14 , 121.92 , 123.95 , 124.83. 129.78 , 133.20 , 133.83 , 137.55 , 141.50 , 147.39 , 148.87 , 154.92 , 157.55 , 158.03 , 159.95 , 171.84 Ms ( ESl ) m / z : found RT 11.34 min. ( Method LCMS ) , 555.05 [ M + 1 ] 1 577.15 [ M + Na ] + , HRMS 555.2285 [ M + H ] + , calcu|ated 555.1705. Example 4 2 - ( 3 - ( ( R ) - 3 - ( 3 , 4 - dimethoxypheny| ) - 1 - ( ( S ) - 1 - ( furan - 3 - y|su|fonyI ) piperidine - 2 - carbony|oxy ) propy| ) phenoxy ) acetic acid ( compound 4 ) . TLC ( hexane : EtOAc : TFA 6 : 3.8 : 0.2 ) : Rf = 0.375 , Yie|d - 25mg , , % Yie|d - 56%. HPLC ( MeCN : H2O CF3COOH ( 0.1% ) gradient of 0 — 100% in 45 min at 1m| / min ) retention time - 24.4 - 24.8 min. 1HNMR ( 300 MHz , CDC|3 ) 5 1.10 - 1.18 ( m , 1H ) , 1.43 - 1.52 ( m , 1H ) , 1.61 - 1.81 ( m , 2H ) , 2.00 - 2.12 ( m , 1H ) , 2.19 - 2.30 ( m , 2H ) , 2.37 ( s , 2H ) , 2.52 - 2.65 ( m , 2H ) , 3.14 - 3.28 ( m , 2H ) , 3.87 ( s , 3H ) , 3.88 ( s , 3H ) , 4.68 ( s , 2H ) , 4.82 ( d , 1H , J = 4.5 Hz ) , 5.70 ( dd. 1H , J = 2.1 , 5.7 Hz ) , 6.58 ( q , 1H , J = 0.9 , 1.2Hz ) , 6.70 ( dd , 2H , J = 2.1 , 4.5 Hz ) , 6.79 - 6.87 ( m , 2H ) , 6.91 - 6.96 ( m , 2H ) , 7.25 ( d , 1H , J = 2.1 Hz ) , 7.44 ( t , 1H , J = 2.4 Hz ) , 7.91 ( q , 1H , J = O.9 Hz ) . 13C NMR ( 75 MHz , CDC|3 ) 6 21.45 , 24.62 , 27.72 , 31.25 , 37.92 , 42.57 , 55.18 , 55.93 , 55.94 , 64.92 , 76.40 , 108.52 , 111.40 , 111.80 , 112.88 , 114.30 , 119.97 , 120.20 , 127.37 , 128.21 , 133.29 , 141.86 , 144.42 , 145.50 , 147.42 , 148.92 , 157.66 , 170.10. MS ( ESl ) m / z : found RT 11.29 min. ( Method LCMS ) , 610.16 [ M + Na ] + , HRMS 588.2354 [ M + H ] + , ca|cu|ated 588.1825. Examp|e 5 2 - ( 3 - ( ( R ) - 1 - ( ( S ) - 1 - ( benzo [ b ] thiophen - 2 - y|su|fony| ) piperidine - 2 - carbonyloxy ) - 3 - ( 3 , 4 - dimethoxy phenyl propy| ) phenoxy ) acetic acid ( compound 5 ) . TLC ( hexane : EtOAc : TFA 6 : 3.8 : 0.2 ) : Rf = 0.625 , Yield - 23.8 mg , % Yie|d - 55%. HPLC ( MeCN : H2O CF3COOH ( 0.1% ) gradient of 0 — 100% in 45 min at 1m| / min ) retention time - 21.8 - 22.2 min. 10. 15. 2O. 25. 3O. 35. WO 2013 / O97947 PCT / EP2012 / OO5387 48. 1HNMR ( 300 MHz , CDC|3 ) 5 1.12 - 1.21 ( m , 1H ) , 1.44 - 1.52 ( m , 1H ) , 1.50 - 1.54 ( m , 2H ) , 1.70 - 1.81 ( m , 1H ) , 1.95 - 2.07 ( m.1H ) , 2.14 - 2.26 ( m , 2H ) . 2.47 - 2.65 ( m , 2H ) , 3.35 ( dt , 1H , J = 3 Hz ) , 3.85 ( s , 3H ) , 3.87 ( s , 3H ) . 4.55 ( s , 2H ) , 4.87 ( d , 1H , J = 4.2 Hz ) . 5.55 ( dd. 1H , J = 2.4 , 5.5 Hz ) , 5.55 - 5.59 ( m , 2H ) , 5.77 - 5.85 ( m , 2H ) , 6.91 ( d , 2H. J = 7.2 ) , 7.24 ( t , 1H , J = 8.1 Hz ) , 7.40 - 7.49 ( m , 2H ) , 7.79 - 7.84 ( m , 3H ) . 13C NMR ( 75 MHz , CDC|3 ) 5 19.87 , 24.47 , 27.45. 31.28 , 37.98 , 43.04 , 55.47. 55.93. 55.94 , 54.90 , 75.44 , 111.39 , 111.84. 112.73 , 114.35 , 119.95 , 120.22 , 122.55 , 125.35 , 125.58 , 127.08. 128.91 , 129.75. 133.35 , 137.53. 141.35 , 141.51 , 141.82. 147.39 , 148.90 , 157.59 , 159.84. Ms ( ES| ) m / z : f0und RT 12.28 min. ( Method LCMS ) , 575.95 [ M + Na ] + , HRMS 732.2501 [ M + DMSO ] 2 ca|cu|ated 554.1753. Examp|e 6 2 - ( 3 - ( ( R ) - 1 - ( ( S ) - 1 - ( 3 - cyanopheny|sulfony| ) piperidine - 2 - carbony|oxy ) - 3 - ( 3 , 4 - dimethoxyphen - y| ) propy| ) phenoxy ) acetic acid ( compound 6 ) . Yie|d - 29.5mg , % Yield - 61%. 1HNMR ( 600 MHz , CDC|3 ) 6 1.02 - 1.10 ( m , 1H ) , 1.40 - 1.47 ( m , 1H ) , 1.60 - 1.64 ( m , 2H ) , 1.72 - 1.78 ( m , 1H ) , 1.99 - 2.06 ( m , 1H ) , 2.16 - 2.22 ( m , 2H ) , 2.49 - 2.59 ( m , 2H ) , 3.15 ( dt , 1H , J = 3 Hz , 13.2 Hz ) , 3.7 ( d , 1H , J = 9.6 Hz ) , 3.86 ( s , 3H ) , 3.87 ( s , 3H ) , 4.67 ( s , 2H ) , 4.81 ( d , 1H , J = 4.8 Hz ) , 5.60 ( dd , 1H , J = 6 Hz ) , 6.67 - 6.69 ( m , 2H ) , 6.81 ( d , 1H , J = 7.8 Hz ) , 6.83 - 6.84 ( m , 1H ) , 6.90 ( d , 1H , J = 7.8 Hz ) , 7.26 ( dd , 1H , J = 7.8 Hz ) , 7.56 ( t , 1H , J = 7.8 Hz ) , 7.78 ( td , 1H , J = 1.2 Hz , 7.8 Hz ) , 7.99 - 7.99 ( m , 1H ) , 8.07 ( t , 1H , J = 1.8Hz ) . 13C NMR ( 150 MHz , CDC|3 ) 5 19.83 , 24.63 , 27.80 , 31.25 , 37.82 , 42.88 , 55.39 , 55.93 , 55.97 , 64.78 , 76.70 , 111.37 , 111.82 , 112.95 , 113.38. 114.23 , 117.30 , 120.00. 120.16 , 129.87 , 130.70 , 131.05 , 133.16 , 135.56 , 141.58 , 141.77 , 147.43 , 148.88 , 157.53 , 169.67 , 171.85. MS ( ES| ) m / z : found RT 13.12min. ( Method LCMS ) , 645.40 [ M + Na ] + , HRMS 701.2628 [ M + DMSO ] + , ca|culated 623.1985. Example 7 2 - ( 3 - ( ( R ) - 3 - ( 3 , 4 - dimethoxypheny| ) - 1 - ( ( S ) - 1 - ( 3 - nitropheny|su|fonyl ) piperidine - 2 - carbony|o - xy propyI ) phenoxy ) acetic acid ( compound 7 ) . TLC ( hexane : EtOAc : TFA 5.5 : 4.5 : 0.2 ) : Rf = 0.44 , Yie|d - 24.0 mg , % Yie|d - 48%. HPLC ( MeCN : H2O CF3COOH ( 0.1% ) gradient of 0 —— 100% in 45 min at 1ml / min ) retention time - 24.4 - 24.8 min. 1HNMR ( 600 MHz , CDCl3 ) 6 1.00 - 1.01 ( m , 1H ) , 1.43 - 1.49 ( m , 1H ) , 1.60 - 1.63 ( m , 2H ) , 1.74 - 1.80 ( m , 1H ) , 1.98 - 2.04 ( m , 1H ) , 2.15 - 2.23 ( m , 2H ) , 2.46 - 2.57 ( m , 2H ) , 3.15 ( dt , 1H , J = 2.4 Hz , 12.6 Hz ) , 3.74 ( td , 1H , J = 2.4 , 9.6 Hz ) , 3.85 ( s , 3H ) , 3.86 ( s , 3H ) , 4.65. 10. 15. 20. 25. 3O. 35. W0 2013 / 097947 PCT / EP2012 / OO5387 49. ( s , 2H ) , 4.85 ( d , 1H. J = 4.2 Hz ) , 5.57 ( dd , 1H , J = 5.5 Hz ) , 5.55 - 557 ( m , 2H ) , 5.79 - 6.82 ( m , 3H ) , 5.87 ( d. 1H , J = 7.8 Hz ) , 7.24 ( dd , 1H , J = 7.8 Hz ) , 7.52 ( t , 1H , J = 7.8 Hz ) , 8.05 - 8.08 ( m , 1H ) , 8.34 - 8.35 ( m , 1H ) , 8.59 ( t , 1H , J = 1.8 Hz ) . 13C NMR ( 150 MHz , CDC|3 ) 5 19.81 , 24.55 , 27.85 , 31.21 , 37.75. 42.88 , 55.47 , 55.92 , 55.93 , 54.75 , 75.73 , 111.35 , 111.77 , 112.98 , 114.14 , 120.12 , 122.34 , 125.91 , 129.85 , 13o.13 , 132.52 , 133.17 , 141.53 , 142.09 , 147.40 , 148.07 , 148.87 , 157.55 , 159.55 , 172.55. Ms ( ES| ) m / z : found RT 13.40 min. ( Method LCMS ) , 555.25 [ M + Na ] + , HRMS 721.2027 [ M + DMSO ] + , ca|cu|ated 543.1883. Examp|e 8 2 - ( 3 - ( ( R ) - 1 - ( ( S ) - 1 - ( 3 - aminophenylsulfonyI ) piperidine - 2 - carbonyloxy ) - 3 - ( 3 , 4 - dimethoxyphenyl ) propy| ) phenoxy ) acetic acid ( compound 8 ) , . TLC ( hexane : EtOAc : TFA 6 : 3.8 : 0.2 ) : Rf = 0.28 , Yie|d - 35 mg , % Yie|d - 66%. HPLC ( gradient A ) retention time - 21.32 - 21.52 min. 1HNMR ( 600 MHz , CDC|3 ) 6 1.21 - 1.29 ( m , 1H ) , 1.46 - 1.52 ( m , 1H ) , 1.60 - 1.66 ( m , 1H ) , 1.69 - 1.74 ( m , 1H ) , 1.79 - 1.86 ( m , 1H ) , 1.89 - 1.96 ( m , 1H ) , 2.07 - 2.13 ( m , 1H ) , 2.42 - 2.56 ( m , 2H ) , 3.10 - 3.25 ( m. 1H ) , 3.74 - 3.79 ( m , 1H ) , 3.84 ( s , 6H ) , 4.66 ( s , 2H ) , 4.70 - 4.74 ( m , 1H ) , 5.53 ( s , 1H ) , 6.60 - 6.68 ( m , 3H ) , 6.74 - 6.80 ( m , 2H ) , 6.82 - 6.86 ( m , 2H ) , 7.13 - 7.20 ( m , 2H ) , 7.36 - 7.54 ( m , 2H ) . 130 NMR ( 150 MHz , CDCl3 ) 5 20.05 , 24.80 , 28.03 , 31.35 , 37.99 , 42.75 , 55.20 , 55.89 , 55.92. 65.02 , 76.38 , 111.33 , 111.68 , 112.54 , 114.44 , 118.69 , 119.84 , 120.12 , 123.19 , 124.25 , 129.94 , 130.21 , 133.19 , 139.69 , 140.92 , 141.93 , 147.39 , 148.87 , 157.64 , 169.72 , 172.07. MS ( ES| ) m / z : found RT 10.87 min. ( Method LCMS ) , 613.12 [ M + 1 ] + , 635.17 [ M + Na ] + , HRMS 613.2704 [ M + 1 ] + , ca|culated 613.2142. Example 9 2 - ( 3 - ( ( R ) - 3 - ( 3 , 4 - dimethoxypheny| ) - 1 - ( ( S ) - 1 - ( 3 - ( 2 - methy|pyrimidin - 4 - yl ) phenyI su|fony| ) piperidine - 2 - carbony|oxy ) propy| ) phenoxy ) acetic acid ( compound 9 ) TLC ( hexane : EtOAc : TFA 6 : 3.8 : 0.2 ) : Rf = 0.22 , Yie|d - 48.3 mg , % Yie|d - 90%. HPLC ( MeCN : H2O CF3COOH ( 0.1% ) gradient of 0 - — 100% in 45 min at 1m| / min ) retention time - 23.1 - 23.5 min. 1HNMR ( 600 MHz , CDC|3 ) 6 1.14 - 1.21 ( m , 1H ) , 1.51 - 1.58 ( m , 1H ) , 1.61 - 1.63 ( m , 1H ) , 1.71 - 1.75 ( m , 1H ) , 1.83 - 1.90 ( m , 1H ) , 1.96 - 2.02 ( m , 1H ) . 2.12 - 2.18 ( m , 1H ) , 2.32 ( d , 1H , J = 13.8 Hz ) , 2.45 - 2.49 ( m , 1H ) , 2.52 - 2.57 ( m , 1H ) , 3.66 ( d , 1H , J = 12 Hz ) , 3.79 ( s , 3H ) , 3.80 ( s , 3H ) , 4.59 ( d , 1H , J = 16.8 Hz ) , 4.67 ( d , 2H , J =16.8 Hz ) , 4.98 ( d , 1H , J = 5.4 Hz ) , 5.51 ( dd , 1H , J = 5.4 Hz ) , 6.66 - 6.64 ( m , 2H ) , 6.75 ( m , 2H , J= 8.4 Hz ) , 6.81 - . 10. 15. 2O. 25. 3O. 35. WO 2013 / O97947 PCT / EP2012 / OO5387 50. 6.86 ( m , 2H ) , 7.26 ( m , 1H ) , 7.66 ( t , 1H , J = 7.8 Hz ) , 8.01 ( d , 1H , J = 6 Hz ) , 8.01 - 8.08 ( m , 1H ) , 8.41 - 8.43 ( m , 1H ) , 8.73 ( t , 1H , J =1.8 Hz ) , 9.07 ( d , 1H , J = 6.6 Hz ) . 13C NMR ( 150 MHz , CDC|3 ) 6 20.19 , 22.94 , 24.75 , 28.08 , 31.23 , 37.79 , 43.03 , 55.21 , 55.87 , 55.88 , 65.36 , 77.06 , 111.41 , 111.61 , 112.78 , 115.21 , 115.33 , 118.94 , 120.22 , 127. o2 , 129.86 , 130.19 , 131.83 , 132.08 , 133.02 , 134.97 , 141.62 , 141.84 , 147.39 , 148.85 , 151.43 , 157.99 , 164.28 , 167.69 , 170.58 , 171.54. MS ( ESl ) m / z : found RT 12.59 min. ( Method LCMS ) , 690.37 [ M + 1 ] + , 712.17 [ M + Na ] + , HRMS 690.2936 [ M + 1 ] + , ca|cu|ated 690.2407. Examp|e 10. 2 - ( 3 - ( ( R ) - 3 - ( 3 , 4 - dimethoxypheny| ) - 1 - ( ( S ) - 1 - ( 3 - ( pyrimidin - 4 - y| ) phenyl sulfony| ) piperidine - 2 - carbony|oxy ) propy| ) phenoxy ) acetic acid ( compound 10 ) TLC ( hexane : EtOAc : TFA 5 : 4.8 : 0.2 ) : Rf = 0.43 , Yie|d - 41.9 mg , % Yie|d - 80%. HPLC ( MeCN : H2O CF3COOH ( 0.1% ) gradient 0f 0 — 100% in 45 min at 1m| / min ) retention time - 24.2 - 24.6 min. 1HNMR ( 600 MHz , CDC|3 ) 6 1.10 - 1.17 ( m , 1H ) , 1.37 - 1.44 ( m , 1H ) , 1.58 - 1.61 ( m , 2H ) , 1.66 - 1.72 ( m , 1H ) , 1.94 - 2.00 ( m , 1H ) , 2.13 - 2.19 ( m , 2H ) . 2.42 - 2.47 ( m , 1H ) , 2.50 - 2.55 ( m , 1H ) , 3.25 ( dt , 1H , J= 3 Hz , 12.6 Hz ) , 3.83 ( d , 1H , J = 6 Hz ) , 3.85 ( s , 3H ) , 3.85 ( s , 3H ) , 4.67 ( d , 2H , J =6 Hz ) , 4.83 ( d , 1H , J = 4.2 Hz ) , 5.60 ( dd , 1H , J =5.4 Hz ) , 6.62 - 6.64 ( m , 2H ) , 6.77 ( d , 1H , J =8.4 Hz ) , 6.80 - 6.82 ( m , 1H ) , 6.86 - 6.88 ( m.2H ) , 7.22 ( t , 1H , J =8.4 Hz ) , 7.28 ( t , 1H , J = 4.8 Hz ) , 7.59 ( t , 1H , J = 7.8 Hz ) , 7.92 - 7.94 ( m , 1H ) , 8.55 ( dd , 1H , J = 1.2 Hz , 7.8Hz ) , 8.85 ( d , 3H , J = 4.8 Hz ) . 13C NMR ( 150 MHz , CDC|3 ) 6 19.99 , 24.53 , 27.41 , 31.28 , 38.02 , 42.93 , 55.35 , 55.88 , 55.92 , 64.85 , 111.31 , 111.74 , 112.30 , 114.60 , 119.88 , 119.95 , 120.17 , 127.01 , 129.17 , 129.45 , 129.71 , 132.08 , 133.42 , 137.71 , 141.12 , 141.77 , 147.27 , 148.79. 157.41 , 157.63 , 162.78 , 170.08 , 172.04. MS ( ES| ) m / z : found RT 13.30 min. ( Method LCMS ) , 676.20 [ M + 1 ] + , 698.33 [ M + Na ] + , HRMS 676.2783 [ M + 1 ] + , ca|cu|ated 676.2251. Examp|e 11 2 - ( 3 - ( ( R ) - 3 - ( 3 , 4 - dimethoxypheny| ) - 1 - ( ( S ) - 1 - ( 3 - fluoropheny|sulfony| ) piperidine - 2 - carbonyloxy ) propy| ) phenoxy ) acetic acid ( compound11 ) , . TLC ( hexane : EtOAc : TFA 5.5 : 4.5 : 0.2 ) : Rf = 0.44 , Yie|d - 23.5 mg , % Yie|d - 49%. HPLC ( gradient A ) retention time - 24.70 - 24.85 min. 1HNMR ( 300 MHz , CDC|3 ) 6 1.24 - 1.33 ( m , 1H ) , 1.41 - 1.53 ( m , 1H ) , 1.63 - 1.85 ( m , 3H ) , 1.94 - 2.06 ( m , 1H ) , 2.12 - 2.27 ( m , 2H ) , 2.45—2.61 ( m , 2H ) , 3.18 ( t , 1H , J= 12.7 Hz ) , 3.74 ( d , 1H , J= 12.6 Hz ) , 3.85 ( s , 6H ) , 4.71 ( s , 2H ) , 4.80 ( d , 1H , J= 4.8Hz ) , 5.63 ( t , 1H , J= 7.8 Hz ) , 6.65 - 6.67 ( m , 2H ) , 6.75 ( d , 1H , J= 8.7 Hz ) , 6.89 - 6.93 ( m , 3H ) , 7.13 - 7.34 ( m , 3H ) , 7.39 - 7.41 ( m , 2H ) . 10. 15. 2O. 25. 3O. 35. WO 2013 / 097947 PCT / EP2012 / 005387 51. 13C NMR ( 75 MHz , CDCl3 ) 5 2o.05 , 24.52 , 27.89. 31.24 , 37.95 , 42.77 , 55.37. 55.88 , 55.93 , 55.32 , 75.34 , 111.38 , 111.78. 112.55. 114.18 , 114.50 , 119.43 , 119.71. 120.18 , 122.83 , 129.86 , 13o.49. 133.29 , 141.77 , 147.39 , 148.89 , 157.75 , 150.53 , 163.86 , 155.31 , 159.73. Ms ( ES| ) m / z : found RT 13.19 min. ( Method LCMS ) , 538.19 [ M + Na ] + , HRMS 515.2488 [ M + 1 ] + ca|cu|ated 515.1938. Example 12 2 - ( 3 - ( ( R ) - 1 - ( ( S ) - 1 - ( 3 - bromopheny|sulfony| ) piperidine - 2 - carbony|oxy ) - 3 - ( 3 , 4 - dimethoxyphenyl ) propyl ) phenoxy ) acetic acid ( compound 12 ) , . TLC ( hexane : EtOAc : TFA 5.5 : 4.5 : 0.2 ) : Rf = O.36 , Yie|d - 29.87mg , % Yie|d - 57%. HPLC ( gradient A ) retention time - 25.89 - 26.02 min. 1HNMR ( 300 MHz , CDC|3 ) 6 1.24 - 1.32 ( m , 1H ) , 1.39 - 1.52 ( m , 1H ) , 1.62—1.85 ( m , 3H ) , 1.94 - 2.05 ( m , 1H ) , 2.11—2.27 ( m , 2H ) , 2.44 - 2.62 ( m , 2H ) , 3.16 ( dt , 1H , J= 2.7 ; 12.6 Hz ) , 3.71 ( d , 1H , J= 9.9 Hz ) , 4.70 ( s , 2H ) , 4.80 ( d , 1H , J= 4.5 Hz ) , 5.65 ( t , 1h , J= 8.1 Hz ) , 6.65 - 6.68 ( m , 2H ) , 6.79 ( d , 1H , J= 8.7 Hz ) , 6.88 - 6.93 ( m , 3H ) , 7.11 ( t , 1H , J= 8.1 Hz ) , 7.31 ( t , 1H , J== 8.25 Hz ) , 7.52 ( dd , 1H , J= 0.9 ; 7.8 Hz ) , 7.59 ( dd , 1H , J= 0.9 , 7.9 Hz ) , 7.87 ( t , 1H , J= 1.8Hz ) . 13C NMR ( 75 MHz , CDC|3 ) 6 20.06 , 24.59 , 27.87 , 31.23 , 37.96 , 42.79 , 55.48 , 55.89 , 55.94 , 64.86 , 76.43 , 111.41 , 111.80. 112.60 , 114.53. 120.09 , 120.21 , 122.73 , 125.64 , 129.89 , 130.33 , 133.32 , 135.46 , 141.60 , 141.75 , 147.37 , 148.86 , 157.75 , 169.81 , 172.68. MS ( ES| ) m / z : found RT 13.33 min. ( Method LCMS ) , 698.31 [ M + Na ] + , 700.12 [ M + 2 + Na ] + , HRMS 676.1716 [ M + 1 ] + , 678.1715 [ M + 3 ] + , ca|cu|ated 676.1138. Examp|e 13 2 - ( 3 - ( ( R ) - 1 - ( ( S ) - 1 - ( 3 , 5 - dich|oropheny|su|fony| ) piperidine - 2 - carbony|oxy ) - 3 - ( 3 , 4 - dimethoxy - phenyl ) propy| ) phenoxy ) acetic acid ( compound 13 ) . TLC ( hexane : EtOAc : TFA 5.5 : 4.5 : 0.2 ) : Rf = 0.58 , Yield - 22.6mg. % Yie|d - 44%. HPLC ( MeCN : H2O CF3COOH ( 0.1% ) gradient of 0 — 100% in 45 min at 1ml / min ) retention time - 26.8 - 27.3 min. 1HNMR ( 600 MHz , CDCl ; : , ) 6 1.03 - 1.10 ( m , 1H ) , 1.40 - 1.47 ( m , 1H ) . 1.60 - 1.63 ( m , 2H ) , 1.71 - 1.77 ( m , 1 H ) , 1.99 - 2.06 ( m , 1H ) , 2.16 - 2.23 ( m , 2H ) , 2.49 - 2.59 ( m , 2H ) , 3.20 ( dt , 1H , J = 2.4 Hz , 12.6 Hz ) , 3.71 ( td , 1H , J = 1.2 , 12.6 Hz ) , 3.85 ( s , 3H ) , 3.86 ( s , 3H ) , 4.66 ( s , 2H ) , 4.78 ( d , 1H , J = 4.8 Hz ) , 5.63 ( dd , 1H , J = 6 Hz ) , 6.66 - 6.68 ( m , 2H ) , 6.79 ( d , 1H , J = 7.8 Hz ) , 6.83 - 6.84 ( m , 1H ) , 6.85 ( t , 1H , J = 2.4 Hz ) , 6.90 ( d , 1H , J = 7.8 Hz ) , 7.26 ( dd , 1H , J = 7.8 Hz ) , 7.49 ( t , 1H , J =1.8 Hz ) , 7.66 ( d , 1H , J =1.8 Hz ) . 10. 15. 2O. 25. 3O. 35. W0 2013 / O97947 PCT / EP2012 / OO5387 52 13C NMR ( 150 MHz , CDC|3 ) 5 19.74 , 24.51 , 27.74 , 31.28 , 37.84 , 42.89 , 55.32 , 55.92 , 54.78 , 75.55 , 111.33 , 111.75 , 112.95. 114.17 , 120.00 , 120.17. 125.45 , 129.87 , 132.42. 133.21 , 135.73 , 141.53. 142.89 , 147.40 , 148.85. 157.53 , 159.57 , 172.53. Ms ( ES| ) m / z : round RT 14.33 min. ( Method LCMS ) , 588.19 [ M + Na ] + , 590.19 [ M + 2 + Na ] + , HRMS 555.1753 [ M + 1 ] 2 558.1713 [ M + 3 ] * , ca|culated 555.1253. Examp|e 14 2 - ( 3 - ( ( R ) - 1 - ( ( S ) - 1 - ( 2 , 3 - dich|orophenylsu|fonyl ) piperidine - 2 - carbony|oxy ) - 3 - ( 3 , 4 - dimethoxy pheny| ) propyl ) phenoxy ) acetic acid ( compound 14 ) . TLC ( hexane : EtOAc : TFA 6 : 3.8 : 0.2 ) : Rf = O.50 , Yie|d - 18.7 mg. HPLC ( MeCN : H2O CF3COOH ( 0.1% ) gradient of 0 — 100% in 45 min at 1m| / min ) retention time - 27.1 - 27.5 min. MS ( ESl ) m / z : found RT 12.79 min. ( Method LCMS ) , 688.14 [ M + Na ] + , 690.11 [ M + 2 + Na ] + , HRMS 688.1090 [ M + Na ] + , 690.1061 [ M + 2 + Na ] + , ca|cu|ated 666.1253. Examp|e 15 2 - ( 3 - ( ( R ) - 3 - ( 3.4 - dimethoxypheny| ) - 1 - ( ( S ) - 1 - ( 3 , 4 - dimethoxyphenylsu|fony| ) piperidine - 2 - carbonyloxy ) propy| ) phenoxy ) acetic acid ( compound 15 ) . Yie|d - 32.89 mg , % Yield - 62%. HPLC ( MeCN : H2O CF3COOH ( 0.1% ) gradient of 0 — 100% in 45 min at 1m| / min ) retention time - 23.1 - 23.5 min. 1HNMR ( 600 MHz , CDC|3 ) 6 1.08 - 1.15 ( m.1H ) . 1.32 - 1.39 ( m , 1H ) . 1.53 - 1.60 ( m , 2H ) , 1.64 - 1.70 ( m , 1H ) , 1.99 - 2.06 ( m , 1H ) , 2.14 - 2.23 ( m , 2H ) . 2.48 - 2.59 ( m , 2H ) , 3.19 ( dt , 1H. J = 3. 10.2 Hz ) , 3.63 ( d , 1H , J = 11.4Hz ) , 3.83 ( s , 3H ) , 3.84 ( s , 3H ) , 3.87 ( s , 3H ) , 3.87 ( s , 3H ) . 4.65 ( s , 2H ) , 4.78 ( d , 1H , J = 4.8 Hz ) . 5.64 ( dd , 1H , J = 1.2 , 6.0 Hz ) , 6.66 ( d , 2H , J = 7.2 Hz ) , 6.73 ( s , 1H , J = 8.4Hz ) , 6.81 - 6.83 ( m , 2H ) , 6.88 - 6.91 ( m , 2Hz ) , 7.22 - 7.24 ( m , 2H ) , 7.41 ( dd , 1H , J = 0.6 , 8.4Hz ) . 13C NMR ( 150 MHz , CDC|3 ) 6 20.04 , 24.43 , 27.53 , 31.25 , 37 , 98 , 42.63 , 55.16 , 55.88 , 55.89 , 56.06. 56.17 , 64.89 , 76.48 , 109.76 , 110.41 , 111.32 , 111.74 , 112.74 , 114.40 , 119.85 , 120.16 , 121.03 , 129.75 , 131.88 , 133.30 , 141.79 , 147.34 , 148.84 , 148.93 , 152.41 , 157.58. MS ( ESl ) m / z : found RT 12.83 min. ( Method LCMS ) , 680.21 [ M + Na ] + , HRMS 680.2753 [ M + Na ] + , ca|cu|ated 658.2244. Examp|e 16 2 - ( 3 - ( ( R ) - 1 - ( ( S ) - 1 - ( 3 - chloro - 4 - methoxyphenylsulfony| ) piperidine - 2 - carbonyl oxy ) - 3 - ( 3 , 4 - dimethoxypheny| ) propy| ) phenoxy ) aceticacid ( compound 16 ) , . TLC ( hexane : EtOAc : TFA 6 : 3.8 : 0.2 ) : Rf = 0.45 , Yie|d - 11.7mg , % Yield - 25%. HPLC ( gradient A ) retention time - 24.98 - 25.12 min. 10. 15. 20. 25. 3O. 35. W0 2013 / O97947 PCT / EP2012 / OO5387 53. 1HNMR ( 300 MHz , CDC|3 ) 5 1.25 - 1.34 ( m , 1H ) , 1.41 - 1.54 ( m , 1H ) , 1.63 - 1.85 ( m , 3H ) , 1.95 - 2.05 ( m , 1H ) , 2.13 - 2.27 ( m , 2H ) , 2.45 - 2.54 ( m , 2H ) , 3.15 ( dt , 1H , J= 2.7 , 12.5 Hz ) , 3.59 ( d , 1H , J= 12.1 Hz ) , 3.85 ( s , 6H ) , 3.89 ( s , 3H ) , 4.72 ( s , 2H ) , 4.81 ( d , 1H , J= 4.5 Hz ) , 5.55 ( t , 1H , J= 5.5 Hz ) , 5.55 - 5.72 ( m , 3H ) , 6.78 ( d , 1H , J= 8.7 Hz ) . 5.91 - 5.95 ( m , 3H ) , 7.32 ( t , 1H , J= 8.3 Hz ) , 7.47 ( dd , 1H , J= 2.4 , 9.3 Hz ) , 7.72 ( d , 1H , J= 2.4 Hz ) 130 NMR ( 75 MHz , CDC|3 ) 5 20.09 , 24.50 , 27.93 , 31.25 , 38.11 , 42.53 , 55.31 , 55.90 , 55.94 , 55.37 , 54.87 , 75.21 , 111.33 , 111.38 , 111.79 , 112.22 , 114.58 , 120.14 , 120.19 , 122.95 , 127.55 , 129.15 , 129.85 , 132.20 , 133.30. 142.00 , 147.40. 148.89 , 157.74 , 158.07 , 159.87 , 172.04. Ms ( ES| ) m / z : found RT 13.48 min. ( Method LCMS ) , 584.27 [ M + Na ] + , HRMS 552.2304 [ M + 1 ] * , 554.2288 [ M + 3 ] + , ca|cu|ated 552.1748. Example 17 2 - ( 3 - ( ( R ) - 1 - ( ( S ) - 1 - ( 3 , 5 - dif|uoropheny|su|fony| ) piperidine - 2 - carbony|oxy ) - 3 - ( 3 , 4 - dimethoxyphenyl ) propyl ) phenoxy ) acetic acid ( compound 17 ) , . TLC ( hexane : EtOAc : TFA 6 : 3.8 : 0.2 ) : Rf = 0.38 , Yie|d - 23.5mg , % Yie|d— 57%. HPLC ( gradient A ) retention time - 25.22 - 25.39 min. 1HNMR ( 300 MHz , CDC|3 ) 6 1.21 - 1.35 ( m , 1H ) , 1.42 - 1.55 ( m , 1H ) , 1.65 - 1.84 ( m , 3H ) , 1.96 - 2.08 ( m , 1H ) , 2.14 - 2.30 ( m. 2H ) , 2.45 - 2.63 ( m , 2H ) , 3.17 ( t , 1H , J= 12 Hz ) , 3.73 ( d , 1H , J= 11.9 Hz ) , 3.85 ( s. 6H ) , 4.78 ( s , 2H ) , 4.72 ( s , 1H ) , 5.66 ( t , 1H , J= 6 Hz ) , 6.65 - 6.68 ( m , 2H ) , 6.79 ( d , 1H , J = 4.4 Hz ) , 6.87 - 6.93 ( m , 4H ) , 7.20 ( d , 2H , J= 1.8 Hz ) , 7.31 ( t , 1H , J= 7.5 Hz ) . 13C NMR ( 75 MHz , CDCl3 ) 5 20.09 , 24.55 , 27.88 , 31.23 , 37.83 , 42.99 , 53.42 , 55.59. 55.87 , 55.93 , 77.23 , 107.66 , 107.98 , 110.43 , 110.79 , 111.39 , 111.76 , 112.74 , 114.49. 120.09 , 120.18 , 129.93 , 133.26 , 141.51 , 143.17 , 147.40 , 148.88 , 157.69 , 160.92 , 164.13 , 169.63. MS ( ES| ) m / z : found RT 13.46min. ( Method ' LCMS ) , 656.19 [ M + Na ] + , HRMS 634.7102 [ M + 1 ] + , ca|cu|ated 634.6568. Examp|e 18 2 - ( 3 - ( ( R ) - 1 - ( ( S ) - 1 - ( 3 , 5 - bis ( trifluoromethy| ) pheny|su|fony| ) piperidine - 2 - carbonyloxy ) - 3 - ( 3 , 4 - dimethoxypheny| ) propyl ) phenoxy ) acetic acid ( compound 18 ) TLC ( hexane : EtOAc : TFA 6 : 3.8 : 0.2 ) : Rf = 0.47 , Yie|d - 30.1 mg , % Yield - 51%. HPLC ( MeCN : H2O CF3COOH ( 0.1% ) gradient of O — 100% in 45 min at 1m| / min ) retention time - 27.5 - 27.8 min. 1HNMR ( 600 MHz , CDC|3 ) 6 0.99 - 1.01 ( m , 1H ) , 1.40 - 1.47 ( m , 1H ) , 1.59 - 1.61 ( m , 2H ) , 1.73 - 1.79 ( m , 1 H ) , 1.99 - 2.05 ( m , 1H ) , 2.14 - 2.23 ( m , 2H ) . 2.46 - 2.56 ( m , 2H ) , 3.09 ( dt , 1H , J = 2.4 Hz ) , 3.69 ( dd , 1H , J = 1.8 Hz ) , 3.84 ( s , 3H ) , 3.85 ( s. 3H ) , 4.64 ( s , 2H ) , 4.83 ( d , 1H , J = 4.2 Hz ) , 5.56 ( t , 1H , J = 6.6 Hz ) , 6.63 - 6.66 ( m , 2H ) , 6.78 ( d , 1H , J = 7.8 Hz ) , . 10. 15. 2O. 25. 3O. 35. W0 2013 / 097947 PCT / EP2012 / 005387 54. 6.80 - 6.82 ( m , 2H ) , 6.88 ( d , 2H , J= 7.8 ) , 7.24 ( t , 1H. J =7. 8 Hz ) . 8.031 ( s , 1H ) , 8.20 ( s , 1H ) . 13C NMR ( 150 MHz , CDC|3 ) 5 19.74 , 24.58 , 27.88 , 31.21 , 37.71 , 42.83 , 55.59 , 55.87 , 55.88 , 54.73. 75.92 , 111.31 , 111.71 , 113.02 , 114.13 , 119.98 , 120.09 , 121.52 , 123.44 , 125.27. 127.29. 127.51 , 129.87 , 133.12 , 141.57 , 142.53 , 147.39 , 148.83. 157.48 , 159.47 , 172.22 Ms ( ES| ) m / z : found RT 14.55 min. ( Method LCMS ) , 755.20 [ M + Na ] + , HRMS 812.2680 [ M + DMSO ] + , calcu|ated 734.1780. Examp|e 19 2 - ( 3 - ( ( R ) - 1 - ( ( S ) - 1 - ( 3 - bromo - 5 - ( trif|uoromethy| ) pheny|su|fony| ) piperidine - 2 - carbonyloxy ) - 3 - ( 3 , 4 - dimethoxyphenyl ) propy| ) phenoxy ) acetic acid ( compound 19 ) . TLC ( hexane : EtOAc : TFA 6 : 3.8 : 0.2 ) : Rf = 0.50 , Yie|d - 28.5mg. % Yie|d - 47%. HPLC ( MeCN : H2O CF3COOH ( 0.1% ) gradient of 0 — 100% in 45 min at 1m| / min ) retention time - 27.5 - 27.8 min. 1HNMR ( 600 MHz , CDC|3 ) 6 0.97 - 1.04 ( m , 1H ) , 1.40 - 1.46 ( m , 1H ) , 1.59 - 1.62 ( m.2H ) , 1.71 - 1.77 ( m , 1H ) , 1.99 - 2.05 ( m , 1H ) , 2.15 - 2.22 ( m , 2H ) . 2.47 - 2.57 ( m , 2H ) , 3.15 ( dt , 1H , J 2.4 , 12.6 Hz , ) , 3.68 ( dd , 1H. J = 2.6Hz ) , 3.84 ( s , 3H ) , 3.85 ( s , 3H ) , 4.65 ( s , 2H ) , 4.80 ( d , 1H , J = 4.8 Hz ) , 5.59 ( t , 1H , J = 7.2 Hz ) , 6.64 - 6.67 ( m , 2H ) , 6.78 ( d , 1H , J = 8.4Hz ) , 6.81 - 6.84 ( m , 2H ) , 6.89 ( d , 1 H , J = 7.2Hz ) , 7.25 ( t , 1H , J = 7.8Hz ) , 7.90 ( s , 1H ) , 7.95 ( s , 1H ) , 8.08 ( s , 1H ) . 13C NMR ( 150 MHz , ch13 ) 5 19.74 , 24.59 , 27.80 , 31.24 , 37.77 , 42.86 , 55.45 , 55.90 , 64.75 , 76.77 , 111.32 , 111.74 , 112.98 , 114.15 , 119 , 99 , 120.14 , 122.80 , 123.32 , 129.87 , 132.12 , 132.15 , 133.17 , 133.25 , 141.60 , 142.89 , 147.39 , 148.84 , 157.49. 169.49 , 172.39. MS ( ES| ) m / z : found RT 14.60 min. ( Method LCMS ) , 766.16 [ M + Na ] + , 768.08 [ M + 2 + Na ] + , HRMS 766.1568 [ M + Na ] + , 768.1556 [ M + 2 + Na ] + , ca|culated 744.1011. Examp|e 20 2 - ( 3 - ( ( R ) - 1 - ( ( S ) - 1 - ( 3 , 5 - bis ( methoxycarbony| ) phenylsu|fony| ) piperidine - 2 - carbonyloxy ) - 3 - ( 3 , 4 - dimethoxypheny| ) propy| ) phenoxy ) acetic acid ( compound 20 ) . TLC ( hexane : EtOAc : TFA 6 : 3.8 : 0.2 ) : Rf = 0.52 , Yield - 22mg , % Yield - 41%. HPLC ( gradient A ) retention time - 24.82 - 25.02 min. 1HNMR ( 400 MHz , CDC|3 ) 6 1.21 - 1.31 ( m , 1H ) , 1.37 - 1.47 ( m , 1H ) , 1.61 - 1.80 ( m , 3H ) , 1.91 - 2.00 ( m , 1H ) , 2.08 - 2.17 ( m , 1H ) , 2.28 ( d , 1H , J= 6.8 Hz ) , 2.40 - 2.55 ( m , 2H ) , 3.15 ( dt , 1H , J= 2.8 , 12.8 Hz ) , 3.78 ( d , 1H , J= 12.6 Hz ) , 3.82 ( s , 3H ) , 3.83 ( s , 3H ) , 3.93 ( s , 6H ) , 4.70 ( s , 2H ) , 4.81 ( s , 1H , J= 2.4 Hz ) , 5.63 ( t , 1H , J= 6.8 Hz ) , 6.61 - 6.63 ( m , 2H ) , 6.75 ( d , 1H , J= 4.2 Hz ) , 6.84 - 6.88 ( m , 3H ) , 7.23 - 7.27 ( m , 1H ) , 8.54 ( s , 1H ) , 8.55 ( s , 1H ) , 8.76 ( t , 1H , J= 1.6 Hz ) . 10. 15. 2O. 25. 3O. 35. W0 2013 / O97947 PCT / EP2012 / OO5387 55. 13C NMR ( 100 MHz , CDC|3 ) 5 20.21 , 24.55 , 27.77 , 31.13 , 37.75 , 43.04 , 52.85 , 55.51 , 55.84 , 55.89 , 64.91 , 76.47 , 111.27 , 111.68 , 112.70 , 114.57 , 120.08 , 120.10 , 129.79 , 131.53 , 131.95 , 133.25 , 134.01 , 141.30 , 141.73 , 147.31 , 148.80 , 157.58 , 164.86 , 169.61 , 172.02. Ms ( ES| ) m / z : round RT 11.80 min. ( Method LCMS ) , 735.15 [ M + Na ] + , HRMs 714.2720 [ M + 1 ] + , ca|culated 714.2142. Examp|e 21 2 - ( 3 - ( ( R ) - 1 - ( ( S ) - 1 - ( 3 , 5 - dichloro - 4 - hydroxypheny|sulfony| ) piperidine - 2 - carbo ny|oxy ) - 3 - ( 3 , 4 - dimethoxypheny| ) propy| ) phenoxy ) acetic acid ( compound 21 ) TLC ( hexane : EtOAc : TFA 4.8 : 5 : 0.2 ) : Rf = 0.50 , Yie|d - 12.3mg , % Yie|d - 23%. HPLC ( MeCN : H2O CF3COOH ( 0.1% ) gradient of 0 - 100% in 45 min at 1ml / min ) retention time - 26.8 - 27.1 min. 1HNMR ( 300 MHz , CDC|3 ) 6 1.00 - 1.10 ( m. 1H ) , 1.38 - 1.53 ( m , 1H ) , 1.60 - 1.68 ( m , 2H ) , 1.74 - 1.87 ( m , 1H ) , 2.01 - 2.12 ( m , 1H ) , 2.16 - 2.26 ( m , 2H ) , 2.53 - 2.62 ( m , 2H ) , 3.21 ( t , 1H , J= 12Hz ) , 3.72 ( d , 1H , J= 12Hz ) , 3.87 ( s , 6H ) , 4.65 ( s , 2H ) , 4.77 ( d , J= 2.7Hz ) , 5.63 ( t , J= 6Hz ) , 6.69 - 6.71 ( m , 2H ) , 6.80 - 6.93 ( m , 4H ) , 7.28 ( s , 1H ) , 7.78 ( s , 1H ) , 7.99 ( s , 1H ) . 13C NMR ( 75 MHz , CDC|3 ) 6 19.66 , 24.66 , 27.85 , 31.34 , 37.88 , 43.01 , 55.4 , 55.95 , 64.82 , 77.21 , 111.44. 111.83 , 113.02 , 114.23 , 119.84 , 120.21 , 122.20 , 127.86 , 128.97. 129.89 , 139.94 , 141.75 , 145.83 , 147.22 , 148.89 , 153.52 , 157.56 , 169.51 , 172.35. MS ( ES| ) m / z : found Rt 13.66 min. ( Method LCMS ) , 704.68 [ M + Na ] + . HRMS 682.1962 , 684.1949 [ M + H ] + , calcu|ated 682.1902 [ M + H ] + . Examp|e 22 2 - ( 3 - ( ( R ) - 1 - ( ( S ) - 1 - ( 3 , 5 - dichloro - 4 - methoxypheny|sulfony| ) piperidine - 2 - carbo ny|oxy ) - 3 - ( 3 , 4 - dimethoxypheny| ) propyl ) phenoxy ) acetic acid ( compound 22 ) . TLC ( hexane : EtOAc : TFA 6 : 3.8 : 0.2 ) : Rf = 0.41 , Yie|d - 18.3mg , % Yield - 39%. HPLC ( gradient B ) retention time - 11.6 - 11.9 min. 1HNMR ( 600 MHz , CDCl3 ) 6 1.02 - 1.09 ( m , 1H ) , 1.39 - 1.46 ( m , 1H ) , 1.59 - 1.62 ( m , 2H ) , 1.70 - 1.76 ( m , 1H ) , 1.99 - 2.05 ( m , 1H ) , 2.15 - 2.23 ( m , 2H ) . 2.49 - 2.59 ( m , 2H ) , 3.18 ( dt , 1H , J 2.4 , 12.6 Hz , ) , 3.68 ( dd , 1H , J = 3 , 12.6 Hz ) , 3.84 ( s , 3H ) , 3.85 ( s , 3H ) , 3.92 ( s , 3H ) , 4.66 ( s , 2H ) , 4.76 ( d , 1H , J = 4.8 Hz ) , 5.61 ( t , 1H , J = 6.6 Hz ) , 6.64 - 6.67 ( m , 2H ) , 6.78 ( d , 1H , J = 8.4Hz ) , 6.81 - 6.84 ( m , 2H ) , 6.89 ( d , 1H , J = 7.8Hz ) , 7.25 ( t , 1H , ' J = 7.8Hz ) , 7.71 ( s , 2H ) . 13C NMR ( 150 MHz , CDC|3 ) 6 19.78 , 24.58 , 27.70 , 31.28 , 37.83 , 42.84 , 55.31 , 55.90 , 60.95 , 64.85 , 76.64 , 111.34. 111.76 , 112.90 , 114.23 , 120.01 , 120.17 , 127.73 , 129.85 , 130.06 , 133.19. 136.95 , 141.66. 147.37 , 148.84 , 155.65 , 157.48 , 169.67. 10. 15. 20. 25. 3O. 35. W0 2013 / 097947 PCT / EP2012 / 005387 55 Ms ( ES| ) m / z : found RT 11.84 min. ( Method LCMS ) , 718.37 [ M + Na ] + , 720.25 [ M + Na + 2 ] “ , HRMS 696.1423 [ M + 1 ] + , 698.2819 [ M + 3 ] + , ca|culated 696.1359. Example 23 2 - ( 3 - ( ( R ) - 1 - ( ( S ) - 1 - ( 4 - acetamido - 3 , 5 - dichlorophenylsulfony| ) piperidine - 2 - carbo ny|oxy ) - 3 - ( 3 , 4 - dimethoxyphenyl ) propyl ) phenoxy ) acetic acid ( compound 23 ) , TLC ( hexane : EtOAc : TFA 6 : 3.8 : 0.2 ) : Rf = 0.48. Yie|d - 10.98 mg , % Yield - 21%. HPLC ( gradient B ) retention time - 22.45 - 22.67min. 1HNMR ( 300 MHz , CDC|3 ) 6 1.27 ( s , 3H ) , 1.63 - 1.81 ( m , 1H ) , 1.95 - 2.05 ( m , 2H ) , 2.12 - 2.33 ( m , 5H ) . 2.51 ( t , 2H , J= 6.9 Hz ) , 3.06 ( t , 1H , J= 10.8 Hz ) . 3.74 ( d , 1H , J= 10.2 Hz ) , 3.85 ( s , 3H ) , 3.86 ( s , 3H ) , 4.67 ( s , 3H ) , 4.80 ( d , 1H. J= 4.8 Hz ) , 5.63 ( t , 1H , J= 6 Hz ) , 6.65 - 6.68 ( m , 2H ) , 6.74 ( s , 1H ) , 6.8O ( d , 1H , J= 8.4 Hz ) , 6.85 - 6.92 ( m , 2H ) , 7.29 ( t , 1H , J= 7.9Hz ) , 7.68 ( s , 2H ) . 13C NMR ( 75 MHz , CDC|3 ) 6 20.14 , 24.80 , 28.02 , 29.69 , 31.24 , 37.65 , 43.11 , 55.61 , 55.86 , 55.96 , 64.97 , 76.72 , 111.41 , 111.77 , 112.99 , 114.45 , 120.25 , 120.30 , 127.00 , 130.00 , 133.20 , 134.24 , 135.52 , 140.49 , 141.28 , 147.38 , 148.84 , 157.66 , 169.49 , 169.60 , 171.46. MS ( ES| ) m / z : found RT 12.25 min. ( Method LCMS ) , 723.02 [ M + 1 ] + , 725.02 [ M + 3 ] + , HRMS 723.2017 [ M + 1 ] + , 725.2081 [ M + 3 ] + , ca|cu|ated 723.1468. Examp|e 24 5 - ( ( S ) - 2 - ( ( ( R ) - 1 - ( 3 - ( carboxymethoxy ) phenyl ) - 3 - ( 3 , 4 - dimethoxypheny| ) propoxy ) carbony| ) piperidin - 1 - y|su|fony| ) - 2 , 3 - dimethoxybenzoic acid ( compound 24 ) , TLC ( DCM : MeOH 9.7 : 0.3 ) : Rf = 0.38 , Yield - 7.23mg. % yie|d 45%. HPLC ( gradient A ) retention time - 22.79 - 22.95 min. 1HNMR ( 400 MHz , DMSO ) 6= 1.58 - 1.73 ( m , 3H ) , 1.94 - 2.05 ( m , 2H ) , 2.15 - 2.30 ( m , 4H ) , 2.71 - 2.97 ( m , 3H ) , 3.67 - 3.71 ( m , 9H ) , 3.80 ( s , 3H ) , 4.22 ( t , 1H , J= 7.6 Hz ) , 4.58 ( s , 2H ) , 5.35 ( s. 1H ) , 6.68 - 6.72 ( m , 1H ) , 6.75 ( s , 1H ) , 6.81 - 6.89 ( m , 4H ) , 6.95 - 6.99 ( m , 1H ) , 7.06 - 7.11 ( m , 1H ) , 7.16 - 7.20 ( m , 1H ) . 13C NMR ( 100 MHz , DMSO ) 6= 21.20 , 25.10 , 31.08 , 31.61 , 36.50 , 51.04 , 52.19 , 55.33 , 55.92 , 56.03 , 56.06 , 61.24 , 64.84 , 108.62 , 111.06 , 112.33 , 112.40 , 112.62 , 114.33 , 120.46 , 120.71 , 129.88 , 133.63. 135.79 , 137.97 , 145.07 , 147.45 , 147.74 , 148.33 , 148.59 , 149.09 , 151.85 , 158.28 , 170.61. MS ( ES| ) m / z : found RT 10.48 min. ( Method LCMS ) , 702.10 [ M + 1 ] + , HRMS 702.2761 [ M + 1 ] + , ca|cu|ated 702.2142. Example 25 2 - ( 3 - ( ( R ) - 3 - ( 3 , 4 - dimethoxyphenyl ) - 1 - ( ( S ) - 1 - ( 7 - nitro - 2 , 3 - dihydrobenzofuran - 5 - y|su|fony| ) piperidine - 2 - carbononxy ) propy| ) phenoxy ) acetic acid ( compound 25 ) . 10. 15. 20. 25. 3O. 35. W0 2013 / 097947 PCT / EP2012 / 005387 57. TLC ( DCM : MeOH 9.7 : 0.3 ) : Rf = 0.43 , Yie|d - 22mg , % yie|d 42%. HPLC ( gradient A ) retention time - 24.08 - 24.24 min 1HNMR ( 400 MHz , CDCl3 ) 6 1.24 - 1.32 ( m , 1H ) , 1.47 - 1.50 ( m , 1H ) , 1.67 - 1.77 ( m , 2H ) , 1.82 - 1.91 ( m , 1H ) , 1.92 - 2.01 ( m , 1H ) , 2.09 - 2.19 ( m , 1H ) , 2.28 ( d , 1H , J= 12.4Hz ) , 2.41 - 2.60 ( m , 2H ) , 2.92 - 3.04 ( m , 1H ) , 3.11 - 3.20 ( m , 2H ) , 3.74 ( d , 1H , J= 12Hz ) , 3.83 ( s , 3H ) , 3.84 ( s , 3H ) , 4.70 ( s , 2H ) , 4.78 - 4.87 ( m , 3H ) , 4.78 - 4.87 ( m , 3H ) , 5.55 - 5.59 ( m , 1H ) , 6.61 - 6.64 ( m , 2H ) , 6.76 ( d , 1H , J= 8Hz ) , 6.80 - 6.88 ( m , 3H ) , 7.27 ( t , 1H , J= 8Hz ) , 7.52 ( d , 1H , J= 2Hz ) , 8.24 ( d , 1H , J= 2Hz ) . 13C NMR ( 100 MHz , CDCl3 ) 6 20.17 , 24.75 , 28.16 , 28.29 , 31.28 , 38.25 , 42.17 , 55.52 , 55.85 , 55.90. 64.78 , 74.88 , 76.31 , 111.30 , 111.62 , 111.97 , 114.46 , 119.62 , 120.12 , 124.34 , 128.80 , 129.83. 132.14 , 133.13 , 133.79. 141.85. 147.37. 148.85 , 157.74 , 157.90 , 169.71 , 171.79 MS ( ES| ) m / z : found RT 11.54 min. ( Method LCMS ) , 707.14 [ M + Na ] + , HRMS 685.2601 [ M + 1 ] + , ca|cu|ated 685.1989. Examp|e 26 2 - ( 3 - ( ( R ) - 1 - ( ( S ) - 1 - ( 7 - amino - 2 , 3 - dihydrobenzofuran - 5 - ylsu|fonyl ) piperidine - 2 - carbononxy ) - 3 - ( 3 , 4 - dimethoxypheny| ) propy| ) phenoxy ) aceticacid ( compound 26 ) TLC ( DCM : MeOH 9.7 : 0.3 ) : Rf = 0.35 , Yie|d - 6.7mg , % yield 14%. HPLC ( gradient A ) retention time - 21.68 - 21.89 min. 1HNMR ( 600 MHz , CDC|3 ) 6 = 1.24 - 1.32 ( m , 1H ) , 1.47 - 1.50 ( m , 1H ) , 1.67 - 1.77 ( m , 2H ) , 1.82 - 1.91 ( m , 1H ) , 1.92 - 2.01 ( m , 1H ) , 2.09—2.19 ( m , 1H ) , 2.28 ( d , 1H , J= 12.4Hz ) , 2.41 - 2.60 ( m , 2H ) , 2.92 - 3.04 ( m , 1H ) , 3.11 - 3.20 ( m , 2H ) , 3.74 ( d , 1H , J= 12Hz ) , 3.83 ( s , 3H ) , 3.84 ( s , 3H ) , 4.70 ( s , 2H ) , 4.78 - 4.87 ( m , 3H ) , 4.78—4.87 ( m , 3H ) , 5.55 - 5.59 ( m , 1H ) , 6.61 - 6.64 ( m , 2H ) , 6.76 ( d , 1H , J= 8Hz ) . 6.84 ( s , 1H ) , 6.90 - 6.98 ( m , 3H ) , 7.27 ( t , 1H , J= 8Hz ) , 8.24 ( d , 1H , J= 2Hz ) . 13C NMR ( 150 MHz , CDC|3 ) 5 = 20.17 , 24.75 , 28.15 , 28.29. 31.28 , 38.25 , 42.17 , 55.52 , 55.85. 55.90 , 64.78 , 74.88 , 76.31 , 111.30 , 111.62 , 111.97 , 114.46 , 119.62 , 120.12 , 124.34 , 128.80 , 129.83 , 131.69 , 132.14 , 133.13 , 137.16 , 141.85 , 147.37 , 148.85 , 157.74 , 157.90 , 169.71 , 171.79. MS ( ES| ) m / z : found RT 12.22 min. ( Method LCMS ) , 655.08 [ M + 1 ] ‘" , 677.25 [ M + Na ] + , HRMS 655.2291 [ M + 1 ] + , ca|cu|ated 655.2247. Example 27 2 - ( 3 - ( ( R ) - 3 - ( 3 , 4 - dimethoxypheny| ) - 1 - ( ( S ) - 1 - ( 2 - methylbenzo [ d ] thiazol - 6 - y|sulf onyl ) piperidine - 2 - carbonyloxy ) propy| ) phenoxy ) acetic acid ( compound 27 ) , TLC ( DCM : MeOH 9.7 : 0.3 ) : Rf = 0.26 , Yie|d - 22mg , % yie|d 43%. HPLC ( gradient A ) retention time - 24.22 - 24.38 min. 10. 15. 2O. 25. 3O. 35. W0 2013 / O97947 PCT / EP2012 / OO5387 58. 1HNMR ( 400 MHz , CDC|3 ) 6= 1.24 - 1.32 ( m , 1H ) , 1.50 - 1.61 ( m , 1H ) , 1.65 - 1.73 ( m , 2H ) , 1.85 - 1.95 ( m , 2H ) , 2.03 - 2.13 ( m , 1H ) , 2.18 ( d , 1H , J=13.6 Hz ) , 2.38 - 2.54 ( d , 2H ) , 2.89 ( s , 3H ) , 3.17 - 3.25 ( m , 1H ) , 3.81 ( s , 3H ) , 3.82 ( s , 3H ) , 4.72 ( d , 1H , J= 8.4 Hz ) , 4.82 ( d , 1H , J= 4.4 Hz ) , 5.44 - 5.47 ( m , 1H ) , 6.58 - 6.61 ( m , 2H ) , 6.68 ( s , 1H ) , 6.74 ( d , 1H , J= 8 Hz ) , 6.98 - 7.02 ( m , 1H ) . 13C NMR ( 100 MHz , CDC|3 ) 6= 19.76 , 19.96 , 24.74 , 28.21. 31.33 , 38.54 , 42.44 , 55.07 , 55.82 , 55.88. 65.29 , 75.86 , 111.25 , 111.55 , 112.34 , 114.90 , 119.22 , 120.06 , 120.93 , 121.81 , 125.10 , 130.15 , 133.14 , 134.98 , 135.77 , 142.02 , 147.34 , 148.83 , 154.03 , 157.70 , 169.43 , 171.12 , 172.52. MS ( ES| ) m / z : found RT 11.66 min. ( Method LCMS ) , 668.16 [ M + 1 ] + , 691.11 [ M + Na ] + , HRMS 669.2459 [ M + 1 ] + , ca|cu|ated 669.1862. Examp|e 28 2 - ( 3 - ( ( R ) - 3 - ( 3 , 4 - dimethoxyphenyl ) - 1 - ( ( S ) - 1 - ( 2 - oxo - 2 , 3 - dihydrobenzo [ d ] thiazol - 6 - y|su|fonyI ) piperidine - 2 - carbony|oxy ) propyl ) phenoxy ) aceticacid ( compound 28 ) , TLC ( DCM : MeOH 9.7 : 0.3 ) : Rf = 0.37 , Yie|d - 24.20mg , % yie|d 46.8%. HPLC ( gradient A ) retention time - 22.74 - 22.94 min. 1HNMR ( 600 MHz , CDCl3 ) 6 1.38 - 1.45 ( m , 1H ) , 1.59 - 1.66 ( m , 1H ) , 1.73 - 1.75 ( m , 2H ) , 1.89 - 1.99 ( m , 2H ) , 2.09 - 2.16 ( m , 2H ) , 2.41 - 2.46 ( m , 1H ) , 2.52 - 2.57 ( m , 1H ) , 3.23 ( t , 1H , J= 10.2 Hz ) , 3.78 ( d , 1H , J= 7.8Hz ) , 3.82 ( s , 3H ) , 3.83 ( s , 3H ) , 4.72 - 4.82 ( m , 3H ) , 5.41 - 5.43 ( m , 1H ) , 6.18 ( d , 1H , J= 8.4Hz ) , 6.58 - 6.65 ( m , 3H ) , 6.76 ( d , 1H , j= 8.4 Hz ) , 6.92 ( d , 1H , J= 6.6Hz ) , 7.01 ( d , 1H , J= 8.4Hz ) . 7.09 ( d , 1H , J= 8.4Hz ) , 7.41 ( t , 1H , J= 7.8Hz ) , 7.66 ( d , 1H , J= 1.8Hz ) . 13C NMR ( 150 MHz. CDC|3 ) 5 19.52 , 24.83 , 28.47 , 31.44 , 38.53 , 42.15 , 54.77 , 55.85 , 55.92 , 64.28 , 75.54 , 111.34 , 111.60 , 111.69 , 113.56 , 118.85 , 120.12 , 121.10 , 124 , 32 , 125.93 , 130.27 , 133.04 , 133.23 , 138.48 , 142.51 , 147.43 , 148.89 , 157.44 , 169.46 , 172.87 , 173.00. MS ( ESl ) m / z : found RT 11.08 min. ( Method LCMS ) , 693.26 [ M + Na ] + , HRMS 671.2268 [ M + 1 ] + , ca|cu|ated 671.1655. Examp|e 29 2 - ( 3 - ( ( R ) - 3 - ( 3 , 4 - dimethoxypheny| ) - 1 - ( ( S ) - 1 - ( 2 - oxoindo|in - 5 - ylsu|fony| ) piperidine - e - 2 - carbony|oxy ) propy| ) phenoxy ) acetic acid ( compound 29 ) . TLC ( hexane : EtOAc : TFA 6 : 4 : 0.1 ) : Rf = 0.25 , yie|d= 6.0mg ( 12.5% ) . HPLC ( gradient A ) retention time= 21 .21 - 21 .40min. 1HNMR ( 600 MHz , CDC|3 ) 6= 1.55 - 1.64 ( m , 1H ) , 1.69 - 1.76 ( m , 2H ) , 1.91 - 2.00 ( m , 2H ) , 2.10 - 2.16 ( m , 2H ) , 2.43 - 2.48 ( m , 1H ) , 2.53 - 2.58 ( m , 1H ) , 3.16 - 3.21 ( m , 1H ) , 3.39 ( d , 1H , J= 22.8 Hz ) , 3.52 ( d , 1H , J= 22.8 Hz ) . 3.73 ( s , 1H ) , 3.82 ( s , 3H ) , 3.83 ( s , 3H ) , 3.87 ( s , 1H ) , 4.71 - 4.81 ( m , 3H ) , 5.43 - 5.45 ( m , 1H ) , 6.25 ( d , 1H , J= 8.4 Hz ) , 6.60 - 6.62. 10. 15. 2O. 25. 3O. 35. W0 2013 / O97947 PCT / EP2012 / OO5387 59. ( m , 2H ) , 5.72 - 5.77 ( m , 2H ) , 5.84 - 5.89 ( m , 1H ) , 7.04 - 7.10 ( m , 2H ) , 7.38 ( t , 1H , J= 8.4 Hz ) , 7.45 ( s , 1H ) . 130 NMR ( 150 MHz. CDC|3 ) 5= 19.53 , 24.79 , 28.43 , 31.39 , 35.15 , 38.51 , 42.13 , 54.81 , 55.83 , 55.90 , 53.93 , 75.75 , 110.47 , 111.35 , 111.51 , 113.15 , 113.50 , 118.85 , 120.14 , 123.25 , 125.28 , 128.33 , 130.10 , 133.09 , 142.50 , 145.55 , 147.37 , 148.85 , 157.49 , 159.55 , 171.81 , 179.45. Ms ( ES| ) m / z : found Rt 11.03 min. ( Method LCMS ) . 575.18 [ M + Na ] + HRMS 553.2503 [ M + H ] + , ca|cu|ated 553.2591 [ M + H ] + . Example 30 2 - ( 3 - ( ( R ) - 3 - ( 3 , 4 - dimethoxypheny| ) - 1 - ( ( S ) - 1 - ( 2 - oxo - 2 , 3 - dihydrobenzo [ d ] oxazo| - 6 - yl - sulfony| ) piperidine - 2 - carbononxy ) propyl ) phenoxy ) acetic acid ( comp. 30 ) TLC ( hexane : EtOAc : TFA 6 : 4 : 0.1 ) : Rf = 0.42 , yie|d= 6.4mg ( 24.6% ) . HPLC ( gradient A ) retention time= 21 .68 - 21 .85min. 1HNMR ( 600 MHz , CDC|3 ) 6= 1.57 - 1.64 ( m , 1H ) , 1.701.75 ( m , 2H ) , 1.91 - 1.99 ( m , 2H ) , 2.10 - 2.16 ( m , 2H ) , 2.43 - 2.48 ( m , 1H ) , 2.53 - 2.59 ( m , 1H ) , 3.19 - 3.24 ( m , 1H ) . 3.36 ( d , 1H. J= 22.2 Hz ) , 3.48 ( d , 1H , J= 22.2 Hz ) , 3.74 ( s , 2H ) , 3.83 ( s. 3H ) , 3.84 ( s. 3H ) , 4.75 ( d , 2H , J= 19.0 Hz ) , 4.80 - 4.81 ( m , 1H ) , 5.44 - 5.46 ( m , 1H ) , 6.20 ( d , 1H , J= 8.4 Hz ) , 6.59 - 6.63 ( m , 2H ) , 6.72 - 6.78 ( m , 2H ) , 6.89 ( d , 1H , J= 8.4 Hz ) , 7.05 ( d , 1H , J= 7.8Hz ) , 7.10 ( d , 1H , J= 7.8 Hz ) , 7.39 ( t , 1H , J= 8.4 Hz ) , 7.44 ( s , 1H ) . MS ( ES| ) m / z : found Rt 14.66 min. ( Method LCMS ) , 677.66 [ M + Na ] + , ca|cu|ated 677.54 [ M + Na ] + . Examp|e 31 ( S ) - ( ( R ) - 3 - ( 3 , 4 - dimethoxypheny| ) - 1 - ( 3 - ( 2 - morpholinoethoxy ) phenyl ) propyl ) 1 - ( 3 , 5 - dichloro - phenylsu|fonyl ) piperidine - 2 - carboxy|ate ( compound 31 ) . TLC ( DCM : MeOH 9.7 : O.3 ) : Rf = 0.48 , Yield - 16.42 mg , % yie|d 62%. HPLC ( MeCN : H2O CF3COOH ( 0.1% ) gradient of 0 — 100% in 45 min at 1m| / min ) retention time - 20.8 - 21.2 min. 1HNMR ( 600 MHz , CDC|3 ) 6 1.28 - 1.31 ( m , 1H ) , 1.38 - 1.47 ( m , 1H ) , 1.64 - 1.79 ( m , 1H ) , 1.98 - 2.04 ( m. 1H ) , 2.15 - 2.21 ( m , 1H ) , 2.27 ( d , 1H , J= 13.8 Hz ) , 2.48 - 2.53 ( m , 1H ) , 2.56 - 2.60 ( m , 1H ) , 3.09 - 3.18 ( m. 3H ) , 3.56 ( t , 2H , J= 4.8 Hz ) , 3.66 ( dd , 1H , J= 2.4 , 13.2Hz ) , 3.76 ( d , 2H , J= 12Hz ) , 3.84 ( s , 3H ) . 3.85 ( s , 3H ) , 3.95 ( t , 2H , J= 12.6 Hz ) , 4.02 ( d , 1H , J= 2.4Hz ) , 4.04 ( d , 1H , J= 2.4 Hz ) , 4.39 ( t , 2H , J= 4.6 Hz ) , 4.79 ( d , 1H , J= 4.8Hz ) , 6.65 - 6.67 ( m , 2H ) , 6.77 ( d , 1H , J= 7.8 Hz ) , 6.80 - 6.82 ( m , 1H ) , 6.85 - 6.86 ( m , 1H ) , 6.91 ( d , 1H , J= 7.8 Hz ) , 7.29 ( t , 1H , J=8.1 Hz ) , 7.46 ( t , 1H , J=1.8Hz ) , 7.55 ( s , 1H ) , 7.55 ( s , 1H ) . 13C NMR ( 150 MHz , CDCl3 ) 5 20.15 , 24.71 , 27.93 , 31.28 , 37.85 , 43.01 , 53.93 , 55.54 , 55.86 , 55.95 , 57.55 , 65.55 , 66.45 , 77.21 , 111.34 , 111.73 , 112.87 , 114.24 , 119.07 , . 10. 15. 20. 25. 3O. 35. W0 2013 / O97947 PCT / EP2012 / OO5387 60 120.13 , 125.53 , 129.82 , 132.35 , 133.33. 135.54 , 141.19 , 142.98 , 147.42 , 148.92 , 158.7 , 159.51 Ms ( ES| ) m / z : found RT 8.75 min. ( Method LCMS ) , 721.55 [ M + 1 ] 2 723.37 [ M + 3 ] * , HRMS 721.2797 [ M + 1 ] 2 723.2755 [ M + 3 ] * , ca|cu|ated 721.2039. Example 32 ( S ) - ( ( R ) - 3 - ( 3 , 4 - dimethoxyphenyl ) - 1 - ( 3 - ( 2 - morpho|inoethoxy ) phenyl ) prop - y| ) 1 - ( benzo [ d ] thi - azo| - 6 - y|sulfonyI ) piperidine - 2 - carboxy|ate ( compound 32 ) . TLC ( DCM : MeOH 9.7 : 0.3 ) : Rf = 0.27 , Yield - 31 .72mg , % yie|d 91%. HPLC ( MeCN : H2O CF3COOH ( 0.1% ) gradient of 0 — 100% in 45 min at 1m| / min ) retention time - 20.78 - 20.98 min. 1HNMR ( 300 MHz , CDCl3 ) 6= 1.61 - 1.74 ( m , 3H ) , 1.77 - 1.87 ( m , 3H ) , 1.94 - 2.06 ( m. 1H ) , 2.13 - 2.31 ( m , 1H ) , 2.47 - 2.66 ( m , 2H ) , 3.05 - 3.23 ( m , 3H ) , 3.55 - 3.57 ( m , 2H ) , 3.66 - 3.81 ( m. 3H ) . 3.85 ( s , 6H ) , 4.00 ( s , 4H ) , 4.46 ( s , 2H ) , 2.90 ( d , 1H , J= 4.5 Hz ) , 5.58 - 5.63 ( m , 1H ) , 6.65 - 6.68 ( m , 2H ) , 6.88 - 6.96 ( m. 3H ) , 7.24 - 7.29 ( m , 1H ) , 7.32 - 7.37 ( m , 1H ) . 7.64 - 7.68 ( m , 1H ) , 7.89 - 7.96 ( m , 1H ) , 8.35 ( s , 1H ) , 9.20 ( s , 1H ) . 13C NMR ( 75 MHz , CDCl3 ) 5 24.55 , 27.80 , 31.30 , 33.33 , 42.74 , 45.50 , 52.74 , 55.42 , 55.85 , 55.93 , 56.47. 62.47 , 63.91 , 76.23 , 111.37 , 111.73 , 112.28 , 114.31 , 119.97. 120.16 , 121.93 , 123.74 , 124.85 , 129.02 , 130.08 , 133.25 , 137.21 , 142.29 , 147.42 , 148.93 , 155.00 , 157.39. 157.99. 169.98. MS ( ES| ) m / z : found RT 8.45 min. ( Method LCMS ) , 710.51 [ M + 1 ] + , HRMS 710.2517 [ M + 1 ] + , calcu|ated 710.2492. Examp|e 33 ( S ) - ( ( R ) - 3 - ( 3 , 4 - dimethoxypheny| ) - 1 - ( 3 - ( 2 - morpho|inoethoxy ) phenyl ) propy| ) 1 - ( 3 , 5 - dich|oro - 4 - hydroxyphenylsu|fony| ) piperidine - 2 - carboxy|ate ( compound 33 ) TLC ( DCM : MeOH 9.7 : 0.3 ) : Rf = 0.45 , Yie|d - 15.96mg. % yield 58%. HPLC ( MeCN : H2O CF3COOH ( 0.1% ) gradient of 0 — 100% in 45 min at 1ml / min ) retention time - 19.28 - 19.61 min. 1HNMR ( 300 MHz , CDCl3 ) 6 1.54 - 2.06 ( m , 6H ) , 2.14 - 2.3O ( m , 2H ) , 2.44 - 2.64 ( m , 2H ) , 2.99 - 3.27 ( m , 3H ) , 3.51 ( s , 2H ) , 3.74 - 3.80 ( m , 3H ) , 3.86 ( s , 3H ) . 3.87 ( s , 3H ) , 4.06 ( s , 4H ) , 4.43 ( s , 2H ) , 4.72 ( d , 1H , J= 4.2Hz ) , 5.53 - 5.59 ( m , 1H ) , 6.65 - 6.69 ( m , 3H ) , 6.78 - 6.85 ( m , 2H ) , 6.92 ( d , 1H , J=7.8 Hz ) , 7.29 - 7.33 ( m , 1H ) , 7.49 ( s , 2H ) . 13C NMR ( 75 MHz , CDC|3 ) 5 20.15 , 24.94 , 28.07 , 31.45 , 37.87 , 42.85 , 53. o5 , 55.25 , 55.87 , 55.95 , 56.81 , 62.50 , 63.96 , 76.25 , 111.39 , 111.71 , 112.71 , 114.02 , 119.57 , 120.15 , 121.53 , 127.30 , 130.22 , 132.31 , 133.18 , 141.75 , 147.47 , 148.95 , 151.71 , 157.01 , 169.52. MS ( ES| ) m / z : found RT 8.76 min. ( Method LCMS ) , 737.04 [ M + 1 ] “ , 739.13 [ M + 3 ] + . HRMS 737.2532 [ M + 1 ] + , 739.2506 [ M + 3 ] + , ca|cu|ated 737.1988. 10. 15. 2O. 25. 3O. 35. W0 2013 / O97947 PCT / EP2012 / OO5387 61. Example 34 ( S ) - ( ( R ) - 3 - ( 3 , 4 - dimethoxyphenyl ) - 1 - ( 3 - ( 2 - morpholinoethoxy ) pheny| ) propy| ) 1 - ( 4 - acetamido - 3 , 5 - dich|oropheny|su|fonyI ) piperidine - 2 - carboxylate ( compound 34 ) TLC ( DCM : MeOH 9.7 : 0.3 ) : Rf = 0.12 , yie|d= 15.4mg ( 70.8% ) . HPLC ( gradient A ) retention time= 19.64 - 19.81min. 1HNMR ( 600 MHz , CDC|3 ) 6= 1.27 - 1.29 ( m , 1 H ) , 1.49 - 1.51 ( m. 1H ) , 1.67 ( d , 1H , J=12.6 Hz ) , 1.73 ( d , 1H , J - 13.2 Hz ) , 1.78 - 1.84 ( m , 1H ) , 1.95 - 2.00 ( m , 1H ) , 2.13 - 2.19 ( m , 1H ) , 2.26 ( s , 4H ) , 2.48 - 2.55 ( m , 2H ) , 3.08 - 3.14 ( m , 3H ) , 3.54 ( s , 2H ) , 3.65 - 3.74 ( m , 3H ) , 3.81 ( s , 3H ) , 3.84 ( s , 3H ) , 3.92 - 3.98 ( m , 2H ) , 4.00 - 4.04 ( m , 2H ) , 4.36 ( m , 2H ) , 4.78 ( d , 1H , J= 4.8Hz ) , 5 , 58 ( t , 1H , J= 7.2 Hz ) , 6.62 - 6.64 ( m , 2H ) , 6.76 - 6.81 ( m , 3H ) , 6.90 ( d , 1H. J= 7.8 Hz ) , 7.28 ( t , 1H , J= 7.8 Hz ) , 7.61 ( s , 2H ) . 13C NMR ( 150 MHz , CDC|3 ) 6= 19.95 , 24.60 , 27.88 , 29.66 , 31.16 , 37.54 , 42.98 , 53.07. 55.76 , 55.93 , 56.80 , 61.99 , 63.80 , 63.82 , 76.65 , 111.38 , 111.68 , 114.17 , 116.07 , 120.06 , 120.30 , 126.96 , 126.97 , 130.13 , 133.21 , 135.30 , 141.68 , 147.29 , 148.76 , 157.19 , 159.79 , 160.05 , 160.32 , 160.58 , 169.76. MS ( ES| ) m / z : found Rt 10.30 min. ( Method LCMS ) , 778.25 , 780.31 [ M + H ] + , 800.23 , 802.20 [ M + Na ] + . HRMS 778.3114 , 780.3122 [ M + H ] + , ca|culated 778.3154 , 780.3162 [ M + H ] + . Example 35 ( S ) - ( ( R ) - 3 - ( 3 , 4 - dimethoxypheny| ) - 1 - ( 3 - ( 2 - morpho|inoethoxy ) phenyl ) propy| ) 1 - ( 2 - oxo - 2 , 3 - dihydrobenzo [ d ] thiazoI - 6 - y|su|fonyl ) piperidine - 2 - carboxy|ate ( compound 35 ) . TLC ( DCM : MeOH 9.7 : 0.3 ) : Rf = 0.39 , Yie|d - 6.4mg , % yie|d 25%. HPLC ( gradient A ) retention time - 18.92 - 19.16min. 1HNMR ( 300 MHz , CDC|3 ) 6 1.71 - 1.81 ( m , 2H ) , 1.84 - 2.01 ( m , 2H ) , 2.06 - 2.22 ( m , 2H ) , 2.39 - 2.62 ( m , 2H ) , 3.01 - 3.12 ( m , 2H ) , 3.26 - 3.37 ( m , 2H ) . 3.54 ( s , 2H ) , 3.80 - 3.91 ( m , 12H ) , 4.06 ( s , 4H ) , 4.26 - 4.50 ( m , 2H ) , 4.74 ( d , 1H , J= 4.8Hz ) , 5.36 - 5.41 ( m , 1H ) , 6.55 - 6.64 ( m. 4H ) , 6.77 ( d , 1H , J= 7.5Hz ) , 6.89 ( d. 1H , J= 6.9 Hz ) , 6.99 ( d , 1H , J= 7.5 Hz ) , 7.19 ( d. 1H , J= 8.4 Hz ) , 7.38 ( t , !h , J= 7.6 Hz ) , 7.62 ( d , 1H , J=1.8Hz ) . 13C NMR ( 75 MHz , CDC|3 ) 5 24.98 , 28.29 , 31.43 , 38.45 , 42.48. 53.47 , 54.79 , 55.87 , 55.94 , 57.28 , 62.02 , 63.93 , 75.83 , 111.03 , 111.37 , 111.69 , 112.73 , 113.79 , 119.18 , 120.17 , 121.54 , 124.28 , 125.73 , 130.46 , 133.10 , 133.39 , 138.88 , 142.22 , 147.47 , 148.93 , 156.99 , 169.62. MS ( ES| ) m / z : found RT 9.47 min. ( Method LCMS ) , 726.29 [ M + 1 ] " , HRMS 726.3111 [ M + 1 ] + . ca|cu|ated 726.2441. 10. 15. 2O. 25. 3O. 35. W0 2013 / 097947 PCT / EP2012 / 005387 52 Example 36 - 64 Compounds 36 to 64 are characterized using MS and HPLC for purity ( tab|e 1 in examp|e 67 ) . Examp|e 65 ( S ) - ( ( R ) - 3 - ( 3.4 - dimethoxyphenyl ) - 1 - ( 3 - ( 2 - morpho|inoethoxy ) pheny| ) propy| ) 1 - ( 3 , 5 - dich|oro - 4 - methoxyphenylsu|fony| ) piperidine - 2 - carboxy|ate ( compound 65 ) TLC ( DCM : MeOH 9.7 : 0.3 ) : Rf = 0.42 , Yie|d - 21mg , % yie|d 75%. HPLC ( gradient A ) retention time - 23.31 - 23.63min. 1HNMR ( 600 MHz , CDC|3 ) 6 1.27 - 1.31 ( m , 1H ) , 1.41 - 1.46 ( m , 1H ) , 1.65 ( d , 1H , J= 13.8Hz ) , 1.71 - 1.80 ( m , 2H ) , 1.99 - 2.05 ( m , 1H ) , 2.17 - 2.23 ( m , 1H ) , 2.28 ( d , 1H , J= 14.4 Hz ) , 2.49 - 2.54 ( m , 1H ) , 2.56 - 2.61 ( m , 1H ) , 3.09 ( t , 2H , J= 11.4Hz ) , 3.15 ( dt , 1H , J= 3 , 12.6Hz ) , 3.54 ( t. 2H , J= 5.2Hz ) , 3.66 ( d , 1H , J= 10.8Hz ) , 3.71 - 3.74 ( m , 2H ) . 3.84 ( s , 6H ) . 3.91 ( s , 3H ) , 3.96 - 4.03 ( m , 4H ) , 4.40 ( d , 2H , J =5.0Hz ) , 4.79 ( d , 1H , J= ' 4.8Hz ) , 5.68 ( q , 1H , J=3. 5.4 Hz ) , 6.65 - 6.67 ( m , 2H ) , 6.77 ( d , 1H , J= 7.8Hz ) , 6.81 - 6.83 ( m , 1H ) , 6.85 ( t , 1H , J= 1.8Hz ) , 6.90 ( d , 1H , J= 7.2Hz ) , 7.29 ( t , 1H , J= 7.8 Hz ) , 7.61 ( s , 2H ) . 13C NMR ( 150 MHz , CDC|3 ) 6 20.05 , 24.56 , 27.73 , 31.26 , 37.95 , 42.93 , 52.87 , 55.57. 55.82 , 55.91 , 56.58 , 60.94 , 62.32 , 63.90 , 76.44 , 111.32 , 111.70 , 112.33 , 141.12 , 120.03 , 120.15 , 127.73 , 129.98 , 130.07 , 133.24 , 137.01 , 141.83 , 147.38 , 148.88 , 155.61. 157.27 , 169.80. MS ( ESl ) m / z : found RT 9.08 min. ( Method LCMS ) . 751.53 [ M + 1 ] " , 753.32 [ M + 3 ] + . HRMS 751.2705 [ M + 1 ] + , 753.2674 [ M + 3 ] + , ca|culated 751.2145. Examp|e 66 Synthesis of reference sulfonamides : . The fo||owing reference structures were synthesized according to |iterature procedures ( Ju|i et a|. , J. Med. Chem , 2011 , 277 ; Choi et a|. , Bio. Med. Chem. Let. , 2002 , 1421y. Synthesis of Ethyl 1 - ( benzy|su|fony| ) piperidine - 2 - carboxy|ate ( Ref .1 ) . Ethy| piperidine - 2 - carboxylate ( 100mg , 0.63 mmo| ) was disso|ved in 5mL of anhydrous DMF , and triethylamine ( 191mg , 1.89 mmo| ) was added drop wise fo||owed by phenylmethanesulfony| ch|oride ( 119.7mg , 0.63 mmo| ) . The reaction was stirred for 6h at RT and subsequently the so|vent was removed in vacuo. The crude mixture was purified using co|umn chromatography ( hexane : EtOAc 8 : 2 ) to yield Ethyl 1 - ( benzy|su|fonyl ) piperidine - 2 - carboxylate_ ( 170mg , 0.55 mmo| , 86% ) . TLC ( hexane : EtOAc 8 : 2 ) : Rf = 0.20. HPLC ( gradient A ) retention time= 23.4 - 23.8 min. 10. 15. 2O. 25. 3O. 35. WO 2013 / 097947 PCT / EP2012 / 005387 63. 1HNMR ( 300 MHz , CDC|3 ) 5= 1.14 - 1.25 ( m , 1H ) , 1.28 ( t , 3H , J= 7.2 Hz ) , 1.34 - 1.49 ( m , 1H ) , 1.54 - 1.58 ( m , 3H ) . 2.14 ( d , 1H , J= 13.5 Hz ) . 3.14 ( dt , 1H , J= 3.3 , 12.5 Hz ) , 3.44 ( d , 1H , J= 12.5 Hz ) , 4.18 - 4.24 ( m , 2H ) , 4.25 ( s , 2H ) , 4.54 ( d , 1H , J= 4.8 Hz ) , 7.31 - 7.38 ( m , 3H ) . 7.43 - 7.48 ( m , 2H ) . 13C NMR ( 75 MHz , CDC|3 ) 5= 14.22 , 20.31 , 25.04 , 27.78 , 43.39 , 55.95 , 58.71 , 51.35 , 128.40. 128.48 , 129.35 , 130.95 , 171.38. Ms ( ES| ) m / z : found Rt 14.28 min. ( Method LCMS ) , 312.12 [ M + H ] * , 334.22 [ M + Na ] + . calcu|ated 312.12 [ M + H ] 1 334.11 [ M + Na ] + . Synthesis of Ethy| 1 - ( 3 - nitropheny|su|fonyl ) piperidine - 2 - carboxy|ate ( Ref .2 ) . Ethyl piperidine - 2 - carboxy|ate ( 100mg , 0.63 mmo| ) was dissolved in 5mL of anhydrous DMF , and triethylamine ( 191mg , 1.89 mmo| ) was added drop wise fol|owed by 3 - nitrobenzene - 1 - sulfonyl chloride ( 139.2mg , 0.63 mmo| ) . The reaction was stirred for 6h at RT and subsequent|y the so|vent was removed in vacuo. The crude mixture was purified using column chromatography ( hexane : EtOAc 8 : 2 ) to yie|d Ethy| 1 - ( 3 - nitropheny|su|fony| ) piperidine - 2 - carboxy|ate ( 195mg , 0.57 mmol , 89% ) . TLC ( hexane : EtOAc 7 : 3 ) : Rf = 0.45. HPLC ( gradient A ) retention time= 23.6 - 24.1 min. 1HNMR ( 300 MHz , CDC|3 ) 6= 1.12 ( t , 3H , J= 7.2 Hz ) , 1.45 - 1.84 ( m , 5H ) , 2.18 ( d , 1H , J=13.8 Hz ) , 3.15 ( dt , 1H. J=3 , 12.6 Hz ) , 3.79 ( d , 1H , J= 12.6 Hz ) . 4.39 - 4.04 ( m , 2H ) , 4.76 ( d , 1H , J= 5.4 Hz ) , 7.68 ( t , 1H , J= 7.8 Hz ) , 8.06 - 8.10 ( m , 1H ) , 8.35 - 8.39 ( m , 1H ) , 8.57 ( t , 1H , J=1.8 Hz ) . 130 NMR ( 75 MHz , CDC|3 ) 5= 14.02 , 19.95 , 24.80 , 27.94 , 42.89 , 55.44 , 51.33 , 122.39 , 126.77 , 130.05 , 132.74 , 142.03 , 148.06 , 170.17. MS ( ES| ) m / z : found Rt 14.27 min. ( Method LCMS ) , 343.06 [ M + H ] + , calculated 343.09 [ M + H ] + . Synthesis of 1 - ( benzy|su|fonyl ) piperidine - 2 - carboxy|ic acid. To Ethy| 1 - ( benzy|su|fony| ) piperidine - 2 - carboxy|ate ( 150mg. 0.48 mmo| ) was added 1M LiOH in MeOH : H2O ( 1 : 1 ) and the reaction stirred for 6h at room temperature. The reaction was acidified to pH=2 by addition of 1M HC|. The aqueous |ayer was extracted with dich|oromethane ( 3x 20m| ) . The combined organic phases were washed with brine ( 30m| ) and dried over MgSO4. The so|ution was concentrated under reduced pressure to furnish the free acid 1 - ( Benzy|sulfony| ) piperidine - 2 - carboxy|ic acid as a white so|id ( 128mg , 0.45 mmol , 94% ) . TLC ( hexane : EtOAc : TFA 6 : 4 : 0.1 ) : Rf = 0.20. HPLC ( gradient A ) retention time= 18.1 - 18.6 min. 10. 15. 2O. 25. 3O. 35. W0 2O 13 / O97947 PCT / EP2012 / OO5387 64. 1HNMR ( 300 MHz , CDCl3 ) 5= 1.25 - 1.45 ( m , 2H ) , 1.57 - 1.72 ( m. 3H ) , 2.15 ( d , 1H , J=14.1 Hz ) , 3. o9 - 3.19 ( dt , 1H , J= 2.7 , 12.5 Hz ) , 3.47 ( d , 1H , J= 13.2 Hz ) , 4.27 ( s. 2H ) , 4.55 ( d , 1H , J= 4.5 Hz ) , 7.34 - 7.37 ( m , 3H ) , 7.40 - 7.45 ( m , 2H ) . ‘3c NMR ( 75 MHz , CDC|3 ) 5= 20.27 , 24.85 , 27.51 , 43.47 , 55.71 , 58.91. 128.57 , 128.61 , 129.09 , 130.91. 177.43. Ms ( ES| ) m / z : round Rt 12.32 min. ( Method LCMS ) , 305.25 [ M + Na ] * , calculated 305.08 [ M + Na ] + . Synthesis of 1 - ( 3 - nitropheny|su|fonyl ) piperidine - 2 - carboxylic acid. To Ethy| 1 - ( 3 - nitropheny|su|fony| ) piperidine - 2 - carboxy|ate ( 175mg , 0.51 mmo| ) was added 1M LiOH in MeOH : H2O ( 1 : 1 ) and the reaction stirred for 6h at room temperature. The reaction was acidified to pH=2 by addition of 1M HC|. The aqueous layer was extracted with dich|oromethane ( 3x 20ml ) . The combined organic phases were washed with brine ( 30ml ) and dried over MgSO4. The so|ution was concentrated under reduced pressure to furnish the free acid 1 - ( 3 - nitropheny|su|fonyl ) piperidine - 2 - carboxylic acid as a white solid ( 152mg , O.48 mmo| , 95% ) . TLC ( hexane : EtOAc : TFA 6 : 4 : 0.1 ) : Rf = 0.27. HPLC ( gradient A ) retention time= 18.7 - 19.1 min. 1HNMR ( 300 MHz , CDC|3 ) 6= 1.20 - 1.36 ( m , 1H ) , 1.45 - 1.61 ( m , 1H ) , 1.69 - 1.87 ( m , 3H ) , 2.22 ( m , 1H , J= 14.4 Hz ) , 3.09 ( dt , 1H , J= 3 , 12.9 Hz ) , 3.78 ( d , 1H , J= 4.8 Hz ) , 7.70 ( t , 1H , J= 8.1 Hz ) , 8.09 - 8.13 ( m , 1H ) , 8.36 - 8.40 ( m , 1H ) , 8.59 ( t , 1H , J= 2.1 Hz ) . 130 NMR ( 75 MHz , CDCl3 ) 5= 20.03. 24.52 , 27.72 , 42.90 , 55.23 , 122.38 , 126.88 , 130.16 , 132.75 , 141.89. 148.07 , 176.47. MS ( ES| ) m / z : found Rt 14.10 min. ( Method LCMS ) , 337.10 [ M + Na ] + , calcu|ated 337.05 [ M + Na ] + . Synthesis of 3 - ( 3 , 4 - dimethoxypheny| ) propy| 1 - ( benzylsu|fony| ) piperidine - 2 - carb0xy|ate ( Ref. 3 ) . A so|ution of a|coho| 3 - ( 3 , 4 - dimethoxypheny| ) propan - 1 - o| ( 37.8mg , 0.193 mmo| ) , acid 1 - ( Benzy|su|fony| ) piperidine - 2 - carboxy|ic acid ( 50mg , 0.176 mmo| ) and DMAP ( 6.4 mg , 0.05 mmo| ) in DCM at room temperature was treated with DCC ( 54.47 mg , 0.264 mmol ) . After stirring for 12 h the mixture was di|uted with EtOAc and fi|tered through a plug of ce|ite. The fi|trate was concentrated and the crude materia| f|ash chromatographed ( hexane : EtOAc 7 : 3 ) to afford compound 3 - ( 3 , 4 - dimethoxypheny| ) propy| 1 - ( benzy|su|fony| ) piperidine - 2 - carboxy|ate ( 65 mg , 0.14 mmo| , 80% ) . TLC ( hexane : EtOAc : 7 : 3 ) : Rf = 0.40. HPLC ( gradient A ) retention time= 26.3 - 26.6 min. 10. 15. 20. 25. 3O. 35. W0 2013 / O97947 PCT / EP2012 / OO5387 65. 1HNMR ( 300 MHz , CDCl3 ) 5= 1.35 - 1.71 ( m , 5H ) , 1.92 - 2.01 ( m , 2H ) , 2.14 ( d , 1H , J= 12 Hz ) , 2.55 ( t , 2H , J= 8.1 Hz ) , 3.15 ( dt , 1H , J= 3. 12.5 Hz ) , 3.44 ( d , 1H , J= 17.7 Hz ) , 3.85 ( s , 3H ) , 3.86 ( s. 3H ) , 4.13 - 4.22 ( m , 2H ) , 4.25 ( s , 2H ) , 4.54 ( d , 1H , J= 4.5 Hz ) , 5.59 - 5.73 ( m , 2H ) , 6.78 - 6.80 ( m , 1H ) , 7.34 - 7.37 ( m , 3H ) . 7.43 - 7.47 ( m , 2H ) . 13C NMR ( 75 MHz , CDC|3 ) 5= 20.35 , 24.99 , 27.79 , 30.41 , 31.53 , 43.44 , 55.84 , 55.93 , 55.04 , 58.80 , 54.53 , 111.34 , 111.78 , 120.22 , 128.45. 128.51 , 129.31 , 130.94 , 133.48 , 147.38 , 148.94 , 171.45. Ms ( ES| ) m / z : round Rt 14.98 min. ( Method LCMS ) , 484.38 [ M + Na ] * , ca|cu|ated 484.18 [ M + Na ] + . Synthesis of 3 - ( pyridin - 3 - y| ) propy| 1 - ( 3 - nitropheny|sulfony| ) piperidine - 2 - carboxy|ate ( Ref. 4 ) . A so|ution of a|coho| 3 - ( pyridin - 3 - yl ) propan - 1 - o| ( 24mg , 0.175 mmol ) , acid 1 - ( 3 - nitropheny|sulfony| ) piperidine - 2 - carboxy|ic acid ( 50mg , 0.159 mmol ) and DMAP ( 5.8 mg , 0.047 mmo| ) in DCM at room temperature was treated with DCC ( 49.2 mg , 0.238 mmo| ) . After stirring for 12 h the mixture was di|uted with EtOAc and fi|tered through a plug 0f ce|ite. The fi|trate was concentrated and the crude materia| ﬂash chromatographed ( DCM : MeOH 9.7 : 0.3 ) to afford compound 3 - ( pyridin - 3 - y| ) propy| 1 - ( 3 - nitropheny|su|fony| ) piperidine - 2 - carboxy|ate ( 60 mg , 0.138 mmo| , 87% ) . TLC ( DCM : MeOH 9.7 : 0.3 ) : Rf = 0.50. HPLC ( gradient A ) retention time= 17.0 - 17.4 min. 1HNMR ( 300 MHz , CDC|3 ) 6= 1.55 - 1.86 ( m , 7H ) , 2.19 ( d , 1H , J=13.5 Hz ) , 2.67 ( t , 2H , J= 8.1 Hz ) , 3.17 ( dt , 1H , J= 3 , 12.6 Hz ) , 3.78 ( d , 1H , J=7.9 Hz ) , 4.02 ( dt , 2H , J= 1.2 , 6.6 Hz ) , 4.80 ( d , 1H , J= 5.1 Hz ) , 7.26 - 7.31 ( m , 1H ) , 7.55 ( d , 1H , J= 7.8 Hz ) , 7.68 ( t , 1H , J= 8.1 Hz ) , 8.10 ( d , 1H , J= 7.8 Hz ) , 8.36 - 8.40 ( m , 1H ) , 8.45 - 8.48 ( m , 2H ) , 8.59 ( s , 1H ) . 130 NMR ( 75 MHz , ch13 ) 5=20.04 , 24.91 , 27.93 , 29.19 , 29.71. 33.92 , 42.95 , 55.49 , 64.28 , 122.39 , 123.76 , 126.85 , 130.10 , 132.69. 136.52 , 136.67 , 142.07 , 146.86 , 148.11 , 148.88 , 170.25. MS ( ES| ) m / z : found Rt 10.62 min. ( Method LCMS ) , 434.26 [ M + H ] + , ca|cu|ated 434.13 [ M + H ] + . Examp|e 67 Medium throughput small sca|e synthesis : . Pre - weighed samples of Fmoc protected immobi|ized pipeco|ate so|id support were distributed to each of 36 we||s of a 96 we|| paral|e| synthesis reactor p|atform obtained from F|exChem® peptide synthesis system. The Fmoc deprotection was carried out individua||y in each 0f the we||s fo||owed by coup|ing with su|fonyl chlorides obtained commercia||y from Maybridge. The unreacted excess su|fony|. 10. 15. W0 2013 / O97947 PCT / EP2012 / OO5387. 55. ch|orides were washed fo|lowed by the c|eavage of the pipeco|ate su|fonamides from the resin under mi|d acidic condition. Out of the 36 compounds 35 compounds were purified by preparative. Ana|ytical HPLC showed the compounds had at |east > 90 % purity with most compounds > 95% purity. The correct identity was confirmed by mass spectroscopy , as summarized in Tab|e 1. Library Testing : . The purified and chemica||y va|idated compounds were tested for their binding to the FK1 domains of FKBP51 and FKBP52 in a f|uorescence po|arization assay ( Kozany , et al. , ChemBioChem 10 , 8. 2009 , 1402—1410 ) . The binding of the compounds to the proteins was ana|yzed by ca|cu|ating the % inhibition at a concentration of 5 pM ( Table 1 ) . . . . . . . . . . Tab|e 1 : Chemica| compounds according to formu|a ( | ) used in Library Testing : Fol|owing compounds : R1—R3 = —H , R5—R6 = —H , R8 & R9 = —OCH3 , R‘° = —H , R4 = —0CH2—C0OH de A Mo| Wt Mo| Wt % FKBP 51 FK1 FKBP52 FK1 No. ca|c. ' Found purity % inhibition % inhibition. HPLC 36 < > a 531.15 554.13 [ M + Na ] * 98 11.7 15.2 37 W 545.19 553.34 [ M + 96 4.3 0 NHd ' 38 < > F 515.19 533. o0 [ M + 96 4.3 6.6 NH. ] * , 538.33 [ M + Na ] + 39 ) O 553.27 552.27 [ M - 1 ] ( a ) 98 8.3 14.2 40 @ca 555.19 588.13 [ M + 99 8.9 12.3 Na ] * . 7o2.13 [ M + K ] * 41 @OPh 589.23 712.33 [ M + 97 7.2 15.2 Na ] * , 725.27 [ M + K ] * . . . . . . . . . W0 2013 / O97947. 67. PCT / EP2012 / OO5387. . { H3. 675.23. 575.13 [ M + 1 ] * , . 598.27 [ M + Na ] * . 99. 16.3. 15.2. . 42. _N. \. \. 598.20. 599.33 [ M + 1 ] + , . 521.20 [ M + Na ] + . 97. 6.6. 9.5. . 43. _N. \ / OPh. 690.22. 589.27 [ M - 1 ] . ( 8 ) . 99. 3.7. 11.4. . 44. 674.23. 575.33 [ M + 1 ] * . 99. 2.6. 8.5. . 45. 631.16. 554.20 [ M + Na ] * , 558.27 [ M. + K ] + . 99. 1.4. 9.5. . 46. 665.13. 588.27 [ M + Na ] * , 705.20 [ M. + K ] + . 99. 3.2. 9.5. . 33 9 9. 631.16. 649.27 [ M + NH. ] * , 554.27 [ M + Na ] * , 570.27. [ M + K ] + . 99. 17.5. 18.0. . 47. Q. °r. 222. 679.22. 579.93 [ M + 1 ] * , 702.33 [ M + Na ] * , 715.33 [ M. + K ] + . 95. 4.9. 3.8. . 48. ——< E>—C F3. C|. 699.15. 715.93 [ M + NH. ] * . 722.2o [ M + Na ] + , 735.27. [ M + KY. 91. - 0.2. 11.4. . 49. \fg / K. 650.23. 573.20 [ M + Na ] * , 589.27 [ M. + K ] ‘”. 95. - 0.8. 6.6. . . . ﬂ. S. . 654.17. . 555. o7 [ M + 1 ] * , . 577.20 [ M + Na ] * . . 93. . 25.5. . 16.1. . . W0 2013 / O97947. 68. PCT / EP2012 / OO5387. . 50. 650.23. 558.20 [ M + NH. ] * , 573.13 [ M + Na ] * , 589.20. [ M + K ] * . 85 ( o ) . 10.0 10.4. . 51 <EO. 668.24. 559.40 [ M + 1 ] t. 93. 9.5 6.6. . 587.18. 510.24 [ M + Na ] * , 525.18 [ M. + K ] “. 97. 15.2 16.2. . 53. 587.18. 510.27 [ M + Na ] * , 524.20 [ M. + K ] ". 97. 2.0 5.7. . —CI. 637.20. 660.13 [ M + Na ] * . 574.33 [ M + K ] * . 99. 5.5 6.6. . 55 8. 603.16. 525.27 [ M + Na ] * . 542.13 [ M. + K ] * . 95. 3.2 8.5. . 679.19. 702.27 [ M + . Na ] + . 99. 3.2 9.5. . 653.18. 575.27 [ M + Na ] * . 591.93 [ M. + K ] ". 98. 12.4 15.2. . 57. 653.18. 575.07 [ M + . Na ] ". 99. 3.2 4.7. . 59. 601.21. oo2.27 [ M + 1 ] * , 524.20 [ M + Na ] * , 540.13 [ M. + K ] * . 97. 2.1 4.7. . . 61. . . 629.24. . 530.27 [ M + 1 ] “ , 552.27 [ M + Na ] * , 668.20 [ M + K ] ". . 97. . 5.5 1.9. . . . 10. . . . . . . . . . . W0 2013 / O97947 PCT / EP2012 / OO5387 69 62 591.25 592.33 [ M + 1 ] * . 94 0.9 4.7 N 714.20 [ M + N\ Na ] ‘ , 728.47 [ M Ph + + K ] . 63 < > 511.22 534.27 [ M + 95 3.2 3.8 Na ] * . Examp|e 68. Generation of bio|ogica| data : F|uorescence polarization assay lC50 va|ues f0r human FKBP51FK1 and human FKBP52FK2 were determined as described ( Kozany , et a|. , ChemBioChem 10 , 8 , 2009 , 1402—1410 ) . Tab|e 2 : Chemica| compounds according to f0rmu|a ( | ) and their binding affinity ( |C5o - . va|ue ) determined in a f|uorescence polarization assay. . Fo||owing compounds of genera| formula ( l ) with : . . . . . . . . . . . . . R‘—R3 = —H , R5—R6 = —H , R8 & R9 = —OCH3 , R10 = —H , R4 = —0CH2—COOH Compd. A Purity FKBP51FK1 FKBP52FK1 No. ( % ) |C5o ( l1M ) |C5o ( PM ) . Ref. 1 ( ® ) >99 >10O >1OO Ref. 2 ( o ) >99 >100 >100 Ref. 3 ( o ) >99 >100 >10o Ref. 4 ( o ) >98 >10o >100 N 1 @N3 >99 52.8 i 10.7 >100 2 Q >98 30.7 i 15.7 32.8 i 14.5 Cl 3 4% >99 11.5¢ 1.1 32.5 : 3.5 S S 5 w >99 57.1 i 12.1 >100 CN 6 ‘QH >98 28.5 i 9.6 69.9 i 65.4 H. . . . . . . . . . . . . . . . . . . . W0 2013 / 097947 PCT / EP2012 / 0O5387 7O F 11 Q2. >99 18.25 z 8.8 37.3 1 13.5 H Br 12 { %H >99 3.05 i o.25 17.09 i 110 H Cl 13 @H >99 22.5 i 8.2 14.3 i 1.8 C| C| 15 QOMe >99 18.8 i 2.4 20.2 i 3.5 H C| 21 QW >99 15.1 i 1.4 55.5 i 12.2 C| C| 22 @We >99 15.4 1 - 1.7 17.7 z1.5 C| C| 23 QM , >98 8.9 i 0.9 15.5 i 2.2 r C| O O 25 >98 27.2 i 3.1 43.9 3 10.1 NO2 S 27 @71 / >98 18.4 i 1.4 25.5 1 4.9 s O 28 @Y >99 147 + 11 555 + 271 NH . _ . . _ . . . . . . . W0 2013 / O97947. 71. PCT / EP2012 / OO5387. . Fo||owing compounds : R1—R3 = - H , . R5 - - R6 = —H , R8 8 R9 = —OCH3 , R‘° = —H , R4 = o. . . . . . . . . . CI 33 OH >99 0.456 i 0.05 O.71 i 0.10 C| C| 34 ‘QTNHM >99 12.3 4 18.9 8.3 4 5.8 C| s O 35 C I >99 1.3 i 0.13 2.5 i 0.38 O - . ® = E GZ ® = \_ / CC o=s=o 0 G1. Reference compounds from : Juli et a|. , J. Med. Chem , 2011 , 277 ; and Choi et a|. , Bio. Med. Chem. Let. , 2002 , 1421. . . . . . . Compd G1 GZ No. Ref.1 @ Et 7% No2 Ref. 2 E1 - %© O\ Ref. 3 @ Aﬂo / No2 / Ref.4 _§© \ 11. . 10. 15. 20. 25. W0 2013 / O97947 PCT / EP2012 / OO5387 72. Claims. 1. Compound of the genera| formula ( | ) : . . wherein. R1 - R17 represent independent|y of each other —H , —OH , —OCH3 , —OC2H5 , —OC3H7 , —O—cyc|o - C3H5 , —OCH ( CH3 ) 2 , —OC ( CH3 ) 3. —OC4H9 , —OCH2—COOH , —OPh , —OCH2—Ph , - OCPh3 , —CH2 - —OCH3 , —C2H4—OCH3 , —C3H5 - OCH3 , —CH2 - OC2H5 , —C2H4 - OC2H5 , —C3H5 - OC2H5 , " —CH2—OC3H7 , . —C2H4—OC3H7 , —C3H6—OC3H7 , —CH2—O— - cyc|o - C3H5 , —C2H4—O—cyc|o - C3H5 , —C3H5—O—cyc|o - C3H5 , —CH2—OCH ( CH3 ) 2 , —C2H4—OCH ( CH3 ) 2 , —C3H6—OCH ( CH3 ) 2 , —CH2—OC ( CH3 ) 3 , —C2H4—OC ( CH3 ) 3 , —C3H6—OC ( CH3 ) 3 , —cH2—oc. , H9 , —C2H4—OC4H9 , —C3H5—OC4Hg , —CH2 - OPh , —C2H4 - OPh , —C3H5—OPh , —CH2—OCH2— - Ph , - C2H4—OCH2—Ph. —C3H6 - OCH2—Ph , - sH , —SCH3. —SC2H5 , —SC3H7 , —S—cyc|o - C3H5 , —SCH ( CH3 ) 2 , —SC ( CH3 ) 3 , —NO2 , - F , —Cl. —Br , —| , - P ( 0 ) ( 0H ) 2. - P ( 0 ) ( 0CH3 ) 2 , - P ( 0 ) ( 0C2H5 ) 2. —P ( 0 ) ( 0CH ( CH3 ) 2 ) 2. - C ( 0H ) [ F ( 0 ) ( 0H ) 2 ] 2 , - Si ( CH3 ) 2 ( C ( CH3 ) 3 ) . - Si ( C2Hs ) 3 - - Si ( CH3 ) s. - N3 , - CN , —OCN , —NCO , —SCN , - NCS , —CHO , —COCH3 , —COC2H5 , —COC3H7 , —CO—cyclo - C3H5 , —COCH ( CH3 ) 2 , —COC ( CH3 ) 3 , —COOH , ——COCN , —COOCH3 , —COOC2H5 , —COOC3H7 , —COO—cyc|o - C3H5 , —COOCH ( CH3 ) 2 , —COOC ( CH3 ) 3 , —OOC—CH3 , —OOC—C2H5 , —OOC—C3H7 , —OOC—cyc|o - C3H5 , —OOC—CH ( CH3 ) 2 , —OOC—C ( CH3 ) 3 , —CONH2 , —CONHCH3. —CONHC2H5 , . —CONHC3H7 , —CONH——cyclo - C3H5 , —CONH [ CH ( CH3 ) 2 ] , —CONH [ C ( CH3 ) 3 ] , —CON ( CH3 ) 2 , —CON ( C2H5 ) 2. —CON ( C3H7 ) 2 , —CON ( cyclo - C3H5 ) 2 , —CON [ CH ( CH3 ) 2 ] 2 , —CON [ C ( CH3 ) 3 ] 2 , —NHCOCH3 , —NHCOC2H5 , —NHCOC3H7 , —NHCO - cyclo - C3H5 , —NHCO—CH ( CH3 ) 2. —NHCO—C ( CH3 ) 3 , . - NHCO - OCH3 , —NHCO—OC2H5 , —NHCO— - OC3H7 , —NHCO - O— - CyC|0 - C3H5 , . 10. 15. 2O. 25. 3O. 35. W0 2O 13 / O97947 PCT / EP2012 / OO5387 73. —NHCO—OCH ( CH3 ) 2 , —NHCO——OC ( CH3 ) 3 , —NH2 , ——NHCH3 , —NHC2H5 , —NHC3H7 , —NH - —cyc|o - C3H5 , - NHCH ( CH3 ) 2 , —NHC ( CH3 ) 3 , - N ( CH3 ) 2 , —N ( C2H5 ) 2 , —N ( C3H7 ) 2 , —N ( cyc|o - C3H5 ) 2 , —N [ CH ( CH3 ) 2 ] 2 , —N [ C ( CH3 ) 3 ] 2 , —SOCH3 , —SOC2H5 , —SOC3H7 , —SO—cyc|o - C3H5 , —SOCH ( CH3 ) 2. —SOC ( CH3 ) 3 , ——SO2CH3. —SO2C2H5 , —SO2C3H7 , —SO2 - cyclo - C3H5 , . —SO2CH ( CH3 ) 2 , - SO2C ( CH3 ) 3 , —SO3H , —SO3CH3 , - SO3C2H5 , - SO3C3H7. —SO3 - cyc|o - C3H5 , —SO3CH ( CH3 ) 2 , —SO3C ( CH3 ) 3 , —SO2NH2 , —SO2NHCH3 , —SO2NHC2H5 , —SO2NHC3H7 , - SO2NH—CyC|0 - C3H5 , —SO2NHCH ( CH3 ) 2 , —SO2NHC ( CH3 ) 3 , —SO2N ( CH3 ) 2 , —SO2N ( C2H5 ) 2 , —SO2N ( C3H7 ) 2 , —SO2N ( cyclo - C3H5 ) 2 , —SO2N [ CH ( CH3 ) 2 ] 2. —SO2N [ C ( CH3 ) 3 ] 2 , —O—S ( =O ) CH3 , ——O—S ( =O ) C2H5 , —O—S ( =O ) C3H7 , —O—S ( =O ) —cyc|o - C3H5 , —O—S ( =O ) CH ( CH3 ) 2 , —O— - S ( =O ) C ( CH3 ) 3 , , — ' S ( =O ) ( =NH ) CH3 , —S ( =O ) ( =NH ) C2H5 , —S ( =O ) ( =NH ) C3H7 , ——S ( =O ) ( =NH ) —cyclo - C3H5 , —S ( =O ) ( =NH ) CH ( CH3 ) 2 , —S ( =O ) ( =NH ) C ( CH3 ) 3 , —NH—SO2—CH3 , —NH—SO2—C2H5 , ——NH—SO2—C3H7 , —NH—SO2—CyC|o - C3H5 , —NH—SO2—CH ( CH3 ) 2 , —NH—SO2—C ( CH3 ) 3 , —O—SO2—CH3 , —O - SO2—C2H5 , —O—SO2—C3H7 , —O—SO2—cyclo - C3H5 , —O - SO2—CH ( CH3 ) 2 , —O—SO2—C ( CH3 ) 3 , —OCF3 , —CH2— - OCF3 , —C2H4 - OCF3 , —C3H5—OCF3 , —OC2F5 , —CH2—OC2F5 , ——C2H4 - —OC2F5 , —C3H6—OC2F5 , —O—COOCH3 , ——O——COOC2H5 , —O—COOC3H7 , - O—COO—cyclo - C3H5. —O - COOCH ( CH3 ) 2 , —o—cooc ( cH3 ) 3. —NH—CO—NH2 , —NH——CO—NHCH3 , —NH—CO—NHC2H5 , —NH—CS—N ( C3H7 ) 2. —NH—CO—NHC3H7 , . ——NH—CO—N ( C3H7 ) 2 , —NH—CO—NH [ CH ( CH3 ) 2 ] , —NH—CO—NH [ C ( CH3 ) 3 ] , —NH—CO—N ( CH3 ) 2 , —NH—CO—N ( C2H5 ) 2 , —NH—CO—NH—cyc|o - C3H5 , —NH—CO—N ( cyc|o - C3H5 ) 2 , —NH—CO—N [ CH ( CH3 ) 2 ] 2 , —NH—CS—N ( C2H5 ) 2 , —NH—CO—N [ C ( CH3 ) 3 ] 2 , —NH—CS—NH2. —NH—CS—NHCH3 , —NH—CS—N ( CH3 ) 2 , —NH—CS—NHC2H5 , —NH—CS—NHC3H7 , —NH—CS—NH—cyc|o - C3H5 , - — - NH—CS—NH [ CH ( CH3 ) 2 ] . ——NH—CS - —NH [ C ( CH3 ) 3 ] . —NH—CS—N ( cyc|o - C3H5 ) 2 , —NH—CS—N [ CH ( CH3 ) 2 ] 2 , —NH—CS—N [ C ( CH3 ) 3 ] 2 , —NH—C ( =NH ) —NH2 , —NH—C ( =NH ) —NHCH3. —NH—C ( =NH ) —NHC2H5 , —NH—C ( =NH ) —NHC3H7 , —O—CO—NH—cyc|o - C3H5 , —NH—C ( =NH ) —NH—cyc|o - C3H5 , —NH—C ( =NH ) —NH [ CH ( CH3 ) 2 ] , —O—CO—NH [ CH ( CH3 ) 2 ] , —NH—C ( =NH ) —NH [ C ( CH3 ) 3 ] , —NH—C ( =NH ) —N ( CH3 ) 2 , —NH—C ( =NH ) —N ( C2H5 ) 2. —NH—C ( =NH ) - N ( C3H7 ) 2 , —NH - C ( =NH ) —N ( cyc|o - C3H5 ) 2 , —O—CO—NHC3H7 , —NH—C ( =NH ) —N [ CH ( CH3 ) 2 ] 2 , . —NH—C ( =NH ) —N [ C ( CH3 ) 3 ] 2. —O—CO—NH2 , —O—CO - —NHCH3. —O—CO—NHC2H5 , —O—CO - NH [ C ( CH3 ) 3 ] , - O—CO—N ( CH3 ) 2 , —O—CO— - N ( C2H5 ) 2 , —O—CO—N ( C3H7 ) 2 , —O - CO—N ( cyc|o - C3H5 ) 2 , —O - CO—N [ CH ( CH3 ) 2 ] 2 , - O - CO—N [ C ( CH3 ) 3 ] 2 , —O—CO - OCH3 , —O—CO—OC2H5 , —O—CO—OC3H7 , —O—CO—O—cyC|0 - C3H5 , —O—CO—OCH ( CH3 ) 2 , —O—CO—OC ( CH3 ) 3 , ——CH2F , —CHF2 , —CF3 , —CH2C| , —CH2Br , —CH2| , - CH2—CH2F , - CH2—CHF2 , —CH2—CF3 , - CH2—CH2C1 , —CH2—CH2Br , —CH2—CH2| , —cyC|0 - C3H15 , —Ph , —CH2—Ph , —CH2—CH2—Ph , —CH=CH—Ph , —CPh3 , —CH3 , . 10. 15. 2O. 25. 30. 35. W0 2013 / O97947 PCT / EP2012 / OO5387 74. —C2H5 , —C3H7 , —CH ( CH3 ) 2 , —C4H9 , —CH2 - CH ( CH3 ) 2 , —CH ( CH3 ) —C2H5 , —C ( CH3 ) 3 , - c5H , , , —CH ( CH3 ) —C3H7 , —CH2—CH ( CH3 ) —C2H5 , —CH ( CH3 ) - CH ( CH3 ) 2 , —C ( CH3 ) 2—C2H5 , —CH2—C ( CH3 ) 3 , —CH ( C2H5 ) 2 , —C2H4—CH ( CH3 ) 2 , —C5H13 , —C7H15 , —C3H17 , —C3H5—CH ( CH3 ) 2 , —C2H4—CH ( CH3 ) —C2H5 , —CH ( CH3 ) —C4Hg , —CH2—CH ( CH3 ) —C3H7 , - CH ( CH3 ) —CH2—CH ( CH3 ) 2 , —CH ( CH3 ) - —CH ( CH3 ) —C2H5 , —CH2—CH ( CH3 ) —CH ( CH3 ) 2 , —CH2—C ( CH3 ) 2—C2H5 , . —C ( CH3 ) 2—C3H7 , —C ( CH3 ) 2—CH ( CH3 ) 2 , —C2H4—C ( CH3 ) 3 , — - CH ( CH3 ) —C ( CH3 ) 3 , —CH=CH2 , —CH2 - CH=CH2 , —C ( CH3 ) =CH2 , —CH=CH—CH3 , —C2H4—CH=CH2. - CH2—CH=CH—CH3 , —CH=CH—C2H5 , —CH2—C ( CH3 ) =CH2 , —CH ( CH3 ) —CH=CH , . —CH=C ( CH3 ) 2. ——C ( CH3 ) =CH—CH3 , —CH=CH—CH=CH2 , —C3H5—CH=CH2 , —C2H4 - CH=CH—CH3 , —CH2—CH=CH—C2H5 , —CH=CH—C3H7 , —CH2—CH=CH—CH=CH2 , —CH=CH—CH=CH—CH3 , —CH=CH—CH2—CH=CH2 , —C ( CH3 ) =CH—CH=CH2 , —CH=C ( CH3 ) —CH=CH2 , —CH=CH—C ( CH3 ) =CH2 , —C2H4—C ( CH3 ) =CH2 , —CH2—CH ( CH3 ) —CH=CH2. —CH ( CH3 ) —CH2—CH=CH2 , —CH2—CH=C ( CH3 ) 2 , ——CH2—C ( CH3 ) =CH—CH3 , —CH ( CH3 ) —CH=CH—CH3 , —CH=CH—CH ( CH3 ) 2 , —CH=C ( CH3 ) —C2H5. —C ( CH3 ) =CH—C2H5 , —C ( CH3 ) =C ( CH3 ) 2 , - C ( CH3 ) 2—CH=CH2 , —CH ( CH3 ) —C ( CH3 ) =CH2 , —C ( CH3 ) =CH - CH=CH2 , —CH=C ( CH3 ) —CH=CH2 , —CH=CH—C ( CH3 ) =CH2 , —C4H3—CH=CH2 , . —C3H5—CH=CH—CH3 , —C2H4—CH=CH—C2H5 , —CH2—CH=CH—C3H7 , —CH=CH—C4Hg , —C3H6 - C ( CH3 ) =CH2. —C2H4—CH ( CH3 ) —CH=CH2 , —CH2—CH ( CH3 ) —CH2—CH=CH2 , . —C2H4—CH=C ( CH3 ) 2 , —CH ( CH3 ) —C2H4—CH=CH2 , — - C2H4—C ( CH3 ) =CH—CH3 , —CH2—CH ( CH3 ) —CH=CH—CH3 , —CH ( CH3 ) —CH2—CH=CH—CH3. —CH2—CH=CH—CH ( CH3 ) 2. —CH2—CH=C ( CH3 ) —C2H5 , —CH2—C ( CH3 ) =CH—C2H5 , —CH ( CH3 ) —CH=CH—C2H5 , —CH=CH—CH2—CH ( CH3 ) 2 , —CH=CH—CH ( CH3 ) —C2H5 , - CH=C ( CH3 ) —C3H7 , —C ( CH3 ) =CH—C3H7 , . —CH2—CH ( CH3 ) —C ( CH3 ) =CH2 , —C [ C ( CH3 ) 3 ] =CH2 , —CH ( CH3 ) —CH2—C ( CH3 ) =CH2 , ——CH ( CH3 ) —CH ( CH3 ) —CH=CH2 , —CH=CH—C2H4—CH=CH2 , —CH2—C ( CH3 ) 2—CH=CH2 , . —C ( CH3 ) 2—CH2—CH=CH2 , —CH2—C ( CH3 ) =C ( CH3 ) 2. —CH ( CH3 ) —CH=C ( CH3 ) 2 , —C ( CH3 ) 2—CH=CH—CH3 , —CH=CH—CH2—CH=CH—CH3 , —CH ( CH3 ) - —C ( CH3 ) =CH—CH3 , - CH=C ( CH3 ) —CH ( CH3 ) 2 , —C ( CH3 ) =CH—CH ( CH3 ) 2 , —C ( CH3 ) =C ( CH3 ) —C2H5. —CH=CH—C ( CH3 ) 3 , —C ( CH3 ) 2~—C ( CH3 ) =CH2 , "CH ( C2H5 ) —C ( CH3 ) =CH2 , ——C ( CH3 ) ( C2H5 ) —CH=CH2 , —CH ( CH3 ) —C ( C2H5 ) =CH2 , —CH2—C ( C3H7 ) =CH2 , —CH2—C ( C2H5 ) =CH—CH3 , —CH ( C2H5 ) —CH=CH—CH3. —C ( C4Hg ) =CH2 , —C ( C3H7 ) =CH—CH3 , —C ( C2H5 ) =CH—C2H5 , —C ( C2H5 ) =C ( CH3 ) 2 , . —C [ CH ( CH3 ) ( C2H5 ) ] =CH2. —C [ CH2—CH ( CH3 ) 2 ] =CH2 , —C2H4—CH=CH - CH=CH2 , —CH2—CH=CH—CH2—CH=CH2 , —C3H5—CEC—CH3 , —CH2—CH=CH—CH=CH—CH3 , —CH=CH—CH=CH—C2H5 , - CH2 - CH=CH—C ( CH3 ) =CH2 , —CH2—CH=C ( CH3 ) —CH=CH2 , —CH2 - C ( CH3 ) =CH—CH=CH2 , —CH ( CH3 ) —CH2—CECH , —CH ( CH3 ) —CH=CH—CH=CH2 , —CH=CH—CHz - C ( CH3 ) =CH2 , —CH ( CH3 ) —CEC—CH3 , . 10. 15. 2O. W0 2013 / O97947 PCT / EP2012 / OO5387 75. —CH=CH—CH ( CH3 ) —CH=CH2 , —CH=C ( CH3 ) —CH2—CH=CH2 , —C2H4—CH ( CH3 ) —CECH , —C ( CH3 ) =CH—CH2—CH=CH2 , —CH=CH—CH=C ( CH3 ) 2. —CH2—CH ( CH3 ) —CH2—CECH , ——CH=CH—C ( CH3 ) =CH—CH3 , —CH=C ( CH3 ) —CH=CH—CH3 , —CH2—CH ( CH3 ) —CECH , ——C ( CH3 ) =CH—CH=CH—CH3 , —CH=C ( CH3 ) —C ( CH3 ) =CH2 , —C ( CH3 ) =CH - C ( CH3 ) =CH2 , —C ( CH3 ) =C ( CH3 ) —CH=CH2 , —CH=CH—CH=CH—CH=CH2 , —CECH , —CEC—CH3 , —CH2 - CECH , —C2H4——C ' =‘CH , —CH2 - CEC— - CH3 , —CEC—C2H5 , —C3H6—CECH , —C2H4—CEC—CH3 , —CH2—CEC—C2H5 , —CEC—C3H7 , —CH ( CH3 ) —C - =. CH , —C4H8—C - =. CH , - C2H4—CEC—C2H5 , —CH2—CEC—C3H7 , —CEC - —C4H9 , —CEC—C ( CH3 ) 3 , —CH ( CH3 ) —C2H4—CECH , —CH2—CH ( CH3 ) —CEC—CH3 , . —CH ( CH3 ) —CH2—CEC—CH3 , —CH ( CH3 ) —CEC—C2H5 , ——CH2—CEC—CH ( CH3 ) 2 , —CEC—CH ( CH3 ) —C2H5 , —CEC—CH2— - CH ( CH3 ) 2 , —CH ( C2H5 ) —CEC—CH3 , ——C ( CH3 ) 2 - CEC—CH3 , —CH ( C2H5 ) —CH2—CECH , —CH2—CH ( C2H5 ) —CECH , —C ( CH3 ) 2—CH2—CECH , —CH2—C ( CH3 ) 2 - CECH , —CH ( CH3 ) —CH ( CH3 ) —CECH , - —CH ( C3H7 ) —CECH , —C ( CH3 ) ( C2H5 ) —CECH , —CH2—CH ( CECH ) 2 , —C‘= ' C - CECH , —CH2—CEC—CECH , —CEC—CEC—CH3 , —CH ( CECH ) 2 , —C2H4—CEC—CECH , —CH2—CEC—CH2—CECH , —C"= ' C - C2H4—CECH , —CH2—CEC—CEC—CH3 , . —CEC—CH2—C - EC—CH3 , —CEC—CEC—C2H5 , —C ( CECH ) 2—CH3 , —CEC—CH ( CH3 ) —CECH , —CH ( CH3 ) —CEC—CECH , —CH ( CECH ) —CH2—CECH , —CH ( CECH ) —CEC— - CH3 , . —0 NmO \_ / w. W0 2013 / O97947. RN\. R11 R12 \ \N / S R 11 / N / RN. N R11 43 5 0 R12 R12 R12 R11 / 0 R12 R15 R14 R13. R R11 R12 0 R14. PCT / EP2012 / OO5387. R11 R“ / S 4. R11 s - . N M R11 R12 / N\N / RN MRH RN R12 R11 / 8 R12 R15 R14 R13 RN\ R11 N R12 4 * N R13 R14. W0 2013 / O97947 PCT / EP2012 / OO5387. 77 R12 R12 0 R11 R12 R13 / N\ R13 0 O 1 R11 R11 W 3 R16 R11 R12 R11 R11 R12 \ R13 N\ R12 \N —N —N —N / ‘ R14 / R13 / R13 R15 R15 R15 R14 R15 R14 R16 R12 0 R11 R12 R15 R17 —N R15 R13 N } 11 \ / >_ O O 7 \ R16 R N / _ 11 NRN R14 R13 N R17 O R14 R 1 R12 R13 13 12 N / N R15 R14 R13 R R R11 0 R15 0 R12 O R11 RN / R12 R13 . R14 R11 R12 R13 R‘l2 R15 / N / RN %NH O R13 R15 8 11 Q. 10. 15. 20. 25. WO 2013 / 097947 PCT / EP2012 / 005387. 14 N R15 R R13 R13 R\N R13 R12 \ 3 0 w O 0 R11 R12 R11 R12 R11 . R13 R12 R13 R12. O N“ R11 0 R11 O / Ko. R” represents the fo||owing —H , —CH2 - 0CH3 , —C2H4—. OCH3 , ——C3H6—OCH3 , —CH2 - OC2H5 , —C2H4—OC2H5 , —C3H6—OC2H5 , —CH2—OC3H7 , —C2H4—OC3H7 , —C3H5—OC3H7 , - CH2—O—CyC|O - C3H5 , —C2H4—O—cyc|o - C3H5 , —C3H5—O—cyc|o - C3H5 , ——CH2—OCH ( CH3 ) 2 , —C2H4—OCH ( CH3 ) 2 , - —C3H5—OCH ( CH3 ) 2 , —CH2—OC ( CH3 ) 3 , —C2H4—OC ( CH3 ) 3 , —C3H5—OC ( CH3 ) 3 , —CH2—OC4Hg , —C2H4—OC4H9 , —C3He - OC4H9 , —CH2—OPh , —C2H4—OPh , —C3H6—OPh , —CH2—OCH2——Ph , —C2H4—OCH2—Ph , . —C3H5—OCH2 - Ph , —CHO , —COCH3 , —COC2H5 , —COC3H7 , —CO - cyc|o - C3H5 , —COCH ( CH3 ) 2 , —COC ( CH3 ) 3 , —COCN , —COOCH3 , —COOC2H5 , —COOC3H7 , —COO - cyC|0 - C3H5 , —COOCH ( CH3 ) 2 , —COOC ( CH3 ) 3 , —CONH2 , —CONHCH3 , —CONHC2H5 , —CONHC3H7 , —CONH—cyc|0 - C3H5 , — - CONH [ CH ( CH3 ) 2 ] , ——CONH [ C ( CH3 ) 3 ] , - CON ( CH3 ) 2 : —CON ( C2H5 ) 2 , —CON ( C3H7 ) 2 , —CON ( cyclo - C3H5 ) 2 , —CON [ CH ( CH3 ) 2 ] 2 , —CON [ C ( CH3 ) 3 ] 2 , —SO2CH3 , —SO2C2H5 , —SO2C3H7 , ~SO2—cyc|0 - C3H5 , —SO2CH ( CH3 ) 2 , —SO2C ( CH3 ) 3 , —CH2—OCF3 , —C2H4—OCF3 , —C3H3—OCF3 , —OC2F5 , —CH2—OC2F5 , —C2H4—OC2F5 , —C3H5—OC2F5 , —CH2F , —CHF2 , —CF3 , ——CH2C| , — - CH2Br , —CH2| , . —CH2——CH2F , —CH2—CHF2 , —CH2— - CF3 , —CH2—CH2Cl , —CH2—CH2Br , —CH2—CH2| , —cyC|0 - C8H15 , —Ph , —CH2—Ph , —CH2—CH2—Ph , —. CH=CH—Ph , —CPh3 , —CH3 , . —C2H5 , —C3H7 , —CH ( CH3 ) 2 , —C4H9 , —CH2—CH ( CH3 ) 2 , —CH ( CH3 ) —C2H5 , —C ( CH3 ) 3 , —C5H11 , —CH ( CH3 ) —C3H7 , —CH2—CH ( CH3 ) —C2H5 , —CH ( CH3 ) —CH ( CH3 ) 2 , —C ( CH3 ) 2—C2H5 , —CH2—C ( CH3 ) 3 , —CH ( C2H5 ) 2 , —C2H4—CH ( CH3 ) 2 , —C5H13 , —C7H15 , —C3H17 , —C3H6—CH ( CH3 ) 2 , —C2H4—CH ( CH3 ) —C2H5 , —CH ( CH3 ) —C4H9 , —CH2—CH ( CH3 ) —C3H7 , —CH ( CH3 ) —CH2—CH ( CH3 ) 2 , ——CH ( CH3 } —CH ( CH3 ) —C2H5 , ——CH2—CH ( CH3 ) —CH ( CH3 ) 2 , —CH2—C ( CH3 ) z - C2H5 , . —C ( CH3 ) 2—C3H7 , —C ( CH3 ) 2—CH ( CH3 ) 2 , —C2H4—C ( CH3 ) 3 , —CH ( CH3 ) —C ( CH3 ) 3 , . 10. 15. 20. 25. 30. 35. WO 2013 / 097947 PCT / EP2012 / 005387 79. —CH=CH2 , —CH2—CH=CH2 , —C ( CH3 ) =CH2 , —CH=CH—CH3 , —C2H4— - CH=CH2 , —CH2—CH=CH—CH3 , —CH=CH—C2H5 , —CH2—C ( CH3 ) =CH2 , —CH ( CH3 ) —CH=CH , . —CH=C ( CH3 ) 2 , —C ( CH3 ) =CH—CH3 , - CH=CH—CH=CH2 , —C3H5—CH=CH2 , —C2H4—CH=CH—CH3 , —CH2—CH=CH—C2H5 , —CH=CH—C3H7 , —CH2—CH=CH—CH=CH2 , — - CH=CH—CH=CH—CH3 , —CH=CH—CH2—CH=CH2 , - C ( CH3 ) =CH—CH=CH2 , —CH=C ( CH3 ) —CH=CH2 , —CH=CH—C ( CH3 ) =CH2 , —C2H4—C ( CH3 ) =CH2 , —CH2—CH ( CH3 ) —CH=CH2 , —CH ( CH3 ) —CH2—CH=CH2 , —CH2—CH=C ( CH3 ) 2 , —CH2—C ( CH3 ) =CH—CH3 , —CH ( CH3 ) —CH=CH—CH3 , —CH=CH—CH ( CH3 ) 2 , —CH=C ( CH3 ) —C2H5 , —C ( CH3 ) =CH - —C2H5 , — - C ( CH3 ) =C ( CH3 ) 2 , ——C ( CH3 ) 2—CH=CH2 , —CH ( CH3 ) - C ( CH3 ) =CH2 , ——C ( CH3 ) =CH - CH=CH2 , —CH=C ( CH3 ) —CH=CH2 , —CH=CH—C ( CH3 ) =CH2 , —C4H8——CH=CH2 , . —C3H5—CH=CH—CH3 , —C2H4—CH=CH—C2H5 , - CH2—CH=CH—C3H7 , —CH=CH—C4H9 , - - C3H6 - C ( CH3 ) =CH2 , —C2H4—CH ( CH3 ) —CH=CH2 , —CH2— - CH ( CH3 ) —CH2—CH=CH2 , . —C2H4—CH=C ( CH3 ) 2 , —CH ( CH3 ) —C2H4—CH=CH2 , —C2H4—C ( CH3 ) =CH—CH3 , —CH2—CH ( CH3 ) —CH=CH—CH3 , —CH ( CH3 ) —CH2—CH=CH—CH3 , —CH2—CH=CH—CH ( CH3 ) 2 , —CH2—CH=C ( CH3 ) —C2H5 , —CH2—C ( CH3 ) =CH—C2H5 , —CH ( CH3 ) —CH=CH—C2H5 , —CH=CH—CH2—CH ( CH3 ) 2 , —CH=CH—CH ( CH3 ) —C2H5 , —CH=C ( CH3 ) —C3H7 , —C ( CH3 ) =CH—C3H7 , . —CHz - CH ( CH3 ) —C ( CH3 ) =CH2 , —C [ C ( CH3 ) 3 ] =CH2 , —CH ( CH3 ) —CH2—C ( CH3 ) =CH2 , ——CH ( CH3 ) —CH ( CH3 ) —CH=CH2 , —CH=CH—C2H4—CH=CH2 , —CH2—C ( CH3 ) 2—CH=CH2 , . —C ( CH3 ) 2 - CH2—CH=CH2 , —CH2—C ( CH3 ) =C ( CH3 ) 2 , —CH ( CH3 ) —CH=C ( CH3 ) 2 , —C ( CH3 ) 2—CH=CH—CH3 , —CH=CH—CH2—CH=CH—CH3 , —CH ( CH3 ) —C ( CH3 ) =CH—CH3 , —CH=C ( CH3 ) —CH ( CH3 ) 2 , —C ( CH3 ) =CH—CH ( CH3 ) 2 , — - C ( CH3 ) =C ( CH3 ) —C2H5 , —CH=CH—C ( CH3 ) 3 , —C ( CH3 ) 2—C ( CH3 ) =CH2 , —CH ( C2H5 ) —C ( CH3 ) =CH2 , —C ( CH3 ) ( C2H5 ) —CH=CH2 , —CH ( CH3 ) —C ( C2H5 ) =CH2 , —CH2—C ( C3H7 ) =CH2 , —CH2 - C ( C2H5 ) =CH—CH3 , —CH ( C2H5 ) —CH=CH—CH3 , —C ( C4Hg ) =CH2 , —C ( C3H7 ) =CH—CH3 , —C ( C2H5 ) =CH - C2H5 , —C ( C2H5 ) =C ( CH3 ) 2 , . —C [ CH ( CH3 ) ( C2H5 ) ] =CH2 , —C [ CH2—CH ( CH3 ) 2 ] =CH2 , —C2H4—CH=CH - CH=CH2 , —CH2—CH=CH—CH2—CH=CH2 , —C3H6—CEC—CH3 , —CH2—CH=CH—CH=CH—CH3 , —CH=CH—CH=CH—C2H5 , —CH2—CH=CH—C ( CH3 ) =CH2. —CH2—CH=C ( CH3 ) —CH=CH2 , —CH2—C ( CH3 ) =CH—CH=CH2 , —CH ( CH3 ) —CH2—CECH , —CH ( CH3 ) —CH=CH—CH=CH2 , —CH=CH—CH2—C ( CH3 ) =CH2 , —CH ( CH3 ) —CEC—CH3 , —CH=CH - CH ( CH3 ) —CH=CH2 , ——CH=C ( CH3 ) —CH2—CH=CH2 , —C2H4—CH ( CH3 ) —C - = - CH , —C ( CH3 ) =CH—CH2—CH=CH2 , —CH=CH—CH=C ( CH3 ) 2. —CH2—CH ( CH3 ) —CH2—CECH , —CH=CH—C ( CH3 ) =CH—CH3 , —CH=C ( CH3 ) —CH=CH—CH3 , —CH2—CH ( CH3 ) —CECH , —C ( CH3 ) =CH—CH=CH—CH3 , —CH=C ( CH3 ) - C ( CH3 ) =CH2 , —C ( CH3 ) =CH—C ( CH3 ) =CH2 , —C ( CH3 ) =C ( CH3 ) —CH=CH2 , —CH=CH—CH=CH—CH=CH2 , —CECH , —CEC—CH3 , —CH2 - CECH , —C2H4—CECH , —CH2 - C5C - CH3 , —CEC - C2H5 , —C3H5 - CECH , —C2H4—CEC—CH3 , —CH2—CEC - C2H5 , . 10. 15. 20. 25. WO 2013 / 097947 PCT / EP2012 / 005387 80. - CEC - C3H7 , —CH ( CH3 ) - —CECH , —C4H3—CECH , —C2H4—CEC—C2H5 , —CH2—CEC - C3H7 , —C‘= ' C—C4H9 , —CEC - C ( CH3 ) 3 , ——CH ( CH3 ) —C2H4—CECH , ——CH2 - —CH ( CH3 ) - CEC—CH3 , . - CH ( CH3 ) —CH2 - — - CEC— - CH3 , —CH ( CH3 ) —CEC—C2H5 , —CH2—CEC - CH ( CH3 ) 2 , —CEC - —CH ( CH3 ) —C2H5 , — - CEC - —CH2—CH ( CH3 ) 2 , —CH ( C2H5 ) —CEC—CH3 , —C ( CH3 ) 2—CEC—CH3 , —CH ( C2H5 ) —CH2— - CECH , —CH2—CH ( C2H5 ) - CECH , —C ( CH3 ) 2—CH2—CECH , —CH2—C ( CH3 ) 2—CECH , —CH ( CH3 ) —CH ( CH3 ) —CECH , —CH ( C3H7 ) —CECH , —C ( CH3 ) ( C2H5 ) —CECH , —CH2—CH ( CECH ) 2 , —CEC—CECH , —CH2—CEC—CECH , —CEC—CEC—CH3 , —CH ( CECH ) 2 , —C2H4 - —CEC—CECH , —CH2—CEC—CH2—CECH , ——CEC—C2H4—CECH , ——CH2—CEC—CEC—CH3 , . —CEC—CH2—CEC—CH3 , —CEC—CEC - —C2H5 , ——C ( CECH ) 2—CH3 , —CEC—CH ( CH3 ) —CECH , —CH ( CH3 ) —CEC—CECH , —CH ( C ' = ' CH ) —CH2—CECH , —CH ( CECH ) —CEC—CH3 ; . and enantiomers , stereoisomeric forms , mixtures of enantiomers , anomers , diastereomers , mixtures of diastereomers , tautomers , hydrates , so|vates and racemates of the above mentioned compounds and pharmaceutical|y acceptabIe sa|ts thereof , except the compound wherein A represents —Ph and R1 to R1° represent —H. 2. Compound according to c|aim 1 , wherein. R11 R12 R11 R12 R“ R12 A represents 0 ' 13 NH N A k R15 R14 R15 S O R15 S R16 R12 represents —H , —C| , —F , —Br , and R13 , R14 and R16 have the meanings as defined in c|aim 1 , and. R11 and R15 represent —H. 3. Compound of the genera| formu|a ( V ) , wherein. %O 0 R4 R15. O=S=0 0 R1. R7. R13. ( V ) . R8 wherein R4 , R7 , R8 , R11 — R15 have the meanings as defined in c|aim 1 , except the compound wherein R4 , R7 , R8 , R11 — R15 are —H. 10. 15. 20. 25. 3O. 35. WO 2013 / 097947 PCT / EP2012 / 005387. 81. Compound according to c|aim 1 se|ected from the group consisting of : . 2 - ( - 3 ( ( R ) - 3 - ( 3 , 4 - - dimethoxypheny| ) - 1 - - ( ( S ) - - - 1 - ( 4 - ( pyrimidin - 2 - yi ) pheny|su|fony| ) pipridine - - 2 - carbony|oxy ) propy| ) phenoxy ) acetic acid , 2 - ( 3 - ( ( R ) - 1 - ( ( S ) - 1 - ( 3 - ch|oropheny|su|fony| ) piperidine - 2 - carbony|oxy ) - 3 - ( 3 , 4 - dimethoxy pheny| ) propy| - phenoxy ) acetic acid , 2 - ( 3 - ( ( R ) - 1 - ( ( S ) —1 - ( benzo [ d ] thiazol - 5 - y|su|fo ny| ) pipe rid ine - 2 - carbony|oxy ) - 3 - ( 3 , 4 - dimethoxy pheny| ) propy| ) phenoxy ) acetic acid , 2 - ( 3 - ( ( R ) - 3 - ( 3 , 4 - dimethoxypheny| ) - 1 - ( ( S ) - 1 - ( furan - 3 - y|sulfony| ) piperidine - 2 - carbony|oxy ) propy| ) phenoxy ) acetic acid , 2 - ( 3 - ( ( R ) - 1 - ( ( S ) - 1 - ( benzo [ b ] thiophen - 2 - y|su|fonyl ) piperidine - 2 - carbony|oxy ) - 3 - ( 3 , 4 - dimethoxypheny| propyl ) phenoxy ) acetic acid , 2 - ( 3 - ( ( R ) - 1 - ( ( S ) - 1 - ( 3 - cyanopheny|su|fony| ) piperidine - 2 - carbony|oxy ) - 3 - ( 3 , 4 - dimethoxypheny| ) propy| ) phenoxy ) acetic acid , 2 - ( 3 - ( ( R ) - 3 - ( 3 , 4 - dimethoxypheny| ) - 1 - ( ( S ) - 1 - ( 3 - nitropheny|su|fonyl ) piperidine - 2 - carbony|oxy propy| ) phenoxy ) acetic acid , 2 - ( 3 - ( ( R ) - 3 - ( 3 , 4 - dimethoxypheny| ) - 1 - ( ( S ) - 1 - ( 3 - ( 2 - methy|pyrimidin - 4 - y| ) pheny|su|fony| ) piperidine - 2 - carbonyloxy ) propy| ) phenoxy ) acetic acid , 2 - ( 3 - ( ( R ) - 3 - ( 3 , 4 - dimethoxypheny| ) - 1 - ( ( S ) - 1 - ( 3 - ( pyrimidin - 4 - y| ) pheny| su|fony| ) piperidine - 2 - carbony|oxy ) propy| ) phenoxy ) acetic acid , 2 - ( 3 - ( ( R ) - 1 - ( ( S ) - 1 - ( 3 , 5 - dich|orophenylsu|fony| ) piperidine - 2 - carbony|oxy ) - 3 - ( 3 , 4 - dimethoxy - phenyl ) propy| ) phenoxy ) acetic acid , 2 - ( 3 - ( ( R ) - 1 - ( ( S ) - 1— ( 2 , 3—dich|oropheny|su|fony| ) piperidine - 2 - carbony|oxy ) - 3 - ( 3 , 4 - dimethoxy pheny| ) propyl ) phenoxy ) acetic acid , . 2 - - ( - 3 ( ( R ) 3 - ( 3 , 4 - dimethoxypheny| ) - 1 ( - ( S ) - 1 - ( 3 , 4 - dimethoxypheny|sulfony| ) piperidine - 2 - - carbony|oxy ) propy| ) phenoxy ) acetic acid , . 2 - 3 ( ( - ( R ) - 1 ( - ( S ) - 1 - - ( 3 , 5 - - bis ( trif|uoromethyl ) pheny|su|fony| ) piperidine - - - 2 carbony|oxy ) - - 3 - - ( 3 , 4 - d - imethoxyphenyl ) propy| ) phenoxy ) acetic acid , . 23 - ( - ( ( R ) - 1 - ( - ( S ) - ( - 3 bromo - 5 - - ( trif|uoromethy| ) pheny|su|fony| ) piperidine - 2 - carbony|oxy ) - 3 - - ( 3 , 4 - - dimethoxypheny| ) propy| ) phenoxy ) acetic acid , . 2 - - ( - 3 ( ( R ) - 1 - ( ( S ) - - 1 - - ( 3 , 5 - dich|oro — - 4 - hydroxypheny|su|fony| ) piperidine - - 2 - carbony|oxy ) - - 3 - - ( 3 , 4 - d - imethoxypheny| ) propy| ) phenoxy ) acetic acid , . 2 - - ( 3 - ( ( R ) - 1 - ( - ( S ) - ( 3 , 5 - dich|oro - - 4 - methoxyphenylsu|fony| ) piperidine - - 2 - carbony|oxy ) - 3 - ( 3 , 4— —dimethoxypheny| ) propy| ) phenoxy ) acetic acid , . ( S ) - ( ( R ) - 3 - ( 3 4 - - dimethoxypheny| ) - - 1 - - ( 3 - ( - 2 morpho|inoethoxy ) pheny| ) propy| ) 1 - . ( 3 , 5 - dich|oro - - pheny|su|fony| ) piperidine - 2 - carboxylate , ( S ) - ( ( R ) - 3 - ( 3 , 4 - dimethoxypheny| ) - 1 - ( 3 - ( 2 - morpho|inoethoxy ) pheny| ) prop - y| ) 1 - ( benzo [ d ] thi - azo| - 6 - y|su|fony| ) piperidine - 2 - carboxy|ate , . 10. 15. 20. 25. 30. 35. WO 2013 / 097947 PCT / EP2012 / 005387. 82. ( S ) - - R ( ( ) - - - 3 - ( 3 , 4 - dimethoxypheny| ) - 1 - ( - 3 ( - 2 - - morpho|inoethoxy ) pheny| ) propy| ) 1 - ( 3 , 5 - dich|oro - 4 - hydroxypheny|su|fony| ) piperidine - - - 2 - carboxylate. ( S ) - ( ( R ) - 3 - ( 3 , 4 - dimethoxypheny| ) - 1 - ( 3— — ( - 2 - morpho|inoethoxy ) pheny| ) propy| ) 1 - ( 3 , 5 - dichloro - 4 - methoxypheny|su|fony| ) piperidine - 2 - - carboxyiate , . ( S ) - ( - ( R ) - 3 - ( 3 , 4 - dimethoxypheny| ) - 1 - ( - 3 ( 2 - morpho|inoethoxy ) pheny| ) propy| ) 1 - ( 2 - oxo - - 2 , 3 - dihydrobenzo [ d ] thiazo| - - 6 - - y|su|fony| ) piperidine 2— carboxy|ate , . 23 - ( - ( - ( R ) - 3 - - ( 3 , 4 - - dimethoxypheny| ) - 1 - ( ( S ) 1 - ( 2 - oxoindolin - 5 - y|su|fony| ) piperidine - 2 - - carbonyloxy ) propyl ) phenoxy ) acetic acid , . 23 - ( - ( ( R ) - 3 - ( 3 , 4 - dimethoxypheny| ) - 1 - ( ( S ) - 1 - ( - 2 - o - xo 2 , 3 - dihydrobenzo [ d ] oxazo| - - 6 - y|su|fony| ) piperidine - 2 - carbony|oxy ) propy| ) phenoxy ) aceticacid , 2 - ( 3 - ( ( R ) - 1 - ( ( S ) - 1 - ( 4 - acetamido - 3 , 5 - dich|oropheny|su|fonyl ) piperidine - 2 - carbo ny|oxy ) - 3 - ( 3 , 4 - dimethoxypheny| ) propy| ) phenoxy ) acetic acid , 5 - ( ( S ) - 2 - ( ( ( R ) - 1 - ( 3 - ( carb0xymethoxy ) pheny| ) - 3 - ( 3 , 4—dimethoxypheny| ) propoxy ) carbony| ) piperidin - 1 - y|su|fony| ) - 2 , 3—dimethoxybenzoic acid , 2 - ( 3 - ( ( R ) - 3 - ( 3 , 4 - dimethoxypheny| ) - 1 - ( ( S ) - 1 - ( 7 - nitro - 2 , 3 - dihydrobenzofuran - 5 - y|su|fony| ) piperidine - 2 - carbony|oxy ) propy| ) phenoxy ) acetic acid , 2 - ( 3 - ( ( R ) - 1 - ( ( S ) —1 - ( 7 - amino - 2 , 3 - dihydrobenzofuran—5 - y|su|fony| ) piperidine - 2 - carbony|oxy ) - - - 3 - ( 3 , 4 - - dimethoxypheny| ) propyl ) phenoxy ) aceticacid , . 23 - ( - ( ( R ) - ——3 — , ( 3 4 - - dimethoxypheny| ) - 1 - - ( ( S ) - 1 - ( - 2 methy|benzo [ d ] thiazo| - - 6 - y - |su|f onyl ) piperidine - 2— carbony|oxy ) propy| ) phenoxy ) acetic acid , . 2 - ( 3 - ( ( R ) - - - 3 - ( 3 , 4— dimethoxypheny| ) - 1 - ( ( S ) - 1 - ( 2 - oxo - 2 , 3 - dihydrobenzo [ d ] thiazo| - - 6 - y|su|fony| ) piperidine - 2 - carbony|oxy ) propy| ) phenoxy ) aceticacid , 2— ( 3— ( ( R ) - 1 - ( ( S ) - 1 - ( 3 , 5 - bis ( methoxycarbony| ) pheny|su|fonyi ) piperidine - 2 - carbony| oxy ) - 3 - ( 3 , 4 - dimethoxypheny| ) propy| ) phenoxy ) acetic acid , 2 - ( 3 - ( ( R ) - 1 - ( ( S ) - 1 - ( 3 , 5 - dif|uoropheny|su|fony| ) piperidine—2 - carbony|oxy ) —3 - ( 3 , 4 - dimethoxyphenyl ) propyI ) phenoxy ) acetic acid , 2 - ( 3 - ( ( R ) - 1 - ( ( S ) - 1 - ( 3 - ch|oro - 4 - methoxyphenyIsu|fony| ) piperidine - 2 - carbony| oxy ) - 3 - ( 3 , 4 - dimethoxypheny| ) propy| ) phenoxy ) aceticacid , . 2 - ( 3 - ( ( R ) - 3 — ( 3 , 4 - dimethoxypheny| ) - 1 ( ( S ) 1 ( 3 - - f|uoropheny|su|fony| ) piperidine - - - 2 carbonyloxy ) propy| ) phenoxy ) acetic acid , 2 - ( 3 - ( ( R ) - 1 - ( ( S ) - 1 - ( 3—bromopheny|su|fony| ) piperidine - 2—carbony|oxy ) - 3 - ( 3 , 4 - dimethoxypheny| ) propy| ) phenoxy ) acetic acid , 2 - ( 3 - ( ( R ) - 1 - ( ( S ) —1 - ( 3 - aminopheny|su|fony| ) piperidine - 2 - carbony|oxy ) - 3 - ( 3 , 4 - dimethoxyphenyl ) propy| ) phenoxy ) acetic acid , 2 - ( 3 - ( ( R ) - 1 - ( ( S ) - 1 - ( 4—ch|oropheny|su|fony| ) piperidine - 2 - carbony|oxy ) - 3 - ( 3 , 4 - dimethoxypheny| ) propy| ) phenoxy ) acetic acid , 2 - ( 3 - ( ( R ) - 1 - ( ( S ) - 1 - ( 4 - tert - butylpheny|su|fony| ) piperidine - 2 - carbony|oxy ) - 3 - ( 3 , 4 - dimethoxypheny| ) propy| ) phenoxy ) acetic acid , . 10. 15. 20. 25. 30. 35. WO 2013 / 097947 PCT / EP2012 / 005387. 83. 2 - - ( 3 - ( ( R ) 3 ( - 3 , 4 - dimethoxypheny| ) - 1 - - ( ( S ) - 1 - ( 4 - f|uoropheny|su|fony| ) piperidine - 2 - carbony|oxy ) propy| ) phenoxy ) acetic acid , 2 - ( 3 - ( ( R ) - 1 - ( ( S ) - 1 - ( 4 - ch|orobenzy|sulfony| ) piperidine - 2 - carbonyloxy ) - 3 - ( 3 , 4— dimethoxypheny| ) propy| ) phenoxy ) acetic acid , 2 - ( 3 - ( ( R ) - 3 - ( 3 , 4 - dimethoxypheny| ) - 1 - ( ( S ) - 1 - ( 4 - ( trif|uoromethy| ) pheny|su|fony| ) piperidine - 2 - carbony|oxy ) propy| ) phenoxy ) acetic acid , 2 - ( 3 - ( ( R ) - 3 - ( 3 , 4 - dimethoxypheny| ) - 1 - ( ( S ) - 1 - ( 4 - phenoxypheny|su|fony| ) piperidine - 2 - - carbonyioxy ) propy| ) phenoxy ) acetic acid , . 2 - - - ( 3 ( ( R ) 3 - ( 3 , 4 - dimethoxypheny| ) - 1 - ( ( S ) - 1 - ( pyridin - 3 - y|su|fony| ) piperidine - 2 - carbony|oxy ) propy| ) phenoxy ) acetic acid , . 2 - ( 3 - - ( ( R ) - 3 - , ( 3 4 - dimethoxypheny| ) - 1 - ( ( S ) - 1 - ( 6 - phenoxypyridin - 3 - y|su|fony| ) piperidine - - 2 - - carbony|oxy ) propy| ) phenoxy ) acetic acid , . 2 - - ( - 3 ( ( R ) - 3 - ( 3 , 4 - - dimethoxypheny| ) - 1 - - ( ( S ) - 1 - ( - 6 pheny|pyridin - - 3 - y|su|fony| ) piperidine - - 2 - - carbony|oxy ) propy| ) phenoxy ) acetic acid , 2 - ( 3 - ( ( R ) - 1 - ( ( S ) - 1 - ( 2 - ch|oropheny|su|fony| ) piperidine - 2 - carbony|oxy ) - 3 - ( 3 , 4 - dimethoxypheny| ) propy| ) phenoxy ) acetic acid , 2 - ( 3 - ( ( R ) - 1 - ( ( S ) - 1 - ( 2 , 6 - dich|orophenylsulfony| ) piperidine - 2 - carbony|oxy ) - 3 - ( 3 , 4 - dimethoxypheny| ) propy| ) phenoxy ) acetic acid , 2 - ( 3 - ( ( R ) - 3 - ( 3 , 4 - dimethoxypheny| ) - 1 - ( ( S ) - 1 - ( 3 - ( 5 - methy| - 1 , 3 , 4 - oxadiazo| - 2 - y| ) pheny|su|fony| ) piperidine - 2 - carbonyioxy ) propy| ) phenoxy ) acetic acid , 2 - ( 3 - ( ( R ) - 1 - ( ( S ) - 1 - ( 3—ch|oro - 4 - ( triﬂuoromethy| ) pheny|su|fony| ) piperidine - 2 - carbony|oxy ) - 3 - ( 3 , 4 - dimethoxypheny| ) propy| ) phenoxy ) acetic acid , 2 - ( 3 - ( ( R ) - 3 - ( 3 , 4 - dimethoxypheny| ) - 1 - ( ( S ) - 1 - ( 1 - methy| - 1H - indo| - 4 - y|su|fony| ) piperidine - 2 - carbony|oxy ) propy| ) phenoxy ) acetic acid , 2 - ( 3 - ( ( R ) - 3 - ( 3 , 4 - dimethoxyphenyl ) - 1 - ( ( S ) - 1 - ( 1 - methy| - 1H - indo|—5 - y|su|fony| ) piperidine - 2 - carbony|oxy ) propyI ) phenoxy ) acetic acid , 2 - ( 3 - ( ( R ) - 3 - ( 3 , 4 - dimethoxypheny| ) - 1 - ( ( S ) - 1 - ( 4 - methy| - 3 , 4 - dihydro - 2H - benzo [ b ] [ 1 , 4 ] oxazin - 6 - y|su|fony| ) piperidine - 2 - carbony|oxy ) propy| ) phenoxy ) acetic acid , . 2 - ( 3 - ( ( R ) - 3 - ( 3 , 4 - dimethoxyphenyl ) - 1 - - ( ( S ) - 1 - ( furan - - 3 - - y|sulfonyl ) piperidine - 2 - - carbony|oxy ) propy| ) phenoxy ) acetic acid , . 2 ( - 3 ( ( R ) - 1 - ( ( S ) - 1 - ( - benzofuran 2 - y|su|fony| ) piperidine - 2 - carbony|oxy ) - 3— — , ( 3 4 - dimethoxypheny| ) propyl ) phenoxy ) acetic acid , 2 - ( 3 - ( ( R ) - 3 - ( 3 , 4 - dimethoxypheny| ) - 1 - ( ( S ) - 1 - ( thiophen - 2 - yisu|fony| ) piperidine - 2 - carbony|oxy ) propy| ) phenoxy ) acetic acid , . 2 - ( 3 - ( ( R ) - 3 - ( 3 , 4 - dimethoxypheny| ) - 1 - - ( - ( S ) 1 - - ( - 5 - pheny|thiophen - 2 - ylsu|fony| ) piperidine - 2 - carbony|oxy ) propy| ) phenoxy ) acetic acid , 2 - ( 3 - ( ( R ) - 1 - ( ( S ) - 1 - ( benzo [ b ] thiophen - 3 - y|su|fonyl ) piperidine - 2 - carbony|oxy ) - 3 - ( 3 , 4 - dimethoxypheny| ) propy| ) phenoxy ) acetic acid , . 10. 15. 20. 25. 30. 35. 10. WO 2013 / 097947 PCT / EP2012 / 005387. 84. 2 - ( 3— ( ( 1 R ) - 3 - ( 3 , 4 - dimethoxyphenyi ) - 1 - ( ( 2S ) - 1 - ( 1 - methy| - 4 , 5—dihydro - 1H - pyrazo| - 5 - yIsu|fony| ) piperidine - 2 - carbony|oxy ) propy| ) phenoxy ) acetic acid , 2 - ( 3 - ( ( R ) - 3 - ( 3 , 4 - dimethoxypheny| ) - 1 - ( ( S ) - 1 - ( 1 , 3 , 5 - trimethyi - 1H - pyrazo| - 4 - y|su|fony| ) piperidine - 2 - carbony|oxy ) propy| ) phenoxy ) acetic acid , 2 - ( 3 - ( ( R ) - 3 - ( 3 , 4 - dimethoxypheny| ) - 1 - ( ( S ) - 1 - ( 3 , 5 - dimethy| - 1 - pheny| - 1H - pyrazo| - 4 - y|su|fony| ) piperidine - 2 - carbony|oxy ) propy| ) phenoxy ) acetic acid , 2 - ( 3 - ( ( R ) - 3 - ( 3 , 4 - dimethoxypheny| ) - 1 - ( ( S ) - 1—tosy|piperidine - 2 - carbony|oxy ) propy| ) phenoxy ) acetic acid , 2 - ( 3 - ( ( R ) - 3 - ( 3 , 4 - dimethoxypheny| ) - 1 - ( ( S ) - 1 - ( 4 - nitropheny|su|fony| ) piperidine - 2 - carbony|oxy ) propy| ) phenoxy ) acetic acid , ( S ) - ( ( R ) - 3 - ( 3 , 4 - dimethoxypheny| ) - 1 - ( 3— ( 2 - morpholinoethoxy ) pheny| ) propy| ) 1 - ( 4 - acetamido - 3 , 5 - dich|oropheny|su|fony| ) piperidine - 2 - carboxy|ate. Compound according to any one of cIaims 1 — 4 for use as pharmaceutica||y active agent in medicine. Compound according to any one of c|aims 1 — 4 for use as inhibitor of the FK506 - binding protein ( s ) 51 ( FKBP51 ) and / or 52 ( FKBP52 ) . Compound according to any one of c|aims 1 — 6 for use in treatment or prophy|axis of psychiatric disorders , neuro|ogica| disorders , cancers , g|ucocorticoid hyposensitivity syndromes , peripheral g|ucocorticoid resistance , infectious diseases , a|opecia , abnorma||y elevated intraocu|ar pressure , macu|ar degeneration , oxidative damage to eye tissues , vision disorder , memory impairment and for neuroprotection , neuroregeneration , promoting hair growth , stimu|ating neurite growth , wound hea|ing , antig|aucomatous medications , improving vision , enhancing memory performance , for the use in |imiting or preventing hemorrhage or neovascu|arization and for the use in treatment of diseases re|ating to neurodegeneration. Compound according to c|aim 7 , wherein the psychiatric diseases is an affective disorder or an anxiety disorder. Compound according to c|aim 8 , wherein the affective disorder is se|ected from the group consisting of : depression , bipo|ar disorder , mania , substance induced mood disorder and seasona| affective disorder ( SAD ) . Compound according to c|aim 8 , wherein the anxiety disorder is se|ected from the group comprising or consisting of genera|ized anxiety disorder , panic. 10. 15. 20. 11. 12. 13. 14. WO 2013 / 097947 PCT / EP2012 / 005387. SS. disorder , panic disorder with agoraphobia , phobias , obsessive—c0mpu|sive disorder , post - traumatic stress disorder , separation anxiety and chi|dhood anxiety dis0rders. Compound according to c|aim 7 , wherein the infectious disease is se|ected from the group consisting of : ma|aria and Legionnaires disease. Pharmaceutical composition comprising at |east one compound according to any one of c|aims 1 — 4 together with at least one pharmaceutica||y acceptab|e carrier , solvent or excipient. Pharmaceutica| composition according to c|aim 12 further comprising at |east one active agent se|ected from the group consisting of an anti - depressant and other psychotropic drugs. Pharmaceutical composition according to cIaim 12 , wherein the anti - depressant is selected from amitriptyline , amioxide c|omipramine , doxepine , du|oxetine , imipramine trimipramine , mirtazapine , reboxetine , cita|oprame , ﬂuoxetine , moc|obemide and sertra|ine. |NTERNAT|ONAL SEARCH REPORT. . |nternationa| app|ication No. PCT / EP2012 / 005387. . . A. CLASS|F|CAT|ON OF SUBJECT MATTER. INV. C07D21l / 60 A6lK3l / 445 ADD C07D409 / l2 C07D4l3 / 12. A6lP25 / 24 C07D417 / 12. C07D40l / l2 C07D405 / l2. According to |nternationa| Patent C|assification ( |PC ) or to both nationa| c|assification and |PC. . B. F|ELDS SEARCHED. . C07D. Minimum documentation searched ( c|assification system fo||owed by c|assification symbo|s ) . . Documentation searched other than minimum documentation to the extent that such documents are inc|uded in the fie|ds searched. . EPO - Internal , CHEM ABS Data , NPI Data. E|ectronic data base consu|ted during the internationa| search ( name of data base and , where practicab|e , search terms used ) . . C. DOCUMENTS CONS|DERED TO BE RELEVANT. . Category * . Citation of document , with indication , where appropriate , of the re|evant passages. Re|evant to c|aim No. . claim 1 pages 47 - 55. paragraph [ 0034 ] . . Y N0 00 / 16603 A2 ( GUILFORD PHARM INC [ US ] ; AMGEN INC [ US ] ) 30 MarCh 2000 ( 2000 - 03 - 30 ) . Y W0 2006 / 069038 A1 ( ARIAD GENE THERAPEUTICS INC [ US ] ; CLACKSON TIMOTHY P [ US ] ; BEDROSIAN C ) 29 June 2006 ( 2006 - 06 - 29 ) . 1 - l4. 1 - 14. _ / __. . . . . . X Further documents are |isted in the continuation of Box C. . . . . X See patent fami|y annex. . . * Specia| categories of cited documents : . "A" document defining the genera| state of the art which is not considered to be of particu|ar re|evance. "E" ear|ier app|ication or patent but pub|ished on or after the internationa| fi|ing date. "L" documentwhich may throw doubts on priority c|aim ( s ) or which is cited to estab|ish the pub|ication date of another citation or other specia| reason ( as specified ) . "O" document referring to an ora| disc|osure , use , exhibition or other means. "P" document pub|ished prior to the internationa| fi|ing date but |ater than the priority date c|aimed. "T" |ater document pub|ished after the internationa| fi|ing date or priority date and not in conf|ict with the app|ication but cited to understand the princip|e or theory under|ying the invention. "X" document of particu|ar re|evance ; the c|aimed invention cannot be considered nove| or cannot be considered to invo|ve an inventive step when the document is taken a|one. "Y" document of particu|ar re|evance ; the c|aimed invention cannot be considered to invo|ve an inventive step when the document is combined with one or more other such documents , such combination being obvious to a person ski||ed in the art. "8t" document member of the same patent fami|y. . Date of the actua| comp|etion of the internationa| search. 11 February 20l3. Date of mai|ing of the internationa| search report. 21 / 02 / 20l3. . Name and mai|ing address of the |SA / . European Patent Office , P. B. 5818 Patent|aan 2 NL - 2280 HV Rijswijk. Te|. ( + 31 - 70 ) 340 - 2040 , . Fax : ( + 31 - 70 ) 340 - 3016. . Authorized officer. Gutke , Hans - Jurgen. . . Form PCT / |SA / 21O ( second sheet ) ( Apri| 2005 ) . page 1 0f 2. . |NTERNAT|ONAL SEARCH REPORT. . . |nternationa| app|ication No. PCT / EP2012 / 005387. . C ( C0ntinuati0n ) . DOCUMENTS CONS|DERED TO BE RELEVANT. . Category * . Citation of document , with indication , where appropriate , of the re|evant passages. Re|evant to c|aim No. . A. . . ISING MARCUS ET AL : "Polymorphisms in the FKBP5 gene region modulate recovery from psychosocial stress in healthy controls" , EUROPEAN JOURNAL 0F NEUROSCIENCE , 0XFORD UNIVERSITY PRESS , GB , . vol. 28 , no. 2 , 1 July 2008 ( 2008 - 07 - 01 ) , pages 389 - 398 , XP0025077l5 , . ISSN : 0953 - 816X , DOI : lO. llll / J.14360 - 9568.2008.06332. X. page 397 , last paragraph. DATABASE REGISTRY [ 0nline ] . CHEMICAL ABSTRACTS SERVICE , COLUMBUS , 0HIO , US ; . 2 0ctober 2010 ( 2010 - 10 - 02 ) , . XP002670948 , . retrieved from STN express. Database accession no. 1056442 - 47 - 7. the whole document. w0 00 / 09l09 A2 ( GUILFORD PHARM INC [ US ] ) 24 February 2000 ( 2000 - 02 - 24 ) . claims 1 , 2. page 37 ; compound 54. pages lO , 57 - 58. CHI CHOI ET AL : "Use of parallel - synthesis combinatorial libraries for rapid identification of p0tent FKBP12 inhibitors" , . BIO0RGANIC & MEDICINAL CHEMISTRY LETTERS , vol. lZ , no. lO , 1 May 2002 ( 2002 - 05 - 01 ) , pages l421 - l428 , XP055052929 , . ISSN : 0960 - 894X , DOI : 10. lO16 / S0960 - 894X ( 02 ) 00147 - 6. cited in the application. table 2. 1 - 14. 1 - 14. 1 - 14. 1 - 14. . . Form PCT / |SA / 21O ( continuation of second sheet ) ( Apri| 2005 ) . page 2 0f 2. . |NTERNAT|ONAL SEARCH REPORT. |nformation on patent fami|y members. . |nternationa| app|ication No. . . . . . . . PCT / EP2012 / 005387 Patent d oooooo t Pub|ication Patent fami|y Pub|ication cited in search report date member ( s ) date N0 0016603 A2 30 - 03 - 2000 AU 1902899 A 10 - 04 - 2000 CA 2344376 A1 30 - 03 - 2000 CN 1336930 A 20 - 02 - 2002 EP 1127049 A1 29 - 08 - 2001 HU 0300719 A2 28 - 11 - 2003 JP 2004538235 A 24 - 12 - 2004 MX PA01002830 A 04 - 06 - 2002 N0 0016603 A2 30 - 03 - 2000 N0 2006069038 A1 29 - 06 - 2006 EP 1838288 A1 03 - 10 - 2007 US 2006194829 A1 31 - 08 - 2006 N0 2006069038 A1 29 - 06 - 2006 N0 0009109 A2 24 - 02 - 2000 AU 5555799 A 06 - 03 - 2000 CA 2344520 A1 24 - 02 - 2000 EP 1109554 A2 27 - 06 - 2001 JP 2002522485 A 23 - 07 - 2002 JP 2011088934 A 06 - 05 - 2011 MX PA01001642 A 04 - 06 - 2002 US 6376517 B1 23 - 04 - 2002 N0 0009109 A2 24 - 02 - 2000. . Form PCT / |SA / 21O ( patent fami|y annex ) ( Apri| 2005 )